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ABSTRACT 
Pulmonary hypertension (PHT) is a progressive and ultimately fatal disease. The 
condition is poorly understood in children. This thesis evaluated non-invasive 
assessment techniques, experience with epoprostenol, atrial septostomy and lung 
transplantation in children. As therapy is guided by patients’ functional capacity, 
studies focused on 6-minute walk test distance (6MWTd) and cardiopulmonary 
exercise testing (CPET). Age-related normal values of 6MWTd were determined, 
and the relationship between 6MWTd and CPET was assessed. Echocardiographic 
markers of impaired myocardial function were investigated using tissue Doppler 
(TDI) and potential risk-factors of mortality were sought using heart rate variability 
(HRV) and B-natriuretic peptide (BNP).   
Parameters of CPET correlated with 6MWTd in highly compromised children but in 
less impaired children the 6MWT represented a sub-maximal test, indicating that a 
CPET is required when 6MWTd exceeds 300m. BNP and HRV were related to 
prognosis but sensitivity and specificity are limited. TDI demonstrated that 
biventricular function is impaired in children with PHT and that left ventricular 
impairment cannot be evaluated adequately using conventional echocardiographic 
techniques. Reviewing our experience with intravenous epoprostenol, it improved 
functional capacity, survival and could be used safely in children with acceptable 
morbidity. Atrial septostomy abolished syncope and improved right ventricular 
function, at the expense of mild systemic arterial oxygen desaturation.  Septostomies, 
with and without a fenestrated device, can close spontaneously with time, stressing 
the need for a more reliable device. When medical therapies were exhausted, 
transplantation dramatically improved quality of life and survival. Listing criteria 
were shown to have been appropriate but more objective criteria are needed.  These 
studies evaluating assessment techniques, prognosticators, and therapies have given 
further insight into the management of children with PHT. Future work should 
include assessment of non-invasive magnetic resonance imaging, exploring a 
combined prognosticator, combination therapy and improving classification of 
clinical status to optimise therapy and facilitate trials of new, urgently needed 
medicines. 
Word count: 300 
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1. INTRODUCTION 
 
The normal pulmonary vascular bed is a compliant system with a low pressure and 
low resistance (1,2). Acute or chronic injury to the pulmonary vasculature may lead 
to an elevation of pulmonary artery pressure (PAP) and pulmonary vascular 
resistance, known as  pulmonary hypertension (PHT) (3). Severe PHT leads to a 
progressive reduction in exercise capacity, right heart failure and death. Survival 
prospects depend primarily on the aetiology of the disease but are generally poor. 
Without treatment, the median survival time in idiopathic pulmonary arterial 
hypertension (IPAH) has been reported to be only 2.8 years in adults (4) and less 
than 1 year in children (5-7). Unfortunately, symptoms are variable and non-specific. 
Therefore, even in the current era the average time from symptom onset to diagnosis 
is 2.8 years (8). Patients may present with increasing exercise intolerance, shortness 
of breath on exertion, tiredness or syncope. Children are often more sick at 
presentation than adults (9). Failure to thrive and fatigue may be noted but symptoms 
can be subtle. Chest pain and peripheral oedema are rare in children, but may occur 
in adults. In IPAH presentation with syncope appears to be more frequent in children 
(7).  
 
The first description of the condition dates back to the 19th century when Julius Klob 
described the case of a 59-year prebendary in 1865, who died of right heart failure 
and pulmonary hypertension (‘endarteriitis pulmonalis deformans’) (10,11) and Ernst 
von Romberg the case of a 24-year old patient with a similar clinical course, 
‘vascular sclerosis’ of the pulmonary artery and no evidence of associated heart- or 
lung disease in 1891 (12). Subsequently, in Argentina Arrillaga, labelled the 
combination of pulmonary hypertension, cyanosis and right heart failure as black 
heart disease (‘cardiacos negros’) or Ayerza’s disease, a tribute to his teacher 
(13,14). He also suggested that the condition may be related to syphilitic pulmonary 
arteritis. This misconception was not undisputed (15) and was eventually disproved 
by Oscar Brenner examining autopsy files at the Massachusetts General Hospital and 
reviewing the available literature in 1935 (16). Further insights into the 
pathophysiology of the condition was provided by the physiological experiments of 
von Euler and Liljestrand (17,18) - demonstrating that acute hypoxia induced 
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pulmonary vasoconstriction  - and the clinical work of Paul Wood and David 
Dresdale (19,20) showing a reduction in pulmonary arterial pressures after infusion 
of vasodilators (acetylcholine and tolazoline, respectively). These observations were 
made possible by advances in cardiac catheterization pioneered by Forssman, 
Cournard and Richards (21-23) who were jointly awarded The Nobel Prize in 
Physiology and Medicine in 1956 for their discoveries. It became apparent that 
vasodilators failed to significantly reduce pulmonary arterial pressures in many 
patients with advanced disease suggesting that vasoconstriction is not the only 
mechanism responsible (24). This interpretation was supported by the typical 
histological findings in patients with PHT such as medial hypertrophy, 
muscularisation of small arteries and plexiform lesions (25). Further research into the 
condition was stimulated in the late 1960 by an epidemic of PAH in some European 
countries and later the US (26-28) related to the use of appetite-suppressants such as 
aminorex and fenfluramine. In response to this epidemic the first WHO meeting on 
PHT took place in 1973 and subsequently a national registry was established in the 
US which provided important epidemiologic, clinical and prognostic information of 
the condition (4). In the past 30 years the understanding of PHT has increased 
exponentially with identification of genetic mutations co-responsible for the 
condition (29) and the identification of important paracrine factors inducing 
vasoconstriction and vascular remodelling (30). Above all, however, based on this 
understanding drugs have become available that have transformed the outcome of 
patients with PHT (31). The first available disease-targeting drug was epoprostenol, 
first successfully used in 1984 (32), followed by other prostacyclins, endothelin-
receptor antagonists and phosphodiesterase-5 inhibitors (33,34).  
 
Definition and Clinical Classification of Pulmonary Hypertension 
In normal individuals the mean pulmonary arterial pressure at rest is 14.0±3.3 mmHg 
(1). Assuming a normal distribution, this gives an upper 95% confidence interval 
(mean+2 standard deviations) limit of 20.5 mmHg. As a consequence, a mean PAP 
below 21 mmHg has been defined as normal at the 4th World Symposium on 
Pulmonary Hypertension held at Dana Point in 2008 (35). A mean PAP between 21 
and 25 mmHg at rest is regarded as borderline PHT, while manifest PHT is defined 
as a mean PAP of more than 25 mmHg at rest (36,37).  Because the pulmonary 
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arterial pressure can vary considerably during exercise in normal individuals (1) the 
previous definition of PHT as an elevated mean PAP of more than 30 mmHg during 
exercise (37) has been abandoned. 
 
The first classification of PHT established at the first World Symposium in 1973 was 
based on an histological grading system (25) and classified PHT only into two 
categories, primary or secondary PHT, depending on the presence or absence of an 
identifiable causes or risk factor (38). Due to increased understanding of the 
condition, the insight that pathological features are shared between many forms of 
PHT and, first of all, the advent of disease-targeting therapies, subsequent 
classification systems attempt to create categories of PHT that share pathologic and 
clinical features as well as therapeutic options (39). The current Dana Point 
classification subdivides PHT into five categories: (1) Pulmonary arterial 
hypertension (PAH), (2) PHT owing to left heart disease, (3) PHT due to lung 
diseases and/or hypoxia, (4) chronic thromboembolic pulmonary hypertension 
(CTEPH) and (5) PHT with unclear or multifactorial mechanisms as shown in Table 
1.1. 
 
 
 
Table 1.1. Clinical classification of pulmonary hypertension (Dana Point, 2008) (39).  
 
Clinical classification of pulmonary hypertension (Dana Point, 2008) 
 
I. Pulmonary arterial hypertension (PAH) 
• Idiopathic PAH 
• Heritable PAH 
• Drug- and toxin-induced 
• PAH associated with  
o Connective tissue disease 
o HIV 
o Portal hypertension  
o Congenital systemic to pulmonary shunts 
o Schistosomiasis 
o Chronic haemolytic anaemia 
o Persistent pulmonary hypertension of the newborn 
• Pulmonary veno-occlusive disease or pulmonary capillary haemangiomatosis 
 
II. Pulmonary hypertension owing to left heart disease 
III. Pulmonary hypertension owing to lung diseases and/or hypoxia 
IV. Chronic thromboembolic pulmonary hypertension (CTEPH) 
V. Pulmonary hypertension with unclear multifactorial mechanisms 
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Idiopathic pulmonary arterial hypertension accounts for approximately 28% of all 
paediatric cases with PHT. The most common aetiology in children is PHT 
secondary to congenital heart disease (approximately 48%, either pre- or 
postoperative, due to complex CHD or Eisenmenger physiology). Other aetiologies 
seen in children are pulmonary hypertension associated to lung disease (13%) or 
connective tissue disease (4%). Approximately 7% are miscellaneous forms of PHT 
(40). These numbers were derived from a cohort of children with PHT, who have 
been refered to the UK Pulmonary Hypertension Service for Children between 2001 
and 2006 (40). Other forms such as chronic thromboembolic, drug or toxin-induced 
or HIV associated pulmonary arterial hypertension are only rarely seen in children.  
Data reporting 63 patients seen in a national referral centre for paediatric PAH in the 
Netherlands, reported a proportion of 46% with IPAH/ or ‘idiopathic like’ PAH. In 
this registry, PAH associated to congenital heart disease accounts for 37% of all 
patients. PAH secondary to respiratory disease and/or hypoxaemia was noted in 12% 
and connective tissue disease 3% (41).  
This thesis focused on children with PAH. The following paragraphs, therefore, 
provide details of the aetiology, pathophysiology and treatment of PAH. Other forms 
of PHT have been reviewed in detail recently by Hoeper et al. (42). 
 
Epidemiology of PAH 
The incidence of PAH in the general population is estimated to 2.4 – 7.6 cases per 
million per year (43,44). A recent study based on the Scottish Morbidity Record 
Scheme estimated a PAH prevalence of approximately 26 - 52 cases per million 
inhabitants (44). This compares with data from a French registry suggesting a 
prevalence of approximately 15 cases per million (43). The incidence of IPAH in 
children in the UK has been recently reported to be 0.48 cases per million per year, 
with a prevalence of 2.1 cases per million (7). Data on the incidence and prevalence 
of PAH in children is lacking, however, data from a Swiss registry suggested that 
IPAH accounts for approximately 1/3 of the paediatric PAH cases (45). 
 
Pathophysiology and Genetic Factors 
The aetiology of pulmonary arterial hypertension is multi-factorial. It is thought that 
different pathophysiologic mechanisms acting synergistically lead to the 
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development and maintenance of pulmonary vascular disease.  Pulmonary vascular 
disease is characterized by muscularization of distal - normally non-muscular – 
arterioles, smooth muscle cell hypertrophy, obstructive intimal proliferation and the 
formation of plexiform lesions (25,46) (47).  Recently, a number of genetic 
mutations have been linked to pulmonary vascular disease (48). The most important 
genetic mutations known to date are those affecting the regulation of the 
transforming growth factor-β family of receptors, the bone morphogenetic protein 
receptor type II gene (BMPR2) and the activin-receptor–like kinase 1 (ALK-1) gene 
(49). These receptors are functionally linked as they form heteromeric complexes 
after ligand binding by the type 2 receptor (for example BMPR2), resulting in 
activation of activin-receptor–like kinase 1 with subsequent phosphorylation of 
cytoplasmic proteins and gene transcription (50,51). However, genetic mutations 
alone are not a sufficient to explain the development of pulmonary vascular disease. 
Instead it has been suggested that pulmonary vascular disease is a multifactorial 
process requiring not only a permissive genotype, but also a vulnerable cell 
phenotype and additional exogenous triggers (52). Pulmonary endothelial damage, 
for example in patients with congenital heart disease and left-to-right shunt lesions, 
may represent such a trigger for developing pulmonary vascular disease in 
susceptible individuals (53). Endothelial damage as a consequence of a high 
pulmonary blood flow and pressure may allow serum factors to infiltrate the vascular 
wall, leading to degeneration and degradation of extracellular matrix as well as 
release of growth factors normally quiescent in the matrix (such as transforming 
growth factor-β and fibroblast growth factor) (54). Endothelial damage also favours 
platelet activation and activation of coagulation pathways. Beyond forming a mere 
barrier between the media and the vascular lumen, the vascular endothelium is the 
source of vasoactive mediators including nitric oxide, endothelin-1 and prostacyclin 
(55-58). Endothelial damage has been reported to shift the balance in favour of 
vasoconstrictors, such as endothelin-1 and thromboxane, and to induce smooth 
muscle cell hypertrophy, proliferation, and failure to sustain normal apoptosis 
pathways, thereby resulting in the known histopathological changes seen in 
pulmonary vascular disease (52).  
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Vascular smooth muscle cell hypertrophy and proliferation are additional features of 
PAH and are, in fact, sometimes the only identifiable vascular lesion (59). This may 
be partly related to vasoconstriction. Calcium influx causes both smooth muscle cell 
contraction and stimulates cell proliferation (59,60). It appears, however, that smooth 
muscle cell hypertrophy and proliferation is mainly related to paracrine factors such 
as platelet-derived growth factor (61),  angiopoietin (62), insulin-like growth factor 
(63), endothelin (64) and eicosanoids (65). In addition, smooth muscle cell 
proliferation has been linked to increased circulating serotonin (5-HT) levels and 
overexpression of the 5-HT transporter (66-69). The free calcium concentration in 
the smooth muscle cell cytosol regulates contraction and also proliferation. The 
cytosolic calcium concentration, in turn, is increased by calcium influx through 
voltage dependant calcium channels and their function is linked to membrane 
potential, largely determined by potassium channels (70). It is not surprising, 
therefore, that reduced potassium channel function and expression has been linked to 
pulmonary vascular smooth muscle cell proliferation and – by different mechanisms 
– reduced apoptosis (60). Pulmonary hypertension is also characterized by adventitial 
thickening and increased collagen and elastin production (71). Recent research has 
highlighted that the vascular adventitia is a highly dynamic structure, regulating 
vasomotor tone and extracellular matrix composition as well as expressing 
endothelin and other growth-factors (72). Additional abnormalities involved in the 
pathophysiology of PAH include immune inflammation with intrapulmonary 
inflammatory infiltration (73), impaired endothelial cell apoptosis and progenitor cell 
homing to the site of pulmonary vascular changes (74). 
 
On a histological level, though the causes of pulmonary vascular disease may vary, 
the structural changes are similar, and medial hypertrophy as well as initimal 
thickening is usually seen (54). In severe disease, the formation of plexiform lesions 
is described. 
 
Although sustained PAH is characterized by pulmonary vascular changes, the 
symptoms and survival prospects are determined by the ability of the right ventricle 
to cope with an increased pulmonary vascular resistance. Chronic right ventricular 
pressure overload leads to right ventricular dilatation, reducing right ventricular mass 
20 
 
 
to volume ratio and increasing wall tension according to Laplace’s law . Increased 
wall stress and reduced systolic coronary perfusion may in turn induce right 
ventricular dysfunction and right ventricular hypertrophy. Over time, compensatory 
mechanisms of the right ventricle fail and right ventricular failure develops. In 
addition to the direct effect on the right ventricle, right ventricular dilation and 
interventricular septal shift may impact on the left ventricular shape and function, 
leading to biventricular dysfunction (75). Besides manifest heart failure, right 
ventricular hypertrophy and myocardial fibrosis (76) may predispose patients to 
malignant ventricular arrhythmias resulting in sudden cardiac death, an aspect of the 
disease that has received relatively little attention so far. 
 
Clinical Features of PAH 
Patients may present with increasing exercise intolerance, shortness of breath on 
exertion, tiredness, chest pain or syncope. Children are often more sick at 
presentation than adults (12). Failure to thrive and fatigue may be noted, but 
symptoms can be subtle. Leading symptom in children at the time of diagnosis is 
dyspnoea (7,41), followed by limitation in exercise (7). In IPAH, presentation with 
syncope appears to be more frequent in children (7), with almost one third of 
children presenting with syncope in the UK. In contrast, a Dutch study reported the 
rate of children who had a syncopal episode at presentation to be only 13% (41). 
Chest pain and peripheral oedema are rare in children but may occur in adults. The 
degree of disability is described by the NYHA or WHO Functional Classification. 
This was developed for use in adults and is used in children although it is difficult to 
apply in this setting. There are 4 classes. Class I is the apparently healthy, 
asymptomatic patient and class IV is the severely incapacitated patient in right heart 
failure. 
 
On auscultation, an accentuated pulmonary component of the second heart sound is 
noted in nearly all patients (7).  A systolic murmur may be audible, as the majority of 
patients with significant PHT have a degree of tricuspid regurgitation. An early-
diastolic decrescendo murmur may also be noticed, generated by a regurgitant 
pulmonary valve. Occasionally a third heart sound may be heard and a right 
ventricular heave is present in the majority of children at presentation.  Jugular veins 
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may be prominent and a visible a wave, the reflection of the atrial systole by a stiff 
right ventricle in diastole may be seen. 
 
Symptoms are usually the consequence of a deteriorating right ventricular function, 
namely hepato-splenomegaly, peripheral or generalized oedema as central venous 
pressures increases.  In children, however, hepatomegaly was only noted in less than 
a quarter of children at the time of diagnosis (7).  
Clubbing, peripheral cyanosis and eventually erythrocytosis may be clinical 
symptoms in patients with end-stage PHT and significant hypoxaemia. Auscultation 
of the lungs should be unremarkable. If inspiratory crackles are heard, interstitial 
lung disease should be ruled out. 
Other symptoms, such as Raynaud phenomenon, teleangiectasia or sclerodactyly 
deserve special attention, as those symptoms do occasionally indicate additional 
underlying problems, such as scleroderma or vasculitis.  
 
Making a diagnosis of PAH 
All children, who present with unexplained shortness of breath, lethargy or syncope 
deserve further investigation and pulmonary hypertension ought to be ruled out. 
Children are often misdiagnosed as being ‘asthmatic’ (77). All children with 
suspected pulmonary hypertension are initially assessed by clinical examination, 
electrocardiogram, chest X ray and echocardiography.  
The electrocardiogram helps to reveal right ventricular hypertrophy or strain and 
shows right atrial dilatation. Voltage criteria of right ventricular hypertrophy and 
right axis deviation are common in patients with IPAH (78). The absence of these 
findings does not necessarily suggest that pulmonary artery pressures are normal, as 
the ECG has limited sensitivity and specificity. Due to a natural right axis deviation 
in infancy, the sensitivity of the ECG is even lower in this setting.  
 
The chest X-ray allows to assess the cardiothoracic ratio and to determine if 
cardiomegaly is present. Furthermore it reveals, if the pulmonary arterial vasculature 
is abnormal. While central pulmonary arteries are expected to be enlarged, there is 
usually a rarefication of peripheral pulmonary arteries, often with an abrupt calibre 
change. 
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The echocardiogram allows an estimation of pulmonary artery pressures in the 
majority of children (79), it provides information of the degree of right ventricular 
impairment, and can give information about left ventricular dysfunction, when tissue 
Doppler imaging is used. This problem will be studied in the work presented in this 
thesis. 
 
 If echocardiography fails to visualize the anatomy adequately, a contrast CT 
angiogram should be considered. Also, if interstitial pulmonary disease or any other 
aetiology is suspected a high-resolution CT scan of the chest should be performed, to 
confirm the diagnosis and evaluate the lung parenchyma. 
 
For diagnosis, accurate measurement and calculation of pulmonary vascular 
resistance, evaluation of pulmonary vascular responsiveness, children should 
undergo a right heart catheterization with vasodilator testing. In children who present 
in a poor condition, in whom either right ventricular function had been severely 
affected, or who presented with frequent pulmonary hypertensive crises, institution 
of treatment is paramount. The aim is to stabilize a child first, to avoid any potential 
additional risk exposing a frail child to an invasive procedure with considerable 
morbidity. Once the clinical situation had improved and pulmonary hypertensive 
crises are controlled, a delayed catheterization is performed, acknowledging that 
measures are flawed and may be lower, as the child is already on treatment. 
 
Children who are old and mature enough are asked to perform a six-minute walk test 
(6MWT), which can be done in our experience from the age of 4-5 years onwards. 
Older children (from 140 cm body height) may undergo formal cardiopulmonary 
exercise testing as a baseline status. Information about the six-minute walk test and 
cardiopulmonary exercise testing is presented and discussed in this thesis. 
 
Management of PAH 
Evidence-based treatment algorithms for adult PAH patients have been published as 
part of current guidelines (3) and the treatment strategies employed at the United 
Kingdom Service for Pulmonary Hypertension in Children (UKSPHC)  have been 
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reported in detail recently (40). Medical treatment is constantly evolving as new 
medicines become available and is guided by evaluation of disease severity, the 
assessment of vasoreactivity and assessment of efficacy of therapy (3). Depending on 
the child’s clinical condition and the aetiology of the PAH children presenting to the 
UKSPHC are given either monotherapy or combination therapy after diagnosis. 
Children are reassessed on a regular basis and therapy is modified when necessary. 
In adult practice the condition of a patient is defined as stable and satisfactory, stable 
but not satisfactory or unstable and deteriorating based on the clinical, non-invasive 
and invasive findings. These include clinical evidence of right ventricular failure, 
progression of symptoms, presence of syncope, WHO functional class, 6-minute 
walk test distance, B-type natriuretic peptide levels, echocardiographic evidence of 
pericardial effusion or reduced right ventricular function and haemodynamic 
parameters such as cardiac index and mean right atrial pressure (3,80). Based on 
these criteria targets are set and medical treatment is escalated if goals are not met 
(81). This goal-orientated strategy requires a set of established risk prognosticators, 
limiting its usefulness in paediatric patients where non-invasive prognosticators are 
less well established. In addition, invasive haemodynamic assessment is associated 
with an increased risk of complications (82). Although most paediatric patients 
require an initial cardiac catheterization to establish the diagnosis of PHT and to 
assess vasoreactivity, repeated right heart catheterizations are avoided and, unlike in 
adult patients, sequential haemodynamic parameters are generally not available to 
guide therapy in children.  Figure 1.1 provides an overview over the treatment 
strategy for children with IPAH employed at the UKSPHC (7,83). 
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Figure 1.1. Treatment algorithm in children with pulmonary hypertension. Modified from 
Haworth et al. (83)  
 
The following paragraphs provide a short overview of pulmonary hypertension 
therapies used in our paediatric population during the study period.  
 
Calcium Channel Blockers 
Treatment with calcium channel blockers is reserved for children who are responsive 
to vasodilator testing (83). The definition of an acute responder is controversial. The 
original definition was a fall in pulmonary vascular resistance and arterial pressure of 
at least 20%, without reduction in cardiac output (84). More recently, a reduction of 
mean pulmonary arterial pressure of more than 10 mmHg, leading to a mean 
pulmonary arterial pressure below 40 mmHg or a fall in pulmonary vascular 
resistance to near normal values has become the accepted definition (7). Using the 
latter definition, a retrospective review of children under follow up at the UKSPHC 
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suggested that only 7.4 % of IPAH and only 6.0 % of APH patients are acute 
responders (40). Acute responders require constant re-evaluation as children may 
deteriorate on a calcium channel blocker and lose vasoreactivity with time. Despite 
these limitations, the survival prospects of acute responders treated with nifedipine 
are reassuring (3,7,85-87). 
 
Prostacyclin and derivates 
Epoprostenol (PGI2, PGX, prostacyclin) is the synthetic sodium salt of a naturally 
occurring metabolite of arachidonic acid (prostaglandin). Prostacyclin is produced by 
the endothelium, acts as a vasodilator and has antiproliferative, platelet inhibitory 
and positive inotropic properties (88). Intravenous epoprostenol was the first 
effective treatment for severe, established PAH (58). Its efficacy has been proven in 
adults and in children (5,89,90). Due to its efficacy epoprostenol is prescribed to 
adults and children with IPAH who are in WHO functional class 3 or 4 and who do 
not show a positive response to acute vasodilator testing. With increasing experience, 
the indications in paediatric practice have widened beyond IPAH and include 
children with severe PAH associated with connective tissue disease, post-repair 
congenital heart disease, HIV associated PHT and portal PHT. According to current 
guidelines it is the drug of choice in patients presenting unstable or in WHO 
functional class 4 (3).  
The half-life of Prostacyclin is only 2-3 minutes and a continuous infusion is 
required to maintain a constant plasma concentration. Chronic administration, 
therefore, generally requires a central line. Sudden ‘rebound pulmonary 
hypertension’ or even deaths are reported in abrupt delivery failure or inadvertent 
drug interruption of any other cause or drug withdrawal. Epoprostenol is usually well 
tolerated in children and adults and side effects are not excessively troublesome. 
Diarrhoea, flushing, jaw pain and light-headedness are described. Epoprostenol is an 
expensive, high maintenance therapy, which demands an ongoing commitment by 
the patient, parents or carers and the cooperation of the child (79). 
Studies on the management of children given epoprostenol are presented in this 
thesis. 
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The subcutaneous analogue of prostacyclin (Treprostinil) is used in adults with WHO 
functional class 2 - 4. The main advantage is avoidance of a central access with its 
associated morbidity, although the drug needs to be continuously delivered via a 
subcutaneous infusion. The half-life of three to four hours is longer than that of the 
intravenous form permitting continuous subcutaneous infusion (91). It has been 
shown to improve exercise tolerance as demonstrated by an increase in 6-minute 
walk test distance (91-93). Due to pain at the injection site and the relative lack of 
subcutaneous tissue its use is problematic in young children.  
 
Inhaled prostacyclin (Iloprost) has gained approval for adult IPAH patients in WHO 
functional class 3 and 4. Exercise tolerance improves but due to the relatively short 
half-life repeated inhalations are required every 2-3 hours (i.e. 6-9 inhalations/day) 
for a sustained beneficial effect. A disadvantage of this application form is that it is 
relatively time-consuming and tiring, as each inhalation takes around 15 minutes 
(94). Due to limited compliance and high rates of discontinuation of treatment in 
children (95) this therapy was very rarely used at the UKSPHC. 
 
Inhaled Treprostinil has been recently described to be well tolerated as well as to 
improve exercise capacity and quality of life in adult patients with PAH (96) when 
added to sildenafil or bosentan therapy. Despite these encouraging early results, data 
in children with PAH is lacking and this drug was not used at the UKSPHC.  
 
Oral prostacyclin (Beraprost) has been used for patients in WHO functional class 2 
or 3. However, long-term data are not convincing, as development of tolerance and 
loss of therapeutic benefit appears to be a concern (97). This drug was not used at the 
UKSPHC.  
 
Dual endothelin receptor antagonists 
Bosentan is a non-selective endothelin-A and endothelin-B receptor antagonist. It is 
approved for the treatment of PAH adult patients in WHO functional class 3 and 4. 
Bosentan was shown to lead to symptomatic improvement and increase in exercise 
tolerance in 2002 (98). The pharmacokinetics, safety and efficacy of Bosentan 
treatment in children with pulmonary hypertension was reported in 2003 by Barst 
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and collegues (99). Further observational reports are available, demonstrating the 
beneficial effect of Bosentan in children (100,101). Derangement of liver function is 
described (102). Liver function needs to be monitored regularly as elevation of 
transaminases may occur. More recently selective endothelin-A (ETA) antagonists 
were introduced (Sitaxentan and Ambrisentan). Trials in adults has shown 
improvement of exercise tolerance (103-105). However, none of the patients 
included in the studies presented in this thesis was treated with a selective ETA 
antagonist as currently no data are available on the efficacy and safety of 
ambrisentan and sitaxentan in paediatric patients. 
 
Phosphodiestrase-5 inhibitors (PDE-5 inhibitors) 
Sildenafil, a phosphodiesterase-5-inhibitor, was shown to be effective in reducing 
pulmonary vascular resistance as well as improving functional class and the 6-minute 
walk test in adult patients with PAH in the SUPER-1 trial (34). Its oral route of 
administration and relatively low cost makes it attractive for use in stable PAH 
patients. However, there are little data on the safety and efficacy of PDE-5 inhibitors 
in paediatric patients. A pilot study in children has suggested that it may also be 
beneficial in this population (106). A randomized controlled trial in children has been 
completed and the results should be available in the near future (83). Overall, 
however, the experience with sildenafil monotherapy in IPAH has been generally 
unsatisfactory in the UKSPHC (40). In the early days of the Service the children 
treated with sildenafil monotherapy who had been given this drug before transfer to 
the UKSPHC were extremely ill on arrival and outcome was usually poor. Given this 
experience, children with IPAH were not started on long-term sildenafil as 
monotherapy, awaiting further data from randomized controlled trials. Instead, 
sildenafil is used in combination with other therapies to maximally stimulate all 
vasodilatory pathways (7). Sildenafil also appears to have a clinical role in 
counteracting rebound pulmonary hypertension after withdrawal of inhaled nitric 
oxide (107). Additional, PDE-5 inhibitors such as Tadalafil have been developed but 
their use has been largely restricted to adult patients (108) until further data on safety 
and efficacy become available. 
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Combination therapies 
Combinations of pulmonary hypertension specific therapies are increasingly used in 
patients with IPAH (109). A recent retrospective UK study suggested that a 
combination of intravenous epoprostenol with either bosentan or sildenafil, or both 
appeared to achieve the best outcome in children with IPAH (40). Although, possible 
drug interactions need to be considered (110,111) the increasing use of combined 
therapies reflects the current clinical practice of goal-orientated drug therapy with a 
need for more aggressive treatment (3).  
 
Balloon atrial septostomy 
Balloon atrial septostomy has been proposed as a therapy option for highly 
symptomatic patients refractory to advanced vasodilator therapy (112-114). The 
artificially created interatrial communication may function as a “pop-off” valve, 
allowing the right ventricle to decompress and to maintain systemic blood flow when 
metabolic demand is increased (115), for example during pulmonary arterial 
hypertensive crises, albeit at the expense of  mild desaturation (116). The reported 
average reduction in arterial oxygen saturation in a study in a paediatric cohort was 
from 97.8% before septostomy to 90% after 3–6 months (113).  Clinically, atrial 
septostomy has been shown to improve haemodynamics and quality of life as well as 
prolong survival (112,117-121). In the paediatric population it is especially useful in 
children presenting with syncope (40). Atrial septostomy is effective in abolishing 
syncope, and can protect against syncope by maintaining systemic cardiac output, 
particularly when the pulmonary arterial pressure rises acutely (113). Atrial 
septostomy augments systemic blood flow, potentially benefiting organs that lack the 
ability to autoregulate blood flow at low blood pressures. It has been suggested that a 
mean arterial pressure of at least 60 mmHg is required to enable cerebral 
autoregulation (122). In the situation of desperately poor systemic blood flow, 
autoregulation may not be able to successfully maintain flow to some vital territories 
- an increase in total flow could permit autoregulatory processes to restore perfusion 
to vital organs. In addition, it has been suggested that atrial septostomy increases 
oxygen delivery to the tissues due to an increase in cardiac output, despite the modest 
reduction in systemic arterial oxygen saturation septrostomy (113). However, a 
recent analytical study revealed this does not coincide with an improved tissue 
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oxygenation and is merely a consequence of the way raw arterial oxygen delivery is 
defined (123). 
 
The problems associated with atrial septostomy in children with PAH are addressed 
in studies presented in this thesis. 
 
Transplantation 
Double-lung or heart-and-lung transplantation is the therapy of last resort for patients 
with severe PHT, when quality of life and exercise tolerance deteriorate despite 
optimized maximal medical therapy. Organ availability - particularly for children - is 
sparse and children with PHT are competing with children listed for transplantation 
for other conditions such as cystic fibrosis. Waiting time is often long and deaths on 
the active transplant list occur. Timing is a major challenge. This issue has been 
addressed in the work presented in this thesis. 
 
 Survival after successful transplantation is limited and mean survival after lung- 
heart-and-lung transplantation nowadays is reported to be approximately 4.2 years 
(124).  
 
Supportive therapy 
Patients require regular assessment and follow up management at expert centres for 
PAH. Strenuous exercise and competitive sports should be avoided. In children 
without contraindications oral anticoagulation is recommended (85,125). In addition, 
patients with signs and symptoms of right heart failure will generally benefit from 
diuretics. Immunization against influenza and pneumococcal infections are 
recommended and endocarditis prophylaxis should be considered in patients with 
congenital heart defects (126,127). In addition, adequate family support is required, 
especially when intravenous treatment along with its high demands and commitment 
to the family is contemplated. 
 
Risk stratification in PAH 
Estimating the prognosis of the individual patient with PAH is paramount for 
optimizing medical therapy and the timing of additional therapeutic options such as 
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atrial septostomy and transplantation. Various studies have explored the risk factors 
of poor outcome in older patients with PAH. The majority of the studies were 
performed in adult patients with IPAH and young children were not included in these 
studies. The topic has been comprehensively reviewed by McLaughlin et al. (128). 
There is inconsistency between studies regarding the prognostic value of various risk 
factors but it appears that the following risk markers (sorted by increasing 
invasiveness) are related to poor outcome in patients with PAH. 
 
Functional parameters 
1. Advanced WHO functional class (treatment naive and on therapy) (4,7,129-133). 
2. Low 6-minute walk test distance (89,134,135).  
3. Low peak oxygen consumption and low peak exercise systolic and diastolic blood 
pressure on cardiopulmonary exercise testing (136). 
 
Biochemical markers: 
1. Elevated atrial or B-type natriuretic peptides (ANP, BNP, NT-pro BNP) 
2. Elevated uric acid levels (136-138) 
 
Electrocardiographic (ECG) measures: 
1. ECG findings of increased P-wave amplitude and voltage criteria of right 
ventricular hypertrophy (78).  
 
Echocardiographic parameters: 
1. Presence of a pericardial effusion (134,139). 
2. Right atrial area (134). 
3. Elevated Doppler echocardiography right ventricular (Tei) index (140,141). 
 
Haemodynamic measures on right heart catheterization: 
1. Elevated mean right atrial pressure (4,78,130-132,134,142-146) 
2. Reduced cardiac index (4,78,132,136,138,139,142,144,146,147) 
3. Elevated mean pulmonary arterial pressure (4,125,130,132,136,139,144-146,148) 
4. Elevated pulmonary vascular resistance (4,78,125,136,142,145,146,149) 
5. Vasodilator responsiveness (131,133,142,150) 
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Additional risk markers include: 
1. Persistence of WHO functional class 3 or 4 in patients treated with epoprostenol 
(130) 
2. Low diffusion capacity (DLCO, < 45% of predicted) in patients with scleroderma-
associated PAH (151) 
3. Younger age at diagnosis in paediatric patients with IPAH (146) 
 
Only a few studies have investigated prognostic markers specifically in children. 
Sandoval et al. (143) assessed 18 children below 16 years of age who had IPAH. Due 
to the small number of children included only increased mean right atrial pressure 
was found to be significantly related to survival on univariate Cox proportional-
hazard analysis, while a trend towards worse outcome was seen in patients with 
higher functional class, signs of heart failure, male sex, vasodilator 
unresponsiveness, reduced mixed venous oxygen saturation, increased pulmonary 
vascular resistance and reduced stroke volume index. On multivariate analysis only 
lower stroke volume index and higher mean right atrial pressures emerged as 
significant predictors of worse survival, thus highlighting the importance of 
haemodynamic parameters for risk stratification in IPAH. Unfortunately, the authors 
did not assess the prognostic value of the 6-minute walk test distance in this study. 
Recently, a retrospective cohort study of 64 children with IPAH (<16 years of age) 
who presented to the UK Service for Pulmonary Hypertension in Children found that 
WHO functional class and low weight z-scores were the only significant predictors 
of death on multivariate survival analysis (7). On univariate analysis, however, right 
ventricular systolic pressure estimated on Doppler echocardiography, the degree of 
right ventricular dilatation and pulmonary vascular resistance index (naive and with 
vasodilator testing) were found to be related to survival (7). These results are largely 
in agreement with a recent Dutch study (152). 
 
The aims of the studies presented in this thesis 
During the last two decades the outcome of patients with PHT has been transformed 
by a better understanding of the pathophysiology of the condition, the advent of new 
medical therapies and in adults, improved risk stratification. Not surprisingly, 
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however, research has focused on adult patient cohorts with limited data being 
available in children. This thesis aims to: 
1) evaluate certain non-invasive tests used to diagnose and monitor children with 
pulmonary hypertension. As medical therapy is largely guided by patients’ objective 
functional capacity, work focuses on the 6-minute walk test distance and parameters 
of cardiopulmonary exercise testing. Although the 6-minute walk test is commonly 
used to assess a patient’s exercise capacity there are limited data on normal values of 
walk test distance in UK children and the 6-minute walk test distance varies 
considerably with the age of the child. One aim of this thesis is, therefore, to 
establish normal values of 6-minute walk test distance in UK children against which 
the performance of children with PHT can be compared in future studies. 
Furthermore, in older children cardiopulmonary exercise testing may be used to 
assess objective exercise capacity, providing additional physiologic information. 
However, the relationship between the 6-minute walk test distance and parameters of 
cardiopulmonary exercise testing in children with PAH is unclear, hampering 
comparison of data between the two modalities and limiting clinical application of 
results. Thus, a further aim was to compare these two modalities. 
2) to investigate potential risk factors of mortality . These prognostic markers include 
echocardiographic markers of impaired biventricular myocardial function, heart rate 
variability and B-type natriuretic peptide  
3) to study the paediatric experience with epoprostenol therapy, use of atrial 
septostomy and the timing of transplantation in children because  data on safety and 
efficacy of therapeutic options are sparse in children with PAH. A case series of 
patients, who underwent implantation of atrial fenestrated devices is presented. 
Taking advantage of the opportunity afforded by having a large centre for paediatric 
PHT collaborating with a large, active paediatric transplantation program, 
considerations for selecting children for listing for lung transplantation are presented. 
Overall, these sub-studies provide further insight into the comprehensive assessment, 
risk stratification and treatment of children with PHT and should assist clinicians in 
providing the optimal therapy for children with this condition, which carries such a 
high morbidity and mortality.  
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2. METHODS OF ASSESSMENT  
 
Introduction  
As the majority of methods used in this thesis are routine clinical procedures, this 
chapter introduces the standards and methods of clinical assessment in more detail. 
As the same methods were used in the various studies presented in this thesis, it is 
hoped that this chapter helps to avoid redundancy for the reader.  This chapter gives 
an overview of the assessment of (WHO) functional class, electrocardiography 
including Holter monitoring, echocardiography, six-minute walk test, 
cardiopulmonary exercise testing, cardiac catheterization, B-type natriuretic peptide 
measurement and the basic statistical methods used in this thesis. 
 
2.1 Assessment of functional class  
The assessment of functional class is based on the classification recommended by the 
World Health Organization (WHO) (153). It represents a modification of the well 
known New York Heart Association functional classification (NYHA) describing the 
level of functional impairment and associated symptoms in cardiovascular disease 
(154).  An increase in NYHA/WHO class reflects a deterioration in functional 
capacity, suggesting that the patient suffers from more severe symptoms and has a 
greater restriction in physical activity. It is used in order to stratify patients who have 
a similar level of severity of symptoms and have a comparable degree of physical 
limitation into one of four groups. Though the assessment of a patient’s functional 
class may well be influenced by the individual or physicians judgement, it represents 
a relatively simple approach to evaluate and categorize a patient’s exercise tolerance. 
These classification systems were designed for use in adults. 
 
Table 2.1. The WHO classification to describe functional status  
 
Functional Class Symptomatic profile 
 
Class 1   
 
 
Patients with pulmonary hypertension but 
without any resulting limitation of physical 
activity. Ordinary physical activity does not 
cause dyspnoea, fatigue, chest pain or near 
syncope. 
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Class 2  
 
Patients with pulmonary hypertension 
resulting in slight limitation of physical 
activity. They are comfortable at rest. 
Ordinary physical activity causes undue 
dyspnoea or fatigue, chest pain or near 
syncope. 
 
Class 3 Patients with pulmonary hypertension 
resulting in marked limitation of physical 
activity. They are comfortable at rest. Less 
than ordinary activity causes undue dyspnoea 
or fatigue, chest pain or near syncope. 
 
Class 4 Patients with pulmonary hypertension with 
inability to carry out any physical activity 
without symptoms. These patients manifest 
signs of right heart failure. Dyspnoea and/ or 
fatigue may even be present at rest. 
Discomfort is increased by any physical 
activity. 
 
 
2.2 Electrocardiogram (ECG) 
Twelve lead electrocardiograms were recorded in a standardized way to assess the 
underlying heart rhythm and rate.  The ECGs were specifically analyzed for evidence 
of right ventricular hypertrophy (RVH) and strain. For RVH, voltage criteria were 
used (R wave amplitude in V1 plus the S wave amplitude in V5 or V6). Right 
ventricular strain was defined as a QRS-T angle > 90° and a T-axis between 0 and -
90°. Possible strain was defined as a QRS-T angle > 90 ° and a T axis between 0 and 
+90° as described by Park et al. (155). 
 
2.3 Assessment of heart rate variability from 24 hour Holter ECG monitoring 
Holter monitoring was performed and data were analyzed using the customized 
Reynolds Pathfinder Software (Hertford, UK). Parameters of heart rate variability 
were determined from the recordings, including SDNN (standard deviation of all 
normal-to-normal intervals), SDANN (standard deviation of mean values for all 
normal-to-normal intervals over 5 min) and RMSSD (square root of the mean square 
differences of successive RR intervals). 
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2.4 Transthoracic echocardiography 
The majority of echocardiograms were performed on a Vivid 7 machine (GE, 
Milwaukee, USA) equipped with Matrix 3.5 and 7 MHz probes. All patients 
underwent a thorough assessment according to the sequential anatomical analysis 
approach to ascertain the underlying cardiac morphology (156). Evidence of right 
ventricular dilatation, hypertrophy and function was assessed. A semiquantitiative 
graduation system for right ventricular impairment, dilatation and hypertrophy, as 
well as the degree of valvar regurgitation was used.  
Right ventricular function was classified as being normal, mildly, moderately or 
severely impaired (157). Valvar regurgitation, right ventricular dilatation and 
hypertrophy were classified as none (0), trivial (1), mild (2), moderate (3) or severe 
(4).  
 
In the presence of a complete Doppler trace envelope of tricuspid regurgitation, an 
estimate of the right ventricular systolic pressure is given using the modified 
Bernoulli equation (158). 
∆P = 4·v2 
 
∆P represents the pressure difference across the valve and v represents the maximal 
measured Doppler velocity. The presence of a pericardial effusion was recorded and 
described when present. 
 
2.5 Six minute walk-test (6MWT)  
All 6MWTs were conducted using a lap 30–50 m in length on flat, hard ground, 
according to the ATS guidelines (159). A portable pulse oximeter (PulsoxTM-3iA, 
Minolta) was used to record the transcutaneous oxygen saturation and heart rate 
before the start of the walk, after every minute during the test and after 1 and 3 
minutes during the recovery period. The pulse oximeter was lightweight (42 g 
excluding batteries, wrist band and probes) and attached to the child’s wrist as shown 
in Figure 2.1. Depending on the child’s age, a finger probe or clip was used as 
transcutaneous sensor and attached to one finger of the same hand. 
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Figure 2.1. Portable pulse oximeter (PulsoxTM-3iA, Minolta), (finger-probe not shown) 
 
The children were asked to walk up and down the measured lap at their best pace but 
not to run, race or dawdle. The same instructions were given to all children before 
undertaking the walk test. All tests were undertaken by each child separately to 
prevent competition. The instructor walked behind the child to make sure that the 
child determined the pace his/herself and also to read the oxygen saturation and heart 
rate as outlined above. While encouragement (e.g.  ‘Keep going’, ‘You are doing 
well’) and announcement of time remaining were given to the children, no 
judgemental comments (such as ‘You could go faster’ or ‘Slow down’) were made 
regarding the child’s performance. Weight, height, gender and ethnic background 
were documented. The total distance walked in 6 minutes was measured. Predicted 
values for 6MWT distance in boys and girls were calculated based on gender, age 
and height according to published data for healthy Caucasian children and 
adolescents (160).  
 
2.6 Cardiopulmonary exercise tests 
Cardiopulmonary exercise testing was performed on a mechanically braked bicycle 
ergometer (Ergoline 900) with respiratory gas exchange analysis (Medgraphics, St 
Paul, Minn., US). A ramp protocol comprising an initial period of loadless cycling to 
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permit equilibration was used. A period of active recovery (slow cycling under 
minimal friction load) was commenced after maximal exertion. Heart rate, blood 
pressure, and oxygen saturation were monitored in all children for the duration of the 
test. Peak oxygen uptake (pVO2) and anaerobic threshold were derived from 
respiratory gas analysis during maximal exercise testing. Anaerobic threshold was 
determined by use of the modified V-slope method (161). Peak heart rate, blood 
pressure, and workload achieved were recorded. Predicted values for peak oxygen 
uptake were calculated according to published data in healthy children (162). 
 
2.7 Cardiac catheterization studies with assessment of pulmonary vascular 
resistance 
The majority of cardiac catheterization studies were performed at our institution. All 
patients were anaesthetized and ventilated for the duration of the study to achieve 
stable conditions. 
Cardiac catheterization with pulmonary vascular responsiveness testing was 
performed in a standardized way. Pressures were measured directly using fluid filled 
catheters according to the child’s size, measuring pulmonary artery pressure, and left 
atrial pressure or pulmonary capillary wedge pressure to derive the trans-pulmonary 
pressure gradient.   
In the majority of cardiac catheterizations (all that were performed at Great Ormond 
Street Hospital), the oxygen consumption was measured  – rather than assumed – 
with a mass spectrometer (Amis 2000, Innovision, Odense, Denmark), to achieve 
maximal accuracy under standard anaesthetic conditions. A considerable discrepancy 
between assumed and measured values, which can lead to a false assumption of 
pulmonary artery resistance is reported in children (163).  
 
Pulmonary vascular responsiveness was tested at baseline and in a single second step 
with an increased fraction of inspired oxygen (FiO2 0.65) and nitric oxide (NO 20 
ppm).  
No further measures are taken to limit catheterization time, as in adults short-term 
morbidity has been reported to correlate with duration of general anaesthetic time 
(164). Pulmonary vascular resistance was calculated according the standard 
equations (165).  
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2.8 B-type natriuretic peptide  (BNP) 
Venous blood samples were obtained and BNP measurements were performed using 
the Triage test (Biosite Diagnostics, San Diego, CA)(166) according to the 
manufacturer’s instructions. This test uses a fluorescent-labeled antibody to BNP and 
has a range from 5 to 5000 pg/ml. 
 
2.9 Statistical analysis  
Throughout the thesis, non-normally distributed data are presented as median (with 
interquartile range or centiles), while normally distributed values are given as mean 
and standard deviation (SD). Parameters were tested for normal distribution by the 
Kolmogorov–Smirnov or the D'Agostino-Pearson test. Comparisons between groups 
were made using the Student’s t test, analysis of variance (ANOVA) or Mann–
Whitney U test for continuous variables (depending on the data distribution) or the 
chi-square (χ2) test as for categorical variables. For all analyses a p-value <0.05 was 
considered significant. All tests were performed two-tailed.  Further details on 
specific statistical methods used to analyze data are outlined in the according 
chapters.  
MedCalc Version 11.1.0  (MedCalc Software, Mariakerke, Belgium), StatView 5.0 
(Abacus Concepts, Berkeley, CA, U.S.A.) and R (Version 2.10.1) statistical package 
were used for statistical analysis (167).  
 
2.10 Ethics approval  
Ethics approval was sought for the review of patients’ records and data collection for 
the retrospective studies.  The prospective walk test study in healthy children was 
approved by the local ethics committee and by the Central Office for Research Ethics 
Committee (COREC). 
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3. NON-INVASIVE EVALUATION OF CHILDREN WITH PHT 
 
Introduction 
 
Children with pulmonary hypertension were assessed routinely as described in 
Chapter 2. Detailed studies were carried out on the six-minute walk test, heart rate 
variability, tissue Doppler imaging and B-type natriuretic peptide and the results of 
these studies are presented in this chapter.  
 
 
3.1 SIX-MINUTE WALK TEST AND CARDIOPULMONARY EXERCISE 
TESTING 
 
3.1. NORMAL SIX-MINUTE WALK TEST DISTANCE VALUES FOR 
HEALTHY UK CHILDREN  
 
3.1.1 Background   
The six-minute walk test (6MWT) is the distance a person can walk at a constant, 
uninterrupted, unhurried pace in six minutes. It is a simple method of assessing 
exercise capacity. This test is often used to assess patients with cardiovascular or 
respiratory diseases (168). In addition, it was one of the first exercise modalities 
approved by the U.S. Food and Drug Administration (FDA) as a clinical endpoint for 
prospective clinical trials in patients with pulmonary hypertension (169). 
It has been shown to be an independent predictor of morbidity and mortality in adult 
patients with heart failure, chronic respiratory disease, cystic fibrosis (170,171) and 
idiopathic pulmonary hypertension (135,172). It is particularly useful for longitudinal 
assessment, to monitor response to treatment and to guide therapy (81). 
The major advantages of the 6MWT are that it is easy to perform and can be repeated 
at low cost. The 6MWT is frequently used in children with pulmonary hypertension 
and cystic fibrosis and in those with severe cardiopulmonary diseases being assessed 
for transplantation (170,173,174). 
Despite its frequent use, no normal values for UK children below the age of 12 years 
are available. This study aimed to establish normal values for UK children, who 
underwent the 6MWT in exactly the same fashion, as one would usually apply it to 
PHT patients.  
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3.1.2 Patients and Methods 
There were 328 normal, healthy children (54% male) aged between 4 and 11 years 
included in this study. Most were recruited from two primary schools. In addition 
healthy siblings and relatives of children attending Great Ormond Street Hospital 
were invited to participate. Parents gave informed consent and any children with 
chronic disease were excluded. Children with mild asthma, not on regular 
bronchodilators and not excluded from physical education classes, were accepted as 
normal. All children willingly agreed to perform the 6MWT. Weight, height, gender 
and ethnic background was documented. The vast majority of children included were 
of Caucasian origin. The ethnic distribution was as follows: 
Caucasian n= 272 (83%), Asian/ Asian-Caucasian n= 33 (10%), Afro-Caribbean/ 
Afro-Caribbean-Caucasian n= 23 (7%). 
The test was conducted as described in detail in Chapter 2 according to ATS 
guidelines (159). The data were obtained by three different investigators. When walk 
tests were analysed according to the supervising investigator no significant 
difference in walk test distance could be found, suggesting that there was no relevant 
inter-observer variation. Thus, the data obtained by different investigators were 
pooled. 
 
Statistical analysis   
The relationships between age, height, weight and 6MWT distance were studied by 
univariate and multivariate regression analysis. To assess linearity in scatterplots, the 
Lowess technique (LOcally Weighted Scatterplot Smoother) was used to draw a 
smooth line representing the average value of distance as a function of weight and 
height.  
 
3.1.3 Results 
All children completed the 6MWT.  The number of individuals in each age group, 
the gender distribution, weight, height, body mass index (BMI), heart rate at 
baseline, maximum heart rate, the oxygen saturation at baseline, the minimum 
oxygen saturation and the distance walked in 6 minutes are outlined in Table 3.1.1.  
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Table 3.1.1. Results of the six-minute walk test in the different age groups.  
 
 
Values are presented as mean ± standard deviation. 6MWTD= Six-minute walk test 
distance; BMI= body mass index; bpm= beats per minute, HR= heart rate; SO2= 
transcutaneous oxygen saturation. 
 
 
Height and weight increased linearly (r= 0.9; p<0.0001 and r=0.77, p<0.0001, 
respectively) with age. Body mass indices in all age groups were on average within 
the normal range as outlined by the Center of Disease Control Growth charts for 
Children (175). 
No significant drop of transcutaneous oxygen saturation was observed during the 
6MWT in this cohort.  The mean oxygen saturation was 97-98% at baseline, and the 
minimum saturation was 95-96% during the walk test. The heart rate increased from 
a baseline of 102±19 bpm reaching a plateau of 136±12 bpm after 1-3 minutes 
(Figure 3.1.1). During exercise the heart rate was higher in girls than in boys (Figure 
3.1.1) (p<0.05). 
 
 
Age (years) 4 5 6 7 8 9 10 11 Total 
 
male/female 
 
18/18 
 
21/19 
 
19/21 
 
22/18 
 
27/18 
 
27/22 
 
30/18 
 
15/15 
 
178/150 
          
Weight (Kg) 18±2 21±4 24±5 26±4 30±6 34±7 38±9 41±9 29±9 
Height (cm) 107±4 115±6 121±6 128±5 133±8 139±7 145±8 149±7 130±15 
BMI 16.0±1.3 15.7±1.7 16.5±2.5 16.0±1.8 16.8±2.6 17.8±2.8 17.8±2.8 18.4±3.4 16.9±2.6 
          
SO2 baseline 97±2 97±1 97±2 97±2 97±1 98±2 98±1 98±1 97±2 
SO2 minimum 95±2 96±2 96±2 95±3 95±2 96±2 95±2 96±2 96±2 
HR baseline (bpm) 108±16 109±20 107±17 109±21 99±15 96±18 95±20 98±16 102±19 
Peak HR  (bpm) 139±10 140±13 141±10 142±14 133±10 133±12 130±11 132±13 136±12 
 
         
6MWTD (m) 383±41 420±39 463±40 488±35 483±40 496±53 506±45 512±41 470±59 
Minimum 300 300 380 438 400 395 400 415 300 
Maximum 472 470 600 583 600 600 601 590 601 
          
Centiles (m) 
         
     10 322 367 415 449 440 424 450 453 396 
     25 357 404 434 453 454 454 480 490 435 
     50 390 428 456 479 480 500 515 518 475 
     75 404 450 479 518 508 537 537 540 515 
     90 438 462 502 538 525 562 560 562 544 
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Figure 3.1.1. Heart rate at baseline, during the six-minute walk test and on recovery 
in boys and girls. The heart rate was significantly higher in the girls (mean±standard 
error; *p<0.05).  
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Figure 3.1.2a. The distance walked in six minutes in boys and girls in each age 
group. Data are shown as box-and-whiskers-plots illustrating the median, 25th and 
75th centile (grey box) and 5th and 95th centile. p-values refer to the difference 
between various age groups, having pooled data from both sexes (unpaired t-test).  
 
The mean distance walked increased from 383±41 m at 4 years to 512±41 m at 11 
years, with no significant difference between boys and girls (Figure 3.1.2a, Table 
3.1.1).  The data from both sexes were therefore pooled (Figure 3.1.2b).  
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Figure 3.1.2b. Walk test difference of different age groups. Data are shown as 
histograms and box-and-whiskers-plots illustrating the median, 25th and 75th centile 
(grey box) and 5th and 95th centile.    
 
The distance walked correlated with age (r=0.64, p<0.0001). The mean 6MWT 
distance increased by 37m between the age of 4 and 5 years (p<0.001), by 43 m 
between 5 and 6 years (p<0.001) and by 25 m between 6 and 7 years of age 
(p=0.002). Beyond 7 years of age the distance walked did not increase significantly 
from one year to the next, there was a significant increase however, between 7 and 
11 years of age (p=0.02).  
 
On univariate linear regression analysis the distance walked correlated with weight 
(r=0.51, p<0.0001) and height (r=0.65, p<0.0001) (Figure 3.1.3), as well as age.  
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Figure 3.1.3. Relationship between distance walked in six minutes and height and 
weight. r and p- values were derived for a linear relationship (black, dotted line). The 
blue curve represents the average value of distance as a function of weight and height 
(Lowess technique). The fitted smooth curve shows a form of response that is clearly 
inconsistent with a linear relationship. It suggests that there is an approximate linear 
relationship up to a weight of ~30 kg and a height of ~130 cm. After these points the 
curve gradually merges into a more horizontal line and especially a further increase 
in body weight appears to be widely unrelated to an improvement in six minute walk 
test distance.  
 
 
On multivariate analysis, 44% of the variation in distance walked by the children 
could be accounted for jointly by age, weight and height (r=0.67, p<0.0001). Age 
alone accounted for 41% of the variation (r=0.64, p<0.0001). Between different 
ethnic groups there was no significant difference in the analysis of walk test distance 
corrected for age. 
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3.1.4 Discussion 
The six-minute walk test was established in adult populations to assess capacity to 
exercise, prognosis and response to therapy in PAH. It reflects a person’s ability to 
perform day-to-day activities. However, in highly compromised patients, due to a 
cardiac or respiratory disease, the 6MWT may represent a maximal exercise (176). 
The 6MWT is also used in children with cardiopulmonary disease, but there are few 
data available on normal children. 
The current study establishes normal values for 6WMT distance in healthy British 
children between 4 and 11 years of age. This study describes the increase in distance 
walked with age. No reference values for 6MWT distance have been available in 
younger children, therefore quantification of exercise intolerance in this population 
was largely based on data extrapolated from older individuals, which is likely prone 
to error. From clinical experience, it is apparent that a 6MWT can be, in principle, 
performed by young children, but obviously depends upon the individual child’s 
motivation and coordination. This study illustrates, however, that with 
encouragement and explanation children from the age of four years perform the 
6MWT well. The variation in walk distance in children of 4 and 5 years of age did 
not differ significantly from that observed in the older children.  
 
 This cross-sectional study suggests that there is a rapid increase in the distance 
walked in children aged 4 to 7 years of age with a further slower increase up to 11 
years of age.   
To date normal values for the 6MWT have only been reported in older cohorts. Li 
and colleagues reported normal values in 78 Chinese children aged between 12 and 
16 years of age (177). The mean distance for the whole group was 660 ±58 m, this 
distance being considerably longer than in the 11 year old children (512±41m) 
studied here. Unfortunately values for the individual age groups are not reported; 
given the age of these children the greater distance might be related to an increase in 
height during and after puberty. Chetta et al reported in a Caucasian cohort aged 20-
50 years a mean distance of 593 m for females and 638 m for males (178). For an 
older age group (40-80 years) Enright reported a median walk distance of 494 m for 
women and 576 m for men. After correction for height there was no gender related 
difference, which is in keeping with the findings of the current study (179). In young 
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adults age was not related to 6MWT distance (179-182). In contrast to this, the 
results of the current study in a paediatric cohort suggest that age alone accounts for 
41% of predicted walk test distance variation.  
 
The heart rate recorded in the current study demonstrates that the 6MWT represents 
sub-maximal effort in healthy children. Estimated peak heart rate during maximal 
exercise of children between 4 and 11 years of age would be approximately 210 bpm 
(220bpm-age) (183). Thus the peak heart rate reached by the children included in this 
study was approximately 65% of the normal predicted peak heart rate for age. In the 
population studied here heart rate increased early during the test with a plateau after 
approximately 1-3 minutes. Heart rate during exercise was higher in girls than in 
boys. A similar observation was made by Mahon who described a lower heart rate in 
boys during sub-maximal exercise on a cycle ergometer (184) and by Armstrong, 
investigating cardiovascular responses to sub-maximal treadmill running in children 
between 11 and 13 years. After adjustment for body size, boys had a greater stroke 
volume than girls when exercising at the same level (185). The authors, therefore, 
speculated that girls compensated for the lower stroke volume with a significantly 
higher heart rate.  
 
Knowledge of normal 6MWT distances for children should be helpful in assessing 
the degree of exercise limitation in children with cardiovascular disease. For example 
the 6MWT is commonly used in children with chronic diseases, such as pulmonary 
hypertension to assess response to advanced therapies (79,106). The current data 
shows that an increase in walk distance needs to be interpreted with caution, 
especially in younger children as a physiological increase could easily be 
misinterpreted as a response to medical therapy, while in fact it reflects the 
physiologic effect of growth.  
 
Study limitations 
Only one 6MWT was performed per child. It has been shown, that there might be a 
training effect and a longer distance might be reached on a repeated tests 
(181,186,187). However a high degree of test-retest reliability has recently been 
reported by Li et al in healthy children (177). It has recently been shown in a study of 
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healthy Singaporean adults that 6MWT distance cannot be predicted using reference 
equations derived from adult Caucasian populations (188). The current study 
enrolled children from different ethnic backgrounds, though the majority were of 
Caucasian origin. Although no significant difference could be found between the 
distance walked by the Caucasian children and the other ethnic groups in the current 
study, this limitation should be considered when extrapolating the results of this 
study to children of non-Caucasian origin.  
 
In conclusion, performing a six-minute walk test is feasible and practical in young 
children. This study provides data on normal UK children against which the 
performance of sick children and the response to therapeutic intervention can be 
judged. 
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3.2 COMPARISON BETWEEN SIX-MINUTE WALK TEST DISTANCE AND 
PARAMETERS OF CARDIOPULMONARY EXERCISE TESTING  
 
3.2.1 Background   
The six-minute walk test (6MWT) is the distance a person can walk at a constant, 
uninterrupted, unhurried pace in six minutes. It represents a simple and cost-effective 
method of assessing exercise capacity and is used routinely to assess patients with 
cardiovascular or pulmonary disease (168). It has been demonstrated to be an 
independent predictor of morbidity and mortality in adult patients with heart failure, 
pulmonary disease and IPAH (171),(135,172). At many centres it is used for 
longitudinal assessment of patients with chronic disease, especially to monitor 
response to treatment and to guide therapy (81).  
 
Cardiopulmonary exercise testing (CPET) with metabolic monitoring is regarded by 
many to be the gold-standard modality to assess exercise capacity (189). While the 
6MWT may or may not represents a maximal exercise test, the CPET does represent 
a maximal exercise test and provides additional measures of exercise tolerance and 
disease severity such as peak oxygen consumption (pVO2), oxygen consumption at 
anaerobic threshold (VO2AT) and ventilatory efficiency (VE/VCO2). Despite its 
apparent advantages and the fact that pVO2 predicts prognosis in adult patients with 
PHT (136), the use of CPET as an endpoint for prospective clinical trials in patients 
with pulmonary hypertension is problematic. The alleged disadvantages of CPET as 
compared to the 6MWT are the requirement for technical training for laboratory 
personnel, standardisation of CPET and calibration of the CPET equipment before 
testing (190). 
It has been demonstrated that CPET can be performed safely in paediatric patients 
with PHT (191) but little is known about the relationship between 6MWT distance 
and variables of CPET in children with PAH. 
 
3.2.2 Patients and Methods 
Forty-one consecutive exercise studies were included in this analysis: 15 exercise 
tests in children with idiopathic PAH (IPAH) (mean age 13.0±3.0 years; 9 female), 
18 in children with PAH associated with congenital heart disease other than the 
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Eisenmenger syndrome (mean age 14.8±2.8 years; 7 female; unrepaired heart defects 
n=3, post-repair PAH 15) and 8 in children with the Eisenmenger syndrome (mean 
age 11.8±2.9 years; 4 female). The mean age±standard deviation was 13.5±3.0 years. 
Of those with IPAH, 35% were on monotherapy and 65% were on combination 
therapy. Children with congenital heart disease (without the Eisenmenger Syndrome) 
were treated with bosentan monotherapy (40%) or combination therapy (30%). Of 
those with the Eisenmenger syndrome, 4 children were on either Bosentan or 
Sildenafil monotherapy, and one other received both drugs. All children underwent 
both tests without complications. Cardiopulmonary exercise testing and 6MWT were 
performed as described in Chapter 2. 
Predicted values for 6MWT distance in boys and girls were calculated based on 
gender, age and height according to published data for healthy Caucasian children 
and adolescents (160). All patients underwent exercise testing as part of their clinical 
follow-up and provided informed consent before exercise testing.  
 
Statistical Analysis  
Relationships between variables of 6MWT and CPET were studied using Pearson 
correlation coefficient (after testing for normal distribution). To explore the 
relationship between variables of 6MWT-distance and CPET in scatterplots the 
Lowess technique (LOcally WEighted Scatterplot Smoother) using a local linear 
polynomial fit to provide a smooth line describing the association between 6MWT-
distance and pVO2 was used (192,193). In addition, a parametric model using 
fractional polynomials was fitted to the data using Generalized Additive Models for 
Location Scale and Shape (GAMLSS) in R as described by Rigby and Stasinopoulos 
(194). To describe the change in heart rate and oxygen saturation during 6MWT a 
linear mixed effects model with higher-than-linear (a+x+x3/2) terms to describe the 
observed shapes and to take into account the repeated measurements structure of the 
data was fitted using the nlme package in R (195). To study the optimal cut-off value 
for 6MWT-distance in predicting pVO2, R2-values were calculated for the linear 
correlation between 6MWT-distance and pVO2 for a subset of 6MWT-distances 
(lowest value to increasing cut-off) and the R2-values for different cut-off values of 
6MWT-distance were  
plotted. 
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3.2.3 Results 
Reduced exercise capacity in children with PAH 
Children with pulmonary hypertension had a reduced exercise capacity as judged by 
6MWT and CPET. Peak VO2 was reduced to 31.5±12.2% of the predicted value (p < 
0.0001) (Figure 3.2.1).  
 
 
Figure 3.2.1. Predicted and measured values for 6 minute walk test distance and 
peak oxygen consumption (peak VO2) in children with PAH. Markers indicate 95% 
confidence interval for the mean. Comparisons between groups were performed 
using Mann-Whitney tests. Reference values were calculated according to published 
data (160,162). 
 
The 6MWT distance was also reduced to 47.7±16.7% of predicted (p < 0.0001). In 
fact, none of the studied children achieved 80% of the 6MWT value predicted for 
healthy children. Interestingly, no significant difference in 6MWT distance could be 
found between children in WHO class 2 or 3 (325±109 vs. 304±132 m, respectively; 
p = 0.67). Nor was there a significant difference in pVO2 between WHO class 2 or 3 
(22.5±6.5 vs. 20.5±6.4 ml/kg/min in WHO class 2 and 3, respectively; p = 0.39). 
These observations illustrate the limitations of assessing exercise tolerance based on 
patients’ subjective physical capacity. The 6MWT distance was lowest in the 
Eisenmenger population (255±132 m; 39.2±21.1% predicted 6MWT distance) 
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compared to patients with IPAH (332±110 m; 50.2±16.0% predicted 6MWT 
distance) and PAH associated with congenital heart disease other than the 
Eisenmenger syndrome (336±102 m, 49.4±14.7% predicted 6MWT distance) but the 
differences were not statistically significant.  
Similarly, patients with the Eisenmenger syndrome (16.8±5.8 ml/kg/min) had a 
significantly lower value for pVO2 compared to patients with PAH associated with 
other forms of congenital heart disease (23.3±6.7 ml/kg/min, p = 0.03) and the mean 
value was lower, although not statistically significant, than in those with IPAH 
(20.2±5.6 ml/kg/min, p = 0.12). Percentage predicted pVO2 was also lower in the 
Eisenmenger group (24.3±9.7 %) compared to patients with either PAH associated 
with congenital heart disease other than the Eisenmenger syndrome (33.6±12.2 %, p 
= 0.07) or idiopathic PAH (32.8±12.6 %, p = 0.12). 
 
Correlations between variables of CPET and 6MWT 
Both the pVO2 and the oxygen consumption at anaerobic threshold (VO2AT) 
correlated with the 6MWT distance (r = 0.49; p = 0.001 and r = 0.40, p = 0.01, 
respectively), and an inverse correlation was found between VE/VCO2 at anaerobic 
threshold and the 6MWT distance (r = -0.43; p = 0.005).   
However, when the relationship between the 6MWT distance and pVO2 was 
investigated further using locally-weighted polynomial regression (lowess) it became 
apparent that a linear correlation between 6MWT distance and pVO2 existed only at 
low levels of exercise capacity.  
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Figure 3.2.2. Locally-weighted polynomial regression (lowess – black curve) with 
and without exclusion of an outlier (†) showing a close to linear association between 
6 minute walk test distance and peak oxygen consumption (peak VO2) up to a 
6MWT distance of approx. 300 m or 20 ml/kg/min with a plateau-phenomenon 
thereafter. In addition, a parametric model using fractional polynomials was fitted to 
the data (red curve) using Generalized Additive Models for Location Scale and 
Shape (GAMLSS) in R as described by Rigby and Stasinopoulos (194).  
 
 
As illustrated in Figure 3.2.2 there appeared to be a close to linear association 
between 6MWT distance and pVO2 up to a 6MWT distance of approx. 300 m or 20 
ml/kg/min, respectively. Visually, there appeared to be a “ceiling-effect” of 6MWT 
distance for higher values of pVO2. 
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Figure 3.2.3. Plot of calculated R2-values for the linear correlation between 6-minute 
walk test (6MWT)-distance and peak oxygen consumption (pVO2) for a subset of 
6MWT-distances (lowest value to increasing cut-off) against different cut-off values 
of 6MWT-distance. The plot supports the notion that there is a relevant reduction in 
the percentage of the variation of pVO2 explained by 6MWT-distance around a cut-
off value of 300 metres and this is in agreement with the impression on visual 
inspection of the data. The red dotted line represents the result of a locally-weighted 
polynomial regression (lowess). 
 
Based on visual inspection of the relationship between pVO2 and 6MWT, as well as 
based on R2 maximization (Figure 3.2.3) a cut-off value of 300 m was chosen to 
further investigate the relationship between pVO2 and 6MWT below and above this 
value.  
This cut-off value is in agreement with data published in adult heart failure patients, 
dividing patients in those with maximal and sub-maximal exercise and identifying 
patients with adverse outcome (176). Using this cut-off value confirmed a significant 
relationship between the pVO2 and 6MWT distance up to a distance of 300m, finding 
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that the 6MWT distance accounted for 71% of the variation in pVO2 when the 
6MWT distance < 300 m, while there was hardly any association between 6MWT 
distance and pVO2 at higher levels of 6MWT distance (Figure 3.2.4). In fact, when 
one apparent outlier (the child with the highest combination of 6MWT distance and 
pVO2 and the highest residual value on correlation analysis – marked with † in 
Figure 3.2.2) was excluded no significant association between 6MWT distance and 
pVO2 was found for patients with a 6MWT distance > 300 m (p = 0.30). 
 
 
Figure 3.2.4. Linear regression comparing the association between 6 minute walk 
test distance and peak oxygen consumption (peak VO2) for patients with a 6 minute 
walk test distance below and above 300 m separately. 
 
 
Similar differences were found for VO2AT (p = 0.046 [R2 = 0.34] for a 6MWT 
distance < 300 m and p = 0.20 [R2 = 0.07] for a 6MWT distance > 300 m) and for 
VE/VCO2 at anaerobic threshold (p = 0.02 [R2 = 0.41] for a 6MWT distance < 300 m 
and p = 0.90 [R2 < 0.01] for a 6MWT distance > 300 m).   
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Does the 6MWT represent a maximal exercise test in patients with PAH? 
To further investigate whether the 6MWT distance represents a measure of maximal 
exercise capacity in children with PAH we compared maximal heart rate during 
CPET and 6MWT.  
 
 
Figure 3.2.5. Heart rate (HR) profile during 6 minute walk test (6MWT) and 
maximal heart rate during cardiopulmonary exercise testing (CPET) in children with 
idiopathic pulmonary hypertension, pulmonary hypertension associated with 
congenital heart disease other than the Eisenmenger syndrom (“Associated PAH”) 
and Eisenmenger syndrome during 6 minute walk test and cardiopulmonary exercise 
testing. Symbols and error bars indicate mean ± standard deviation. To describe the 
change in heart rate during 6MWT a linear mixed effects model with higher-than-
linear (a+x+x3/2) terms to describe the observed shapes and to take into account the 
repeated measurements structure of the data was fitted using the nlme package in R 
(red dotted lines) (195): Curve 1: HR=95.7+15.8*t-.4.3*t1.5, p<0.002 for all 
coefficients; curve 2: HR=87.3+17.9*t-5.2*t1.5, p<0.0001 for all coefficients; curve 
3: HR=79.2+15.9*t-4.9*t1.5, p<0.0001 for all coefficients. t=time in minutes. 
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As illustrated in Figure 3.2.5, maximal heart rate during CPET was significantly 
higher in the entire patient cohort (152±24 vs. 120±17 /min; p < 0.0001), and in all 
three individual patient-subgroups (p-value between 0.0002 and 0.01) compared to 
maximal heart rate during 6MWT, supporting the notion that the 6MWT represents a 
sub-maximal exercise test. Furthermore, within the Eisenmenger population the 
minimal oxygen saturation recorded during exercise testing was lower during CPET 
compared to the 6MWT, although there was little difference in minimal oxygen 
saturation between the two tests in children with IPAH and other congenital heart 
disease associated pulmonary hypertension (Figure 3.2.6).  
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Figure 3.2.6. Transcutaneous oxygen saturation (SO2) in children with idiopathic 
pulmonary hypertension, pulmonary hypertension associated with congenital heart 
disease (“Associated PAH”) and the Eisenmenger syndrome during the  6 minute 
walk test and cardiopulmonary exercise testing (CPET). Note that minimal 
transcutaneous oxygen saturation in Eisenmenger patients is lower during CPET 
compared to the 6 minute walk test. Symbols and error bars indicate mean ± standard 
deviation. To describe the change in SO2 during 6MWT a linear mixed effects model 
with higher-than-linear (a+x+x3/2) terms to describe the observed shapes and to take 
into account the repeated measurements structure of the data was fitted using the 
nlme package in R (red dotted lines) (195): Curve 1: SO2=95.8-4.5*t+1.4*t1.5, 
p<0.01 for all coefficients; curve 2: SO2=92.4-4.0*t+1.4*t1.5, p<0.0001 for all 
coefficients; curve 3: SO2=76.5-14.9*t+4.9*t1.5, p<0.0001 for all coefficients. 
t=time in minutes. 
 
 
To further investigate the relationship between maximal heart rate during CPET and 
6MWT the difference between these two variables was calculated for each individual 
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patient. Correlating pVO2 with the heart rate difference between CPET and 6MWT 
revealed a close correlation between these variables as shown in Figure 3.2.5 (p = 
0.0004; r = 0.53). While some patients with a pVO2<20 ml/kg/min had a similar or 
even lower maximal heart rate during CPET compared to 6MWT all children with a 
pVO2>20 ml/kg/min exhibited higher maximal heart rates during CPET compared to 
6MWT, consistent with the notion that the 6MWT distance represents a maximal 
exercise test in sicker children while it is a marker of sub-maximal exercise capacity 
in less compromised patients (Figure 3.2.7).   
 
 
 
Figure 3.2.7. Scatterplot exploring the relationship between the difference in 
maximal heart rate during cardiopulmonary exercise testing (CPET) and 6 minute 
walk test (6MWT). The plot illustrates that while some patients with a peak oxygen 
consumption (pVO2) below 20 ml/kg/min had similar or even lower heart rates 
during CPET compared to the 6 minute walk test (left lower quadrant), patients with 
a pVO2 > 20 ml/kg/min had consistenly higher heart rates during CPET compared to 
the 6 minute walk test and the difference in heart rate increased with increasing 
exercise tolerance (right upper quadrant). 
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3.2.4 Discussion 
 
This study shows that children with PAH have a markedly depressed exercise 
capacity. In children with a 6MWT distance below ~ 300 meters or a pVO2 below ~ 
20 ml/kg/min a close correlation was found between measures of exercise capacity 
derived from CPET and the 6MWT distance. In contrast, there was a much weaker, if 
any, association between these assessments of exercise capacity in less compromised 
patients. Therefore, it appears that the 6MWT distance fails to reflect maximal 
exercise tolerance in less impaired children with PAH and that CPET may be a 
useful adjunct in the comprehensive assessment of patients with a 6MWT distance 
above 300 meters.    
 
Peak oxygen consumption is an established and reliable measure of exercise 
intolerance and is widely employed in the assessment of adult  patients with 
congenital heart disease and PAH (157,196). In the present study a significantly 
reduced pVO2 and 6MWT distance was seen in children with PAH compared to 
reference values derived from healthy children of similar age (160). These findings 
are in keeping with data obtained in similar studies carried out on adult patients with 
PAH (106,135,197,198). However, there is little data available on the 6MWT 
distance and especially on CPET in children with PAH. As a consequence, 
considerable controversy exists regarding the merits of performing CPET in these 
children. While the 6MWT is easy to perform and can be repeated at low cost, CPET 
with metabolic monitoring requires expensive equipment, technical expertise and 
training of the subject. It does however, provide additional objective measures of 
exercise capacity such as oxygen uptake and ventilatory efficiency, which can be 
regarded a surrogate variables of pulmonary blood flow (189,199). In addition, VO2 
at anaerobic threshold and markers of ventilatory efficiency can be calculated based 
on CPET. A modest correlation between 6MWT distance and VE/VCO2 at anaerobic 
threshold – a parameter of ventilatory efficiency – was found in the current study. 
Recently, measures of ventilatory efficiency such as VE/VCO2 at anaerobic threshold 
and the VE/VCO2-slope have been found to be related to prognosis in various adult 
cardiovascular cohorts (196,200-203). Conceptually these measures are appealing 
due to their robustness and the fact that they are independent of patient effort. In fact, 
61 
 
 
studies in adult patients with congenital heart disease and congestive heart failure 
have established that VE/VCO2-slope is superior to pVO2 in predicting prognosis 
(189,200). Whether these parameters relate to prognosis in children with PAH as 
they do in adults with PAH and without a persistent foramen ovale (136) remains to 
be established. In patients with right-to-left shunting at rest or during exercise the 
value of parameters of ventilatory efficiency may be limited. For example, 
parameters of ventilatory efficiency do not carry important prognostic information in 
cyanotic patients, such as patients with Eisenmenger syndrome, for reasons discussed 
in detail by Dimopoulos et al. (196). Briefly, it has been speculated that in cyanotic 
patients the limitation to exercise does not arise from poor ventricular function, 
vascular remodelling or autonomic dysfunction but rather from exercise induced 
increase in right-to-left shunting. The limitation of exercise capacity is, therefore, 
below that which would have been set by the usual pathophysiologic abnormalities 
that in turn are responsible for the impaired prognosis. Therefore, survival prospects 
are not as poor as would be predicted from the exercise capacity (204). However, in 
selected children with PAH, parameters of ventilatory efficiency may be useful in 
assessing disease severity, for assessing response to drug therapy and for 
consideration as potential endpoints in future trials on drugs used to treat PAH. 
 
Remarkably, the correlation coefficient between 6MWT distance and pVO2 in the 
current paediatric study (0.49) is almost identical with that published in a large 
cohort of adult patients who underwent exercise testing as part of a multicentre 
clinical trial evaluating sitaxsentan – an endothelin receptor antagonist (r=0.483) 
(190). Oudiz and colleagues suggested that the correlation was modest at least in part 
due to lack of standardization of CPET and a different level of experience at centres 
participating in this drug trial. The current study demonstrates that even when all 
tests are performed at a single institution using a standardized protocol, skilled 
technicians and properly calibrated CPET equipment the correlation between the 
6MWT distance and pVO2 is only modest and the 6MWT distance cannot be used as 
a surrogate for pVO2.  
 
The heart rate recorded during the 6MWT in the current study demonstrates that the 
6MWT represents sub-maximal effort in many children. Estimated peak heart rate 
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during maximal exercise of children with an average age of 13 years would be 
approximately 195 bpm  (220 bpm minus age) (183). Thus the peak heart rate in the 
current study was approximately 60% of the normal predicted peak heart rate for age.  
In contrast, the maximal heart rate during CPET averaged 152 bpm, representing 
78% of the predicted value. As illustrated by Figure 3.2.5 heart rate increased early 
during the 6 minute walk test with a plateau after 1-3 minutes consistent with the 
concept of a steady-state metabolism reached after this point in analogy to patients 
performing a sub-maximal test or a CPET below the anaerobic threshold (205). 
Furthermore, Figure 3.2.7 illustrates that heart rate difference between the CPET and 
the 6MWT was biggest in children with high values of pVO2, supporting the notion 
that the 6MWT represents a sub-maximal test in this setting with lower peak heart 
rate.  
 
Clinical Implications 
Knowing how far a child with PAH can walk in six minutes is helpful in assessing 
the degree of exercise limitation, and in evaluating prognosis and response to 
medical therapy. Although changes in the 6MWT distance are routinely used as an 
end-point in clinical trials of PAH drugs and provide valuable information when 
managing children with PAH, this study suggests that CPET should be considered as 
a complimentary test in less impaired children with PAH with a 6MWT distance of 
more than 300 m, because the 6MWT distance appears to represent a sub-maximal 
test in these children.  None of the patients included in the current study suffered any 
adverse events during either CPET or performing the 6MWT. This suggests that 
exercise testing is safe even in children with PAH and this is in agreement with 
previous studies in adult patients with congenital heart disease and pulmonary 
hypertension including patients with IPAH and with the Eisenmenger syndrome 
(157,189). Exercise tests in children with PAH should, however, be supervised by a 
trained exercise physiologist and a physician with experience managing children 
with PAH should be present at all times. The UKSPHC operates a policy of starting 
performing a regular 6MWT from the age of approximately 4 years onwards. 
Initially these tests are performed to accustom the children to doing a 6MWT. Most 
children can perform a 6MWT from the age of 5-6 years reliably, although other 
investigators have recommended that walk tests in children with PAH should not be 
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performed below the age of 7 years for safety reasons (206). In the present study 
cardiopulmonary exercise tests were performed on a bicycle ergometer and this 
requires a minimal height of 140 cm.  
 
There appears to be no doubt that in healthy individuals the 6MWT represents a sub-
maximal exercise test, mainly reflecting the patient’s ability to perform day to day 
activities. Roul and colleagues, investigating adult patients with heart failure, 
suggested that in highly compromised patients the 6MWT may represent a maximal 
exercise test (176). As in the present paediatric study, the 6MWT distance in adults 
in heart failure correlated with pVO2 only when the 6MWT distance was less than 
300 m. In addition, the 6MWT distance was predictive of survival in heart failure 
patients walking less than 300 m in 6 minutes. The present study establishes for the 
first time that pVO2 relates closely to the 6MWT distance in children with PAH who 
have a poor exercise capacity (i.e. a 6MWT distance below approx. 300 m or a pVO2 
below approx. 20 ml/kg/min). For higher values of 6MWT distance this association 
is weak or absent. Therefore when assessing the effect of medical therapies on 
exercise capacity in children with higher exercise capacity a CPET should be the 
preferred exercise testing modality. 
 
Study limitations 
Predicted values for the 6MWT distance were derived from a study published 
recently by Geiger (160) and colleagues who used a measuring wheel to record the 
walking distance. This represents a slight modification from conventional practice. It 
is difficult to know whether and to what extent this would have influenced their 
results. Future studies will focus on studying exercise capacity in PAH of different 
aetiologies and attempting to correlate performance with outcome. This was a cross-
sectional analysis and further longitudinal studies are required to assess whether 
serial CPET or 6MWT represent effective efficacy endpoint for pulmonary 
hypertension trials. Further prospective studies are clearly required to assess whether 
CPET alone or in combination with the 6MWT distance is superior to the 6MWT 
distance in guiding therapy and assessing prognosis in children in PAH. 
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In conclusion, performing 6-minute walk tests and CPET in children with PAH is 
feasible and safe. The 6MWT reflects maximal exercise capacity in PAH children 
with a 6MWT distance of less than 300m or a pVO2 of less than 20 ml/kg/min. 
CPET should be considered as a complimentary test in children whose exercise 
tolerance is well above these thresholds.  
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3.3 HEART RATE VARIABILITY  
 
3.3.1 Background 
Little is known about heart rate variability (HRV) in patients with pulmonary 
hypertension. Autonomic dysfunction is however thought to be an important feature 
of severe PAH and has been described in adult patients with idiopathic PAH (IPAH) 
and with the Eisenmenger syndrome.  Two studies have reported an increase in 
sympathetic tone (207,208) and an early loss of circadian rhythm has been 
demonstrated (208). Folino reported lower values of HRV in 9 adults with IPAH 
compared to healthy controls (207). An abnormal HRV has been shown to be a 
powerful and independent predictor of adverse prognosis in paediatric patients with 
congenital heart disease without PAH (209-211), adults with ischaemic heart disease 
(212-216) and in the general population (217). HRV data can be derived from 
conventional Holter-ECG recordings, which are frequently performed as part of 
routine care in patients with PAH.  
The prognostic value of impaired cardiac autonomic nervous activity in children with 
PAH is unknown. The objective of the current study was to assess the prognostic 
value of HRV for risk stratification in children with PAH.  
 
3.3.2 Patients and Methods 
Forty-seven children (27 male; mean age 11.4±5.5 years) with PAH were included in 
this retrospective study [IPAH n=21, associated PAH (APAH) n=26].  Cases of 
APAH included 21 with congenital heart disease, 4 with chronic or interstitial lung 
disease and 1 child with vasculitis. The children underwent Holter-ECG for a variety 
of reasons. These included a history of syncope in 11 children, presyncopal attacks in 
6, uncertain chest pain in 5, palpitations in 6, an increase in shortness of breath and 
reduction in exercise tolerance in 8, and an abnormal 12-lead ECG (bradycardia, 
ventricular ectopics) in 7 children. In 4 other patients Holter ECG recording formed a 
routine part of the assessment for transplantation. Holter monitoring was performed 
for a mean duration of 23.76±2.0 hours (Reynolds Pathfinder Software, Hertford, 
UK). Parameters of heart rate variability were determined from the recordings, 
including SDNN (standard deviation of all normal-to-normal intervals), SDANN 
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(standard deviation of mean values for all normal-to-normal intervals over 5 minutes) 
and RMSSD (square root of the mean square differences of successive RR intervals).  
The clinical features assessed included WHO Functional Class, a six-minute walk 
(6MWT) (total distance walked and minimal arterial oxygen saturation during 
exercise), semi-quantitative echocardiographic study of right ventricular function 
(normal=1b; mildly=2; moderately=3; severely=4 impaired) [(157,218)], and at 
cardiac catheterization, the mean pulmonary artery pressure (PAP), pulmonary 
vascular resistance index (PVRI) at baseline and following vasodilator testing.  
Baseline demographic data are shown in Table 3.3.1.  
 
Table 3.3.1.   Selected baseline characteristics 
 
Characteristic All patients Dead or Tx  Alive P  Value 
 (n=47) (n=17) (n=30)  
     
Age (years)    11.4 ± 5.5 10.2 ± 6.1 12.1 ± 5.0 0.35 
Gender male / female 27/20 12/5 15/15 0.29 
% IPAH patients 44.7 % 58.8 % 36.7 % 0.24 
     
WHO II / III / IV (n)  17 / 29 / 1 1 / 15 / 1 16 / 14 / 0 0.003 
6MWT distance (m) 292.2±123.4 182.3±67.6 351.7±104.6 <0.0001 
History of syncope 26.1 % 27.5 % 23.5 % 1.00 
     
RV function 1 / 2 / 3 / 4† 9 / 19 / 14 / 
4 
0 / 3 / 10 / 3 9 / 16 / 4 / 1 0.0003 
RV dilatation 1 / 2 / 3 / 4† 1 / 9 / 19 / 
16 
0 / 1 / 9 / 7 1 / 8 / 10 / 9 0.23 
RV hypertrophy 1 / 2 / 3 / 4† 13 / 28 / 5 / 
1 
1 / 13 / 3 / 0 12 / 15 / 2 / 
1 
0.054 
     
Mean PA pressure (mmHg) 58.4±23.2 61.6±15.5 56.3±27.3 0.33 
PVR baseline (WU) 22.1±13.1 26.8±14.3 19.2±11.6 0.38 
PVR NO/FiO2 0.6 (WU) 17.9±2.0 23.0±13.7 14.8±9.8 0.16 
Right atrial pressure (mmHg) 8.3±3.8 6.8±1.8 9.0±4.4 0.31 
     
 
p-values (Mann-Whitney U-test/ Chi-square test) for comparison between event-free 
survivors and patients who died or underwent transplantation. FiO2 = inspiratory 
oxygen concentration; HRV = heart rate variability; NO = nitric oxide; PVR = 
pulmonary vascular resistance; RMSSD = square root of the mean square differences 
of successive RR intervals; SDANN = standard deviation of mean values for all 
normal-to-normal intervals over 5 minutes; SDNN = standard deviation of all 
normal-to-normal intervals; Tx = transplantation. WHO = World Health 
Organization functional class; WU = Wood units (=80 dyn·s·cm-5). † indices of right 
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ventricular hypertrophy, size and function were quantified semi-quantitatively as: 
normal=1; mildly=2; moderately=3; severely=4 impaired.  Plus-minus values are 
mean ± standard deviation 
 
After a period of follow up the patients were divided into two groups, those still alive 
and those who died or had had a lung or heart-lung transplant. Data from all the 
children were analysed and then data from those with IPAH and APAH were 
analysed separately.  
 
Statistics  
To compare different predictive values, receiver operating curve analysis (ROC) was 
performed and areas under the curve (AUC) for sensitivity and specificity were 
constructed. Kaplan-Meier cumulative survival plots were constructed to illustrate 
the results.  The relationship between co- variables and survival was initially studied 
by univariate Cox proportional hazard analysis. Significant parameters were 
subsequently included into bivariate Cox proportional hazard models in a stepwise 
forward selection procedure. The hazard ratio with 95% confidence interval (CI) and 
p-values are presented. Hazard ratios for continuous variables apply per unit of the 
analysed variable. 
 
 
3.3.3 Results  
The mean follow up period after Holter-ECG recording was 19±11.5 months (1.8-
49.1 months). During this time ten children died (4 with IPAH), and seven were 
successfully transplanted (6 with IPAH). Two of those who died had been listed for 
transplantation, both with IPAH. Death or transplantation was used as the combined 
endpoint (10 IPAH, 7 APAH). All 47 children were on advanced therapies for the 
treatment of pulmonary arterial hypertension. None of the patients received 
antiarrhythmic drugs. 
For the whole group, the children who died or underwent transplantation had 
significantly lower values for SDNN, SDANN and RMSSD than the survivors 
(Table 3.3.2, Figure 3.3.1).  
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Figure 3.3.1 Box and whiskers plot diagram with parameters of HRV (SDANN, 
SDNN and RMSSD) of patients who died or were transplanted versus the event-free 
survivors. 
 
When subdivided into patients with IPAH or APAH, lower values were seen in 
patients who died or underwent transplantation in both groups (Table 3.3.2).   
 
Parameters of HRV were not significantly different between boys and girls and no 
correlation with patient age was found (Table 1). All parameters of HRV were 
significantly lower in children in WHO Functional Class III than Class II (SDANN: 
87.5±43.3 vs. 139.4±62.1; p=0.002; SDNN: 93.1±45.3 vs 157.4±63.8; p=0.0005; 
RMSSD: 32.3±28.6 vs 56.9±34.3; p=0.004). The HRV also decreased as 6MWT 
distance decreased: r=0.551; p=0.0009, r=0.610; p=0.0003, r=0.529; p=0.0015 for 
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SDANN, SDNN and SDNN respectively.  Correlation coefficients between 6MWT 
and HRV were better in IPAH than in the whole group of 47 children:  r=0.716, 
p=0.0008; r=0.814, p=0.0008 and r=0.864, p=0.0004 in SDANN, SDNN and SDNN 
respectively (Figure 3.2.2).  
 
 
 
 
Figure 3.3.2 Correlation of SDANN and 6MWT for patients with APAH and IPAH. 
 
 
Parameters of HRV did not correlate with either the semi-quantitative assessment of 
right ventricular function or the haemodynamic findings. Nor did any HRV 
parameter correlate with the occurrence of either supraventricular (median 2.0, IQR 
0-31.5) or ventricular ectopic beats (median 5.0, IQR 0-71.5). 
On univariate Cox-proportional-hazards analysis, for the whole group all parameters 
of HRV predicted death or need for transplantation (p<0.01 for all) (Table 3.3.3). 
This was also true of the IPAH subgroup, (p<0.005) but in the APAH subgroup only 
SDANN was related to the endpoint (p=0.037). Considering mortality alone, 
SDANN and SDNN were predictive for the whole group (p<0.01). In addition, WHO 
functional class, six-minute walk test distance, echocardiographic assessment of right 
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ventricular hypertrophy and function and PVRI at baseline and on vasodilator testing 
also predicted the combined end point (Table 3.3.3). The frequency of ventricular 
and supraventricular ectopic beats was not related to outcome in the whole group, 
IPAH or APAH, nor the arterial oxygen saturation at rest or history of syncope 
(Table 3.3.3). 
Receiver-operating characteristics (ROC) curve analysis demonstrated that all three 
parameters of HRV were significantly related to the combined endpoint (SDANN 
[ms] 0.822 [95% CI 0.682-0.918], SDNN [ms] 0.784 [95% CI 0.639-0.890], RMSSD 
[ms] 0.666 [95% CI 0.514-0.797]).  
As SDANN, SDNN and RMSSD correlated with each other (SDANN vs SDNN 
r=0.983, p<0.0001; SDANN vs RMSSD r=0.656, P<0.0001; SDNN vs RMSSD 
r=0.714, P<0.0001) and provide similar information we used SDANN (having the 
greatest AUC) for all subsequent analyses. A cut-off value (representing highest 
sensitivity and specificity) of 112 ms was identified as being the best predictor of 
patients who met the endpoint criteria, both for the whole patient group  and for the 
IPAH subgroup (entire group: Sensitivity 94.1%, specificity 63.3%; IPAH: 
Sensitivity 90.0%, specificity 72.7%). For the whole group, patients with a SDANN-
value <112 ms had a 5.8 fold increased risk of death/transplantation (event free 
survival at 24 months: 41.7% vs. 90.5% in those >112ms); p=0.008) and a 7.2 fold 
increased risk of death (survival at 24 months: 57.9%vs. 95.0%; p=0.03) (Figure 
3.3.3). 
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Figure 3.3.3  Kaplan Meier curves for combined endpoint and survival alone. 
 
 
Extending the analysis, bivariate Cox-proportional-hazards analysis (Table 3.3.4) 
showed that SDANN was a superior predictor of the end-point than either WHO 
Functional Class or the PVRI, both at baseline and on vasodilator testing. It was 
comparable to the echocardiographic assessment of right ventricular function and 
hypertrophy. Only the 6MWT distance was superior to SDANN for prediction of 
death or transplantation in the whole group. Findings in the IPAH subgroup were 
similar but in addition to the 6MWT, the PVRI on vasodilator testing was also 
superior to SDANN as a prognostic marker (Table 3.3.4). In the APAH population, 
WHO functional class was a slightly better predictor of the end-point than SDANN 
but the 6MWT was not. The limited prognostic value of the 6MWT in those with 
APAH may be due to the lower number of deaths and transplantations in this 
subgroup. SDANN predicted outcome independently of right ventricular hypertrophy 
and PVRI at baseline and with vasodilator testing (Table 3.3.4).  
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Table 3.3.2 Comparison between parameters of heart rate variability between patients who died or underwent transplantation 
 SDANN SDNN RMSSD 
 Dead or Tx  Alive p  Value Dead or Tx  Alive p  Value Dead or Tx  Alive p  Value 
          
All patients (ms) 70.7±30.9 119.2±57.2 0.0001 79.5±30.5 129.9±63.6 0.0002 22.3±11.7 47.7±34.5 0.0001 
IPAH (ms) 68.9±34.1 132.7±45.9 0.001 73.4±33.3 149.2±58.6 0.0008 13.9±6.0 49.3±32.5 0.002 
APH (ms) 66.6±27.6 124.1±60.9 0.020 79.4±28.9 132.6±64.2 0.024 33.3±14.8 52.6±38.0 0.285 
 
 (Tx) and event-free survivors. P-values (Mann-Whitney U-test/ Chi-square test) for comparison between event-free survivors and 
patients who died or underwent transplantation. APH = pulmonary hypertension associated with congenital heart disease; IPAH = 
idiopathic pulmonary hypertension; RMSSD = square root of the mean square differences of successive RR intervals; SDANN = 
standard deviation of mean values for all normal-to-normal intervals over 5 minutes; SDNN = standard deviation of all normal-to-
normal intervals. 
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Table 3.3.3 Univariate predictors of death or need for transplantation in all children.  
Variable Hazard Ratio  
(95% confidence 
interval) 
p value χ2 Value 
    
Parameters of HRV   
SDANN (ms) 0.974 (0.958 – 0.990) 0.002 10.01 
SDNN (ms) 0.980 (0.968 – 0.992) 0.002 10.05 
RMSSD (ms) 0.956 (0.925 – 0.988) 0.008 7.03 
    
Parameters of functional 
capacity 
   
Six-minute walk test distance 0.986 (0.979 – 0.994) 0.0006 11.67 
WHO class 3 (vs. WHO 2) 10.790 (1.438 – 80.947) 0.02 5.24 
  
 
 
Echocardiographic parameters    
RV dilatation † 1.474 (0.786 – 2.763) 0.23 1.45 
RV hypertrophy † 3.088 (1.332 – 7.164) 0.009 6.83 
RV function † 3.929 (2.025 – 7.621) 0.0001 16.22 
    
Haemodynamic parameters    
Mean PA pressure (mmHg) 1.012 (0.991 – 1.033) 0.28 1.18 
PVR baseline (WU) 1.055 (1.008 – 1.105) 0.021 5.30 
PVR NO/FiO2 0.6 (WU) 1.061 (1.011 – 1.113) 0.019 5.72 
Right atrial pressure (mmHg) 0.711 (0.416 – 1.096) 0.12 2.36 
    
Other parameters    
Arterial oxygen saturation (%) 0.993 (0.928 – 1.063) 0.84 0.41 
Clinical history of syncope 0.937 (0.307 – 2.861) 0.94 0.13 
Supraventricular ectopic beats 0.465 (0.205 – 1.056) 0.07 3.31 
Ventricular ectopic beats  0.736 (0.386 – 1.404) 0.36 0.86 
    
 
FiO2 = inspiratory oxygen concentration; HRV = heart rate variability; NO = nitric 
oxide; PVR = pulmonary vascular resistance; RMSSD = square root of the mean 
square differences of successive RR intervals; SDANN = standard deviation of mean 
values for all normal-to-normal intervals over 5 minutes; SDNN = standard deviation 
of all normal-to-normal intervals; WHO = World Health Organization functional 
class. WU = Wood units (=80 dyn·s·cm-5). † indices of right ventricular hypertrophy, 
size and function were quantified semi-quantitatively as normal=1; mildly=2; 
moderately=3; severely=4 impaired. 
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Table 3.3.4 Bivariate predictors of death or need for transplantation in children.  
 All patients IPAH APAH 
Variable Hazard Ratio  
(95% confidence interval) 
P value Hazard Ratio  
(95% confidence interval) 
P value Hazard Ratio  
(95% confidence interval) 
P value 
       
SDANN (ms) - - - - * - 
6 MWT distance 0.986 (0.979 – 0.994) 0.0006 0.981 (0.966 – 0.995) 0.01 * - 
       
SDANN (ms) 0.973 (0.957 – 0.990) 0.0018 0.975 (0.955 – 0.995) 0.0013 - - 
WHO class 3 (vs. 2) - - - - 20.21 (1.75 – 234.4) 0.017 
       
SDANN (ms) 0.975 (0.959 – 0.990) 0.0014 0.975 (0.955 – 0.995) 0.0026 0.933 (0.888 – 0.980) 0.006 
RV hypertrophy† 2.582 (1.204 – 5.539) 0.015 - - 14.38 (1.92 – 109.88) 0.01 
       
SDANN (ms) 0.977 (0.962 – 0.993) 0.0045 0.976 (0.958 – 0.993) 0.0077 - - 
RV function† 3.709 (1.871 – 7.349) 0.0002   6.8532 (1.285 – 36.562) 0.025 4.19 (1.62 – 10.82) 0.003 
     - - 
SDANN (ms) 0.969 (0.951 – 0.987) 0.0007 0.978 (0.957 – 0.999) 0.0036 0.951 (0.914 – 0.989) 0.01 
PVRI baseline (WU) - - - - - - 
       
SDANN (ms)        0.969 (0.951 – 0.986) 0.0006 - - 0.951 (0.914 – 0.989) 0.01 
PVRI NO/FiO2 0.6 
(WU) 
        - -    1.093 (1.0137 – 1.179) 0.0021 - - 
 
6MWT = six-minute walk test; 95% CI = 95% confidence interval; APAH = pulmonary hypertension associated with congenital heart disease; FiO2 = inspiratory 
oxygen concentration; IPAH = idiopathic pulmonary hypertension; NO = nitric oxide; PVRI = pulmonary vascular resistance index; SDANN = standard deviation 
of mean values for all normal-to-normal intervals over 5 minutes; WHO = World Health Organization functional class; WU = Wood units (=80 dyn•s•cm-5). † 
indices of right ventricular hypertrophy, size and function were quantified semi-quantitatively as normal=1; mildly=2; moderately=3; severely=4 impaired. * For 
the APAH cases the 6MWT distance was not significantly related to outcome on univariate Cox proportional hazard analysis, and was therefore not included into 
the bivariate model. 
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3.3.4 Discussion 
The purpose of this study was to assess the prognostic value of HRV in children with 
PAH. We found that measures of HRV (SDANN, SDNN and RMSSD) were 
predictive of death or transplantation in a group of children with IPAH and APAH 
with a mean age of 11.4 years. An SDANN of less than 112 ms was associated with 
an unfavourable outcome. WHO Functional Class, the 6MWT distance, the 
echocardiographic assessment of RVH and function and the PVR at baseline and on 
vasodilator testing were all independent predictors of the combined end-point. 
Bivariate analysis however, showed that HRV was either a superior or comparable 
predictor of outcome with the exception of the 6MWT, which was a superior 
predictor.   
 
This is, to our knowledge, the first time that a low HRV has been associated with an 
adverse outcome in children with PAH but it is a well recognised feature of left 
ventricular failure (214-216) and has been noted in a small number of adults with 
IPAH (207). It indicates autonomic dysfunction and appears to be a feature of 
ventricular dysfunction. The right ventricle is severely compromised in patients with 
advanced PAH. It is well recognised, that the integrity of the right ventricular 
function rather than the degree of pulmonary vascular injury is the main determinant 
of symptoms and survival (219). Right ventricular mass, volume, and function were 
recently shown to be independent predictors of mortality and treatment response in 
adults with IPAH (220). The left ventricle is also compromised as the 
interventricular septum hypertrophies and shifts to compress the left ventricle.  
 
The cause of autonomic dysfunction is uncertain. Left ventricular failure is generally 
associated with an increase in sympathetic activity and downregulation of the beta-
adrenergic receptors (221). This receptor is also downregulated in pulmonary 
hypertensive monocrotaline treated rats (222), by 57% in the right ventricle and 22% 
in the left ventricle. When the sympathetic innervation of the heart was demonstrated 
in adult patients with IPAH using 123-I metaiodobenzylguanidine there was a low 
heart:mediastinal  activity ratio in the left ventricle (223). The ratio correlated with 
total pulmonary vascular resistance, right ventricular ejection fraction, and survival. 
Chronically hypoxic rats had a low HRV associated with an increase in sympathetic 
activity (224). Neuroendocrine activation in human PAH is evidenced by an increase 
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in ANP, BNP, ET-1 and norepinephrine, changes which relate to NYHA Functional 
Class and the development of congestive cardiac failure (218). Summarizing the 
published evidence, ventricular dysfunction appears to be associated with heightened 
neuroendocrine activity associated with downregulation of the beta- adrenergic 
receptor. The frequency of supraventricular and ventricular ectopic beats did not 
relate to HRV.  In adults with IPAH vagal activity appeared greater in those with 
recurrent syncope(207) although this was not seen in our paediatric population.  
 
In the present study HRV correlated with the 6MWT and was lower in those in 
WHO Functional Class III than II. These assessments are generally thought to reflect 
well-being and disease progression in PAH to the extent that they have been used as 
end-points to determine whether patients have benefited from drug administration.  
The 6MWT correlates with several parameters of cardiopulmonary exercise testing 
and as in the present study in children, is a predictor of outcome in adults (135,169). 
Using ROC analysis, the extent to which the 6MWT was a predictor in adults was 
similar to that seen in the present paediatric series (225). Determination of HRV 
could be an adjunct to the 6-minute walk test in older children and be a realistic, 
more reliable prognostic indicator in children too young to perform a walk test 
reliably. The WHO /NYHA functional classifications applied to children have the 
disadvantage of relying on the parents’ opinion of their child’s physical limitations 
and the interpretation of their opinion by the physician. Even in adult studies these 
functional classifications are generally used as a secondary endpoint or a part of a 
combined endpoint in clinical trials (169,226).  
 
Analysing the data from the more homogeneous subgroup of children with IPAH we 
found that the PVR on vasodilator testing as well as the 6-minute walk test was a 
better prognostic indicator than HRV. In adults with IPAH the baseline PVR was 
shown to be a predictor of survival on univariate analysis in several studies before 
the advent of pulmonary hypertension specific therapies (4,142) but not in 
epoprostenol treated patients (130,131). All our patients had received pulmonary 
hypertension specific therapies, 20 of them on epoprostenol. Unlike previous adult 
studies neither the mean PAP nor the mean right atrial pressure (130) was predictive 
of outcome, the right atrial pressure being relatively low in all children and the PAP 
consistently high. 
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In children with APAH the HRV and all clinical and haemodynamic parameters were 
predictive of outcome, as in IPAH, but the results of bivariate analysis were 
different. WHO Functional Class and the echocardiographic assessment of the right 
ventricle were superior to HRV, while the 6MWT and PVR were not. The inferiority 
of an assessment of exercise capacity and PVR might be explained by the diversity 
of the different types of congenital heart and lung disease included in this group.  
The limitations of using WHO Functional Class particularly in children have been 
noted above. 
 
The echocardiographic assessment of right ventricular hypertrophy and function 
predicted outcome in both IPAH and APAH, as in adult studies (169,227). It was not 
however superior to HRV in predicting outcome, with the single exception of right 
ventricular hypertrophy in APAH. The predictive value of echocardiography might 
have been better had we used a more sophisticated interrogative and analytical 
approach, such as determining tricuspid annular plane systolic excursion rather than 
using a semi-quantitative assessment. But echocardiographic variables generally 
reflect the long-term consequences of PAH rather than recent change. At the Venice 
2003 WHO Symposium on Pulmonary Hypertension it was concluded that 
echocardiographic variables were helpful as secondary rather than as primary 
endpoints in clinical trials, helping validate the clinical benefit or otherwise of a 
therapeutic intervention (169). HRV may be a more exact measure of current status.  
 
The principle limitations of the present study are that we did not study HRV in 
consecutive children presenting to the service in order to establish the incidence of 
abnormalities at presentation and did not carry out longitudinal studies on individual 
children. A prospective longitudinal study would have established whether a change 
in HRV correlated with, or could predict, change in clinical status rather than just 
death or transplantation. Prediction of arrythmias, syncope, need for atrial 
septostomy would be particularly helpful. We did not find a correlation between 
HRV and syncope but adults with IPAH and recurrent syncope appeared to have 
greater vagal activity (207). Also, the analytical assessment of HRV could be 
improved. We used time domain parameters but spectral analysis might enhance the 
prognostic power of HRV.  
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In conclusion, the present study shows that a low HRV is predictive of death or 
transplantation in children with PAH. HRV can be studied easily and repeatedly even 
in small children.  Its use as a non-invasive tool to monitor clinical progress deserves 
further study, as does its own potential as an independent risk factor for cardiac 
arrhythmia and sudden death.  
 
Whether beta-blockade would be helpful in these patients is unknown. Theoretically 
beta-blockade could reduce the increase in L-type calcium current and cytosolic 
calcium transients in response to beta-adrenergic surges and so reduce calcium 
mediated arrhythmias and risk of sudden death. 
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3.4 ECHOCARDIOGRAPHY AND TISSUE DOPPLER IMAGING   
 
3.4.1 Background 
Despite the use of new pulmonary hypertension-specific medicines, PHT remains a 
progressive disease without a cure and significant mortality.  It is eventually right 
ventricular performance that determines exercise tolerance and prognosis (219). Due 
to its complex morphology and myocardial architecture and dependence on loading 
conditions, however, objective quantification of right ventricular function remains 
challenging (228,229). Furthermore, right ventricular dilatation, hypertrophy and 
dysfunction affect the left ventricle and its filling dynamics. These ventricular-
ventricular interactions in severe PAH are poorly understood.  
This study tested the hypothesis that in children in whom the right ventricle is 
chronically exposed to high pulmonary pressures, left ventricular function may be 
impaired due to underfilling, although this has not been seen on conventional (2D / 
M-mode) echocardiography. This study also aimed to assess ventricular interactions 
using both conventional echocardiographic techniques as well as colour-coded tissue 
Doppler imaging (TDI), a method known to sensitively detect myocardial 
dysfunction (230).  
 
3.4.2 Patients and Methods 
Forty-one children (18 male) with a mean age of 7.9 ± 5.6 years with PAH and a 
structurally normal heart were assessed using echocardiographic techniques 
including tissue Doppler imaging. In addition 44 age-matched healthy controls (23 
male) were investigated (mean age 7.7 ± 4.1 years¸ p vs. patients = 0.82). Patient 
demographics are presented in Table 3.4.1. 
 
Table 3.4.1 Patients’ demographics 
 
 Controls (n=44) PHT (n=41)   
  Mean ± SD Mean ± SD p - Value 
Age (years) 7.7 ± 4.1 7.9 ± 5.6 ns 
Height  (cm) 126.1 ± 23.7 117.6 ± 34.2 ns 
Weight  (kg) 31.1 ± 16.5 26 ± 17.5 ns 
Heart rate (bpm) 97 ± 28 105 ± 23 ns 
 
bpm= beats per minute, cm=centimetre, kg=kilogram, ns= not significant, PHT= 
pulmonary hypertension, SD=standard deviation 
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Twenty-seven children included were diagnosed with IPAH, whereas 14 children 
had a structurally normal heart and associated PAH (interstitial and chronic lung 
disease n=6, connective tissue or autoimmune disease n=5, late closure of a 
persistent arterial duct n=2, drug [busulphan] associated n=1).  
In 31 children the presence of significant pulmonary hypertension was confirmed on 
cardiac catheterisation. In the remaining 10 children echocardiographic assessment 
and estimation of right ventricular systolic pressures clearly indicated the presence of 
pulmonary hypertension. Only patients with a maximum tricuspid regurgitation 
velocity of 3 m/s or greater were included into this study.  All patients were treated 
with advanced specific PAH therapies.  
 
Conventional echocardiography 
All patients underwent a standard echocardiographic assessment as described in 
Chapter 2. In addition, on two-dimensional (2D) and M-mode echocardiography 
right and left atrial areas (apical 4-chamber view), diameters of the tricuspid, mitral 
(apical 4-chamber view), pulmonary (tilted parasternal long axis view) and aortic 
valve (parasternal long axis view) and branch pulmonary arteries (high parasternal 
short axis view) were measured; all measurements were expressed in z-scores for 
body surface area (231). 
To quantitatively determine the degree of interventricular septal shift the left 
ventricular eccentricity index (LVEI) was quantified from a parasternal short axis 
view, using the ratio of the diameter of the left ventricular cavity perpendicular to the 
interventricular septum and its diameter on a perpendicular view as described 
previously (232,233). From M-mode parasternal long axis views, right and left 
ventricular end-diastolic and systolic dimensions and interventricular septal as well 
as posterior left ventricular free wall measures were obtained. Ejection fraction was 
assessed using the Teichholz formula as described in previous reports (234). An M-
mode measurement from an apical 4-chamber view of the tricuspid valve annulus 
was performed to assess the tricuspid annular plane systolic excursion (TAPSE) 
(235,236).  
Using Doppler techniques, in presence of a complete Doppler envelope, the tricuspid 
valve maximal velocity, was documented to estimate pulmonary artery pressures/ 
right ventricular pressures according to the modified Bernoulli equation. Pulmonary 
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acceleration time was determined from the pulmonary artery pulsed Doppler trace 
signal. 
 
Tissue Doppler imaging 
TDI spectral analysis velocity measures were performed at tricuspid valve level of 
the right ventricular free wall, of the left ventricular free wall at the level of basal 
mitral annulus and the interventricular septal crest. Three cardiac cycles were 
recorded and measures at tricuspid valve level were taken at breathhold in all 
cooperative children. Imaging was optimized to acquire a tissue Doppler frame rate 
of >160 f/s.  
Tissue Doppler imaging data was compared with conventional echocardiographic 
parameters reflecting pulmonary artery pressures (pulmonary arterial acceleration 
time, tricuspid regurgitation [TR] velocity, TR severity [0= none, 1=trivial, 2=mild, 
3=moderate, 4=severe TR]) and right ventricular functional parameters such as 
TAPSE, semiquantitative right ventricular function (1=normal, 2=mildly, 
3=moderately, 4=severely impaired), and left ventricular eccentricity index as 
quantitative expression of the degree of interventricular deviation, caused by the 
interaction of ventricular pressure-loading conditions. 
 
3.4.3 Results 
No significant difference in patients’ gender, age, weight, height or heart rate was 
found between normal healthy controls and children with PAH (Table 3.4.1).  
 
Conventional echocardiographic measures of ventricular dimensions and function 
were significantly different in PAH patients and normal children. As expected, 
planimetric measurements of bi-atrial areas (right: 12.4 ± 6.2 vs. 9.6 ± 2.5 cm2; 
p=0.02, left: 7.6 ± 3.7 vs. 9.2 ± 2.8 cm2; p<0.04), pulmonary artery (PA) dimensions 
(right PA 1.3 ± 0.5 vs. 1.1 ± 0.29 cm; p=0.002; left PA 1.4 ± 0.5 vs. 1.1 ± 0.27 cm; 
p<0.01), tricuspid (2.6 ± 0.75 vs. 2.2 ± 0.19 cm; p<0.01) or mitral valve diameter 
(1.8 ± 0.59 vs. 2.1 ± 0.45 cm; p=0.03) and diastolic right intraventricular diameter 
(2.7 ± 1.3 vs. 1.8 ± 0.8 cm; p<0.01) were abnormal in PAH patients. (Figure 3.4.1)  
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Figure 3.4.1 Comparison of z-scores for right atrial area (RA), mitral valve (MV) 
and mean pulmonary artery diameter (PA) in controls (white bars) and children with 
pulmonary hypertension (grey bars).  
 
The pulmonary acceleration time (65 ± 23 vs. 120 ± 32 ms; p<0.0001) was shorter in 
children with PHT, and the tricuspid annular plane systolic excursion (1.4 ± 0.34 vs. 
1.9 ± 0.23 cm; p <0.0001) was significantly decreased. In the left ventricle, the 
ventricular eccentricity index was also found to differ significantly from normal 
healthy controls as shown in Table 3.4.2.  
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Table 3.4.2 Baseline echocardiographic data in control subjects and patients with 
pulmonary hypertension (PHT).  
 
 Controls PHT  
  n=44 n=41  
  Mean ± SD  Mean ± SD p - Value 
RA  z-score 0.8 ± 1.7 3.8 ± 3.7 <0.0001 
LA  z-score 0.7 ± 2.3 -0.6 ± 1.6 0.02 
TV  z-score 0.1 ± 1.6 2.6 ± 4 0.002 
PV  z-score -0.24 ± 2.0 1.99 ± 2.3 <0.0001 
RVIDd (cm) 1.83 ± 0.72 2.73 ± 1.29  
RVIDs (cm) 1.5 ± 0.52 3.6 ± 6.5  
TR velocity (m.s-1) 2 ± 0.4 4.5 ± 1 < 0.0001 
PA acceleration (msec) 119.7 ± 31.8 65.3 ± 22.7 < 0.0001 
MV z-score -1 ± 1.7 -2.7 ± 2.3 0.01 
LVEId 1 ± 0 1.6 ± 0.5 < 0.0001 
LVEIs 1.1 ± 0.1 2.1 ± 0.8 < 0.0001 
TAPSE (cm) 1.9 ± 0.2 1.4 ± 0.3 < 0.0001 
EF (%) 58.7 ± 12.6 66.3 ± 16.6 ns 
 
EF = ejection fraction, IVS = interventricular septum, LA  = left atrium, LVEId and 
–s = left ventricular eccentricity index in diastole and systole, MV = mitral valve, PA 
= pulmonary artery, PV = pulmonary valve, RA = right atrium, RVIDd and –s = 
diastolic and systolic right ventricular inflow diameter, TAPSE = tricuspid annular 
plain systolic excursion, TR = tricuspid regurgitation, TV = tricuspid valve, SD = 
standard deviation. ns = non significant. 
 
Patients had a significantly larger LVEI compared to normal controls. On 
conventional Teicholz measurements, the mean left ventricular ejection fraction was 
higher in the children with pulmonary hypertension compared with normal children 
(66.3 ± 16.6 vs. 58.7 ± 12.6 %). However, this trend did not reach statistical 
significance (p=0.065). 
 
Tissue Doppler measures of biventricular function 
Children with PAH had lower systolic (S) (tricuspid 0.11 ± 0.03 vs. 0.13 ± 0.02; 
p<0.0001; septal 0.06 ± 0.02 vs. 0.08 ± 0.01; p <0.0001) and early diastolic (E) 
velocities at the tricuspid and septal level (tricuspid 0.12 ± 0.04 vs. 0.19 ± 0.15; 
p<0.0001; septal 0.072 ± 0.03 vs. 0.14 ± 0.02; p<0.0001). Despite preserved left 
ventricular function on conventional M-mode echocardiography - calculated using 
the Teicholz formula - we found that left ventricular systolic performance was 
markedly impaired on TDI in children with PAH. Tissue Doppler LV velocities (S, 
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E, A) were impaired in children with PAH (S: 0.06 ± 0.018 vs. 0.09 ± 0.02; 
p<0.0001; E: 0.11 ± 0.04 vs. 0.18 ± 0.05; p<0.0001; A: 0.06 ± 0.02 vs. 0.07 ± 0.017; 
p=0.0015), as shown in Table 3.4.3 and Figure 3.4.2 and illustrated on examples in 
Figure 3.4.3. 
 
Table 3.4.3 Tissue Doppler Imaging parameters. In control subjects and patients 
with pulmonary hypertension (PHT):  Comparisons were performed between normal 
controls and patients with PHT.  
 
 Controls (n=44) PHT (n=41)   
  Mean ± SD Mean ± SD P– Value 
Lateral tricuspid valve level 
S TV  (m/s)  0.13 ± 0.02 0.11 ± 0.03 < 0.0001 
E TV (m/s)  0.19 ± 0.15 0.12 ± 0.04 < 0.0001 
A TV  (m/s)  0.11 ± 0.02 0.11 ± 0.03 Ns 
 
   
Interventricular septal level 
S IVS (m/s)  0.08 ± 0.01 0.06 ± 0.02 < 0.0001 
E IVS (m/s)  0.14 ± 0.02 0.07 ± 0.03 < 0.0001 
A IVS (m/s)  0.07 ± 0.01 0.06 ± 0.01 Ns 
     
Lateral mitral valve level 
S MV (m/s)  0.09 ± 0.02 0.06 ± 0.02 < 0.0001 
E MV (m/s)  0.18 ± 0.05 0.11 ± 0.04 < 0.0001 
A MV (m/s)  0.07 ± 0.02 0.06 ± 0.02 0.0015 
 
A = late diastolic velocity, E = early diastolic velocity, IVS = interventricular 
septum, MV = mitral valve, ns = non significant, PA = pulmonary artery, S = 
systolic velocity, SD = standard deviation, TV = tricuspid valve 
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Figure 3.4.2 Comparison of spectral tissue Doppler velocities of controls and 
children with pulmonary hypertension at the lateral tricuspid, septal and lateral mitral 
valve level. S’ indicates systolic velocity, E’ early and A’ late diastolic velocity. 
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Figure 3.4.3 Representative spectral tissue Doppler images at lateral tricuspid (TV 
lat), septal (IVS) and lateral mitral valvar (MV lat) level in a control patient and a 
child with PAH.   
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Although left ventricular function is preserved on conventional M-mode 
echocardiography using the Teichholz formula, children with pulmonary 
hypertension showed marked impairment of left ventricular systolic performance on 
TDI. Systolic and early diastolic (S ,E) Tissue Doppler velocities were reduced in 
children with PHT at all measured levels compared to the normal controls. The a 
wave was reduced at tricuspid and septal level, whereas the a velocity at mitral valve 
level was not significantly different to normal controls. 
 
Correlations between conventional echocardiographic and tissue Doppler 
Imaging 
Higher values for systolic tissue Doppler (S) velocities at tricuspid (r=0.42, p=0.016) 
and septal (r=0.52, p=0.002) level were associated with a longer pulmonary 
acceleration time (a marker of less severe PAH). Systolic tissue Doppler (S) velocity 
at tricuspid (r=0.56, p=0.0002) and septal level (r=0.36, P=0.02) were also associated 
with higher TAPSE values.  At mitral valve level no relationship was found between 
the systolic function (S wave velocity) and Pac. In contrast, a shorter Pac was related 
to a lower early diastolic (E) (r=0.44, p=0.01) and a higher atrial (A) (r=-0.38, 
p=0.03) tissue Doppler velocity, suggesting a higher degree of diastolic dysfunction 
in patients with more severe PAH. 
Tissue Doppler velocities of systolic and diastolic function measured at 
interventricular septal were significantly associated with semi-quantitative right 
ventricular function [(S): (r=-0.34, p=0.03); (E): (r=-0.63, p<0.0001); (A): (r=-0.39, 
p=0.01)], whereas no such association could be established at the tricuspid valve or 
mitral level (Table 3.4.4).  
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Table 3.4.4 Correlations between systolic velocities (S) at lateral tricuspid (TV lat.), 
interventricular (IVS) and lateral mitral (MV lat.) level and echocardiographic 
parameters of degree of pulmonary hypertension, right ventricular dysfunction on 
conventional echocardiography and measures of left ventricular eccentricity.  
 
 
 
S TV lat. (cm/sec) 
 
S IVS (cm/sec) 
 
S MV lat. (cm/sec) 
 
  
 
 
PAc time (ms) 
 
r=0.42; P=0.016 
 
r=0.52; P=0.002 
 
r=-0.10; P=ns 
TAPSE (cm) r=0.56; P=0.0002 r=0.36; P=0.02 r= 0.25; P=ns 
TR velocity (m/s) r=0.24; P= ns r=-0.07; P= ns r=-0.09; P= ns 
TR severity (1-4) * r=-0.02; P= ns r=-0.22; P= ns r=-0.23; P= ns 
RVF (1 – 4) * r=-0.17; P= ns r=-0.34; P=0.03 r=-0.23; P= ns 
dp/dt (mmHg/s) r=-0.18; P= ns r=-0.23; P= ns r=-0.19; P= ns 
LVEI syst. r=-0.15; P= ns r=-0.22; P= ns r=-0.28; P= ns 
LVEI diast. r=-0.01; P= ns r=-0.21; P= ns r=0.003; P= ns 
 
PAc = pulmonary acceleration time, TAPSE = tricuspid annular plain systolic 
excursion, TR = tricuspid regurgitation, RVF = right ventricular function, dp/dt = 
right ventricular pressure increase, LVEI syst. and – diast. = left ventricular 
eccentricity index in systole and diastole. r = Pearson correlation coefficient; * = 
Spearman rank correlation.  
 
 
 
3.4.4 Discussion 
Although left ventricular function appeared to be preserved on conventional 2D- and 
M-mode echocardiography, TDI analysis of longitudinal left ventricular wall motion 
suggested an impaired left ventricular function in children with PAH. This finding 
may reflect the detrimental impact of right ventricular dysfunction, dilatation and 
hypertrophy, on left ventricular function (i.e. ventricular-ventricular interaction) and 
cardiac output in patients with pulmonary hypertension. Septal flattening and 
leftward deviation (characteristic “D-shaped” left ventricle) do occur as a 
consequence of increased right ventricular pressures and an underfilled left ventricle. 
In this context, it is noteworthy, that despite similar degree of pulmonary 
hypertension, patients with Eisenmenger syndrome generally present with a better 
preserved right ventricular function and less severe septal deviation than patients 
with pulmonary hypertension and a structurally normal heart.  These observations 
might help explain the better outcome of the Eisenmenger patients compared to 
patients with idiopathic pulmonary hypertension (237) and emphasize the importance 
of understanding the close interaction between biventricular geometry and function. 
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This study compares data of children with PAH and normal healthy controls, 
focusing on measures of longitudinal contractility using tricuspid annular 
displacement (TAPSE) on M-mode echocardiography and TDI measures at annular 
and septal basal myocardial segments. These parameters of longitudinal function are 
particularly useful in assessing right ventricular systolic function.  
 
The left ventricle ejects a significant proportion of its stroke volume as a result of 
torsional shape changes. In contrast, right ventricular stroke volume grossly depends 
on longitudinal shortening (238). Anatomical studies demonstrated that the deeper 
right ventricular muscle fibres are predominantly arranged in a longitudinal fashion 
from the tricuspid valve annulus to the apex (239). Therefore, longitudinal tricuspid 
annular motion and velocity closely reflect the right ventricular free wall function 
and may precede circumferential right ventricular dysfunction. Furthermore, 
parameters of longitudinal right ventricular function can be assessed quantitatively. 
As expected, in children with PHT geometrical biplanar measures of the right heart 
were increased compared to normal healthy controls. In addition, tissue Doppler 
measures for assessment of both systolic and diastolic ventricular function were 
impaired in the patient group, which is in keeping with the findings of a recent study 
on adults with PHT (240). Paediatric data are sparse and only one recent study, 
investigating 15 infants with PHT secondary to congenital diaphragmatic hernia, 
made observations similar to those in our present study (241).  
 
The reduction in E-wave velocity across the mitral valve on spectral Doppler 
analysis in patients with PHT is suggestive of filling impairment. Left ventricular 
filling is compromised by the septal deviation of the hypertrophied and pressure 
overloaded right ventricle. Thus, the left ventricular myocardium is not working at 
the optimal level of the Frank-Starling curve (242-244). The TAPSE and pulmonary 
artery flow acceleration time (PAc) did not correlate with left ventricular S wave 
velocity but the PAc-time correlated with transmitral E and A wave velocities at 
mitral valve level. These findings suggest that pulmonary hypertension had a greater 
impact on the diastolic rather than the systolic cycle of the left ventricle. In patients 
with severe PHT and who had a shorter PAc, diastolic E and A Doppler filling 
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patterns were markedly lower, suggestive of a significantly reduced left ventricular 
preload.  
 
Echocardiographic assessment of right ventricular function and volumes based on 
conventional volumetric variables such as ejection fraction remains a challenge due 
to the complicated geometry of the right ventricle (75,245). Cardiac magnetic 
resonance imaging may be a more accurate method to assess right ventricular 
function, however due to the relatively long acquisition time it requires general 
anaesthesia or heavy sedation in young children, which are a considerable risk for 
patients with pulmonary hypertension. Echocardiographic techniques allow direct 
evaluation of cardiac function by assessing myocardial deformation. Longitudinal 
function can be assessed by measuring annular plain systolic excursion and tissue 
velocities. One possible limitation of using annular plain systolic excursion and 
tissue velocity is that these parameters could be affected by tethering effects. This 
could lead to an overestimation of myocardial function.  This could represent a 
limitation of the current study. However, while this is a potential concern in patients 
with ischaemic cardiomyopathy and regional wall motion abnormalities, tethering 
effects are less likely in patients with PAH, where right ventricular function is 
uniformly affected. In addition, a recent study has demonstrated a good correlation 
between tricuspid annular peak systolic velocity and RV ejection fraction (246). 
 
Tissue Doppler echocardiography has emerged as a quantitative modality to assess 
ventricular function. Unlike conventional visual assessment of right ventricular 
function, requiring extensive training, experience and subjective interpretation, tissue 
Doppler echocardiography uses easily identifiable cardiac structures and velocities 
can be quantified objectively.  Tissue Doppler imaging techniques may therefore 
allow to demonstrate sub-visual changes of the right and left ventricular function. 
However, prognostic implication of TDI is still unclear and more studies are required 
in children and adults. Due to the prospective design of the study and the short 
follow-up period the number of children, who died (n=2) or underwent 
transplantation (n=3) was low. Therefore, this study is not suited to provide 
information on the prognostic value of the studies echocardiographic variables. 
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There is ongoing controversy on the potential benefits of speckle-tracking based 
assessment of myocardial deformation compared to tissue Doppler 
echocardiography. While the latter is angle dependent, speckle-tracking is 
theoretically angle independent. However, as axial resolution is superior to lateral 
resolution, speckle-tracking perpendicular to the ultrasound beam may be 
suboptimal. Furthermore, in the current study we focused on longitudinal function, 
which can be equally well assessed by both modalities.  
 
In conclusion, despite not being evident on conventional 2D echocardiography, LV 
systolic performance is impaired in children with pulmonary hypertension. 
Quantitative TDI assessment of ventricular function and biventricular interactions in 
this setting might provide further insights into the mechanisms leading to end stage 
PHT, and may encourage clinicians to optimize anti-failure treatment earlier in the 
course of the disease process. Further studies with a longer follow up period are 
required to assess the potential value of tissue Doppler echocardiography in 
assessing prognosis and guiding therapy in children with pulmonary hypertension. 
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3.5 B-TYPE NATRIURETIC PEPTIDE 
 
3.5.1 Background 
Pulmonary hypertension leads to right heart failure and the prognosis was extremely 
poor until new pulmonary hypertension-specific medicines were introduced over the 
last two decades. These drugs have improved quality of life and survival. Monitoring 
progress, assessing the need for escalation of therapy and determining the time to 
transplantation, however, remains a challenge, especially in children where invasive 
assessment is associated with considerable risks (82). In adult patients B-type 
natriuretic peptide (BNP) has been shown to be a useful diagnostic tool in patients 
with cardiac or pulmonary disease (247,248). BNP has been shown to predict both 
left and right ventricular dysfunction (247,249-251). Previous studies have also 
shown that BNP correlates closely with New York Heart Association functional class 
(247,252,253) and haemodynamic parameters (254,255).  In adult patients with 
IPAH, previous publications have demonstrated that BNP correlates with the mean 
pulmonary artery pressure (PAP), total pulmonary vascular resistance index (PVRI) 
(252,256), right atrial pressure and right ventricular end-diastolic pressure (257). 
Nagaya et al. have also shown BNP values at baseline to be predictive of survival in 
adults with IPAH (137). There are no comparable data in children with PHT but 
elevated levels have been described in children with congenital heart disease (258-
262), Kawasaki disease (263), cardiomyopathy (264) and heart failure (265,266).  
BNP is synthesized as pro-BNP - a prehormone - predominantly by ventricular 
cardiomyocytes. It is cleaved into the biologically active BNP, which represents the 
C-terminal fragment and the biologically inactive N-terminal fragment (NT-
proBNP). Both NT-proBNP and active BNP have been used as biomarkers for 
diagnosis and risk-stratification in patients with cardiovascular conditions, and their 
diagnostic significance is comparable (267,268).  BNP-production is augmented by 
an increase in pressure and/or volume overload (250), resulting in increased 
myocardial wall stretch. Synthesis of BNP can also be increased by tachycardia, 
glucocorticoids, thyroid hormones and vasoactive peptides (250,269,270).  
This study tested the hypothesis that plasma BNP levels are elevated in children with 
PHT, relate to WHO functional class and predict death or the need for 
transplantation. 
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3.5.2 Patients and Methods 
Fifty patients (32 male) from the UK Pulmonary Hypertension Service for Children 
seen between 01/2004 and 09/2006 were studied. Baseline characteristics are shown 
in Table 3.5.1. Patients had a mean age of 8.4±5.1 years (range 0.3-18.4). Twenty-
seven children (14 male) had IPAH. Twenty-three children had pulmonary 
hypertension associated with other diseases (APH) including congenital cardiac 
disease (n=17) four patients with lung disease, and one patient each with vasculitis 
and HIV. All children were treated with advanced specific therapies for pulmonary 
hypertension (epoprostenol, bosentan and sildenafil) or a combination of these drugs. 
Twenty-seven patients were on monotherapy (epoprostenol n=4, bosentan n=15, 
sildenafil n=8). Eighteen children were on dual therapy (epoprostenol and bosentan 
n=12, bosentan and sildenafil n=6) and 5 children were on triple therapy 
(epoprostenol/inhaled prostanoid, bosentan and sildenafil).  
 
The children were followed-up for a mean of 14.0±7.5 months (range: 0.2-33.1) after 
measuring the BNP level. All children underwent a physical examination, assessment 
of WHO Functional Class and transthoracic echocardiography at the time of BNP 
sampling.  A concomitant six-minute walk test was available in 14 children who 
were well and old enough to do the test reliably. The walk test was performed in a 
standardized matter as described in the General Methods section.   
 
Fourteen patients underwent a cardiac catheterization study with assessment of the 
pulmonary vascular resistance at the time of BNP sampling. The mean PAP was 62.4 
± 29.7 mmHg and the mean PVRI was 19.5 ± 13.2 units m2.  On vasodilator testing 
with inhaled nitric oxide during cardiac catheterization the mean PVRI was 
16.2±12.2 units m2 (Table 3.5.1). 
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Table 3.5.1  Selected characteristics. Patients are classified into those who died or 
underwent transplantation and those who survived. 
Characteristic All patients Combined 
endpoint 
Event free survival  
 (n=50) (n=14) (n=36)  
     
Age (years)    8.4 ± 5.1 7.6 ± 4.0 8.7 ± 5.53  
Gender (male / female) 32/ 18 11 / 3 21/ 15  
Weight (kg) 30.5 ± 23.1 33.6 ± 33.9 29.2 ± 17.5  
Age at diagnosis (years) 5.2 ± 4.5 4.9 ± 4.0 5.3 ± 4.7  
IPAH / Associated PAH  27 / 23  7 / 7 20 / 16  
WHO II / III / IV 20 / 26 / 4 0 / 11 / 3 20 / 15 / 1 ** 
 
     
BNP (pg/ml) 143.5 ± 236.2 229.0 ± 235.4 110.3 ± 236.2  
Six minute walk distance (m) 286.9 ± 91.1 233.8 ± 70.0  310.3 ± 90.6 * 
 
Oxygen saturation at rest (%) 91.4 ± 9.0 88.4 ± 11.2 92.5 ± 7.8  
     
Echocardiography     
 
RV dilatation I / II / III / IV 
 
1 / 11 / 21 / 17 
 
0 / 1 / 5 / 8 
 
1 / 10 / 16 / 9 
 
RV dysfunction I / II / III / IV 5 / 28 / 11 / 6 0 / 5 / 5 / 4 5 / 23 / 6 / 2 *  
RV hypertrophy I / II / III / 
IV 
1 / 20 / 26 / 3 0 / 4 / 9 / 1 1 / 16 / 17 / 2  
TR severity I / II / III / IV  17 / 15 / 16 / 2 3 / 4 / 7 / 0 14 / 11 / 9 / 2  
TR velocity (m/sec) 4.5 ± 0.9 4.5 ± 0.6 4.5 ± 1.0  
     
Invasive haemodynamic data     
 
Mean PAP baseline (mmHg) 
(n=13) 
62.4 ± 29.7 
(n=1) 
46.0 
 
63.7 ± 30.6 
 
Right atrial pressure (mmHg) 9.1 ± 7.0 5 9.5 ± 7.3  
PVRI baseline 19.5 ± 13.2 12.5 20.0 ± 13.6  
PVRI nitric oxide 16.2 ± 12.2 6 17.1 ± 12.3  
     
 
Mean ± standard deviation are given. t-test, Mann-Whitney U-test or Chi-square test 
were made for comparison between patients who died/underwent transplantation or 
were listed for transplantation and the remaining population. BNP = B-type 
natriuretic peptide. IPAH = idiopathic pulmonary arterial hypertension. PAP = 
pulmonary arterial pressure. PVRI = pulmonary vascular resistance index. RV = 
right ventricular. TR = tricuspid regurgitation. WHO = World Health Organization 
Functional Class (II-IV). Combined endpoint= death, listing for transplantation/ 
transplantation  
** p<0.001 * p<0.05   
 
Right ventricular function, dilatation and hypertrophy were assessed at the time of 
BNP sampling by echocardiography and described semi-quantitatively as being 
normal, mildly, moderately or severely impaired (113,218). Tricuspid regurgitation 
was described as trivial, mild, moderate and severe (I-IV). Right ventricular systolic 
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pressure was estimated from the tricuspid regurgitation signal using the modified 
Bernoulli equation. 
BNP measurements were performed on EDTA blood using the Triage test (Biosite 
Diagnostics, San Diego, CA) (166) according to the manufacturer’s instructions. 
This test uses a fluorescent-labelled antibody to BNP and has a range from 5 to 5000 
pg/ml (254). BNP values were correlated with gender, WHO Functional Class, 
echocardiographic and haemodynamic findings, the six-minute walk test and 
outcome. For normal adults, 99.5% have a value less than 100 pg/ml. In children, 
Koch and colleagues (271) reported a mean BNP value (Triage test) in normal 
children older than 2 weeks of age (n=152) of 7.0±5.9 (SD) pg/ml in boys and 
10.1±8.6 (SD) pg/ml in girls. No BNP value was greater than 32.7 pg/ml. Law and 
colleagues (261) reported a mean value of 22±5 (SEM) pg/ml, range 5 to 63 pg/ml in 
16 children age 0.3 to 18.5 years, mean 10.1 years.  Soldin (272) evaluated 808 
children, using the same Triage test, and found a maximum 97.5thcentile value of 173 
pg/ml in children over 1 year of age.  
 
Statistical analysis  
As there was evidence of significant departure from the normal distribution log 
transformed BNP values were used for all correlation analyses. For statistical 
analysis, WHO class was considered as a continuous variable and the Spearman rank 
correlation was used to estimate correlation between WHO class and log transformed 
BNP values. To determine the optimal cut-off value of BNP the areas under the 
curve (AUC) for sensitivity and specificity were calculated using receiver-operating 
characteristics (ROC) analysis to assess the prognostic accuracy of BNP values. 
Kaplan-Meier survival plots were constructed to illustrate the association between 
BNP and survival using death or transplantation as the end-point.  
 
3.5.3 Results 
The mean BNP of all the children with PH was significantly increased, 143.5 ± 236.2 
pg/ml (range <5-1250) (p<0.01) compared with a normal mean value described by 
Koch (271). There was no significant difference between those patients with IPAH 
and those with APH (mean 119.9 ± 168.9 pg/ml, range <5-644.0, versus 171.1±298.4 
pg/ml, range <5-1250, respectively; p=0.60). However, considering the children 
individually and taking 32.7 pg/ml (271) as the upper limit of normal, 56% of all 
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children with PH had an abnormally high value and the proportion of those with an 
elevated level was greater in IPAH than APH, 70% v. 39%. There was no difference 
between the results for boys and girls (p=0.45). 
 
 
 
 
Figure 3.5.1 Distribution of B-type natriuretic peptide levels related to World Health 
Organization Functional Class. Bars and error markers represent median, lower and 
upper quartile. Kendall's Tau rank correlation was used for comparison. 
 
There was a positive association between BNP value and WHO Functional Class as 
illustrated in Figure 3.5.1. Patients in Functional Class 3 and 4 had significantly 
higher BNP values compared with those in a lower class (50.8±61.3; 196.9±291.2; 
280.0±276.5 in WHO class 2, 3, and 4, respectively; p=0.01). The patients on 
intravenous epoprostenol alone or in combination (n=21) had a significantly higher 
BNP than those on oral therapies (256.1±324.7 vs. 61.9±76.8 pg/ml, p =0.01). 
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BNP levels correlated with the echocardiographic findings, including right 
ventricular dilatation (p<0.01), right ventricular hypertrophy (p<0.01) and right 
ventricular function (p<0.01). When the IPAH and APH groups were studied 
independently both groups showed a similar significant relationship. A small 
pericardial effusion was seen in two cases. There was no correlation between BNP 
value and patient age (p=0.53), oxygen saturation at rest (p=0.53) or six-minute walk 
test distance (p=0.26) for the whole group, nor when the IPAH and APH were 
analyzed separately. 
In children with IPAH there was a significant positive correlation between the mean 
PAP in an inspired oxygen concentration of 30%, as well as PAP and PVRI when on 
inhaled nitric oxide (n=9; r=0.72, p=0.03; r=0.68, p=0.044 and r=0.78, p= 0.02, 
respectively) and BNP. In contrast, there was no correlation between BNP and 
haemodynamic findings in patients with APH (n=5).   
 During the mean follow up period of 14.0±7.5 months (range 0.2-33.1 months) 
seven patients died, six with APH (interstitial lung disease n=1; congenital heart 
disease n=5) and one patient with IPAH. Five children underwent a lung- or heart-
lung transplantation (4 IPAH, 1 lung disease). Two patients (both IPAH) were listed 
for transplantation and are still waiting for a donor organ offer (Table 3.5.1).  
The mean BNP in the survivors was not significantly different from that in children 
who were later transplanted or died (P =0.15) (Table 3.5.1, Figure 3.5.2), nor was 
there a significant difference in age, gender, weight, systemic arterial oxygen 
saturation, echocardiographic and haemodynamic parameters. The six-minute walk 
test, (P =0.01) and the WHO Class (P =0.0004) were however, significantly better in 
children who survived (Table 3.5.1). The survivors walked 70 meters (median) 
further than those who subsequently underwent transplantation or died. 
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Figure 3.5.2  Distribution of B-type natriuretic peptide levels by outcome. Patients 
were classified into survivors and those who with a combined endpoint (death, 
transplantation or admission to the active transplant list). Bars and error markers 
represent median, lower and upper quartile. 
 
A BNP value above 130 pg/ml was identified as the cut-off value best predicting a 
combined end-point of death or transplantation/listing for transplantation but there 
was a limited sensitivity of 57.1% and a specificity of 83.3% in the whole cohort. 
Analyzing patients with IPAH and APH separately showed a higher sensitivity of 
71.4% and a specificity of 90.0% (p<0.028) for the children with IPAH; Log-rank 
analysis of survival time showed a trend, which was not significant (p=0.07).  
 In contrast no association between BNP value and outcome was found in patients 
with APH (sensitivity was 42.9%, specificity 81.2%, p=0.85), the Log-rank test for 
survival time was not significant (p=0.37). 
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Figure 3.5.3 Kaplan–Meier plots for patients classified according to endpoint of 
admission to the active transplantation list, transplantation or death and a B- type 
natriuretic peptide value below or above 130 pg/ml. 
 
Kaplan-Meier survival curves were constructed to illustrate the better outcome of 
patients with BNP values less than 130 pg/ml at baseline (Figure 3.5.3). Figure 3.5.2 
illustrates the substantial overlap in BNP values between patients who survived and 
those who were listed/underwent transplantation or died. The mean BNP level was 
not significantly different in children who died or were transplanted (p=0.15) (Table 
3.5.1). Four patients who died (IPAH n=1; interstitial lung disease n=1; congenital 
heart disease n=2) and three who had a transplant (IPAH n=3, lung disease n=1), had 
lower BNP levels, than the 97.5th centile for normal as given by Soldin (272). The 
time between BNP measurement and death or transplantation was 3.8- 20.3 months. 
There was no correlation between BNP value and the time difference between BNP 
sampling and death or transplantation (p= 0.46). 
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3.5.4. Discussion 
This study shows that the BNP levels correlate with functional status in children with 
PHT. The BNP level was higher in those patients requiring intravenous epoprostenol 
treatment rather than oral therapies. These findings are similar to those in adults, 
where higher BNP levels have been reported in patients with greater physical 
disability (273). In the current study BNP levels did not correlate with 6-minute walk 
test distance, probably because children were tested over a wide age range and 
underlying diagnosis was heterogeneous. There was no correlation with age and BNP 
levels were not different between boys and girls. The main limitations of this study 
are that it BNP levels were not measured at the time of cardiac catheterization and 
longitudinal data is not available, thus making it impossible to relate BNP values 
directly to response to therapy and disease progression.  
 
Plasma BNP correlated with echocardiographic measures of right ventricular 
performance, including right ventricular dilatation, hypertrophy and ventricular 
function.  In a study of 55 adults with pulmonary hypertension, including 36 with 
IPAH, BNP correlated positively with diastolic right ventricle/left ventricle ratio 
area, inversely with acceleration of right ventricular ejection time and with the 
presence of a pericardial effusion (274). In children with congenital heart disease, 
BNP or NT-BNP values correlated with echocardiographic features of heart failure 
and right ventricular volume overload (266). The majority of published studies have 
related BNP to the hemodynamic rather than the echocardiographic findings. In the 
present study children with IPAH showed a positive correlation between the BNP 
level and the mean PAP and PVRI on inhaled nitric oxide at cardiac catheterization. 
This implies that a correlation is best achieved in children when the pulmonary 
vascular resistance is at its lowest and most stable. Also, correlations between BNP 
and hemodynamic status might have been better had there been no delay between 
cardiac catheterization and blood sampling. In adult patients with IPAH, one study 
reported a correlation between the BNP level and mean PAP, mean right atrial 
pressure, right ventricular end diastolic pressure and total pulmonary vascular 
resistance index (137,257) while another study found an association between BNP 
and PAP and pulmonary vascular resistance (252). In the current study no correlation 
was found between BNP and the haemodynamic parameters in children with APH. 
This is perhaps surprising given that an elevated BNP has previously been reported 
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in PHT associated with both congenital heart disease and in children with acute 
respiratory distress associated with congestive heart failure (265,275). The patients 
included in the current study might have been expected to have had higher BNP 
levels because they had a pressure overloaded right ventricle rather than the volume 
overloaded right ventricle of a ventricular septal defect. Lin et al and Nagaya et al 
(257,276) found that patients with RV pressure overload due to IPAH and 
thromboembolism have higher BNP levels than those with right ventricle volume 
overload due to an atrial septal defect . 
 
Evaluating the response to therapy and likely time to deterioration and the need for 
transplantation is extremely difficult, particularly in children.  Using receiver-
operating characteristics (ROC) analysis to assess the prognostic accuracy of BNP 
value revealed that children with elevated BNP values >130 pg/ml had a worse 
prognosis. The BNP level was shown to be an independent predictor of mortality in 
adult patients with IPAH. In this adult population a baseline BNP value of 150 pg/ml 
has been described as the best cut-off value distinguishing survivors and non-
survivors (137). In adults with chronic heart failure higher concentrations of BNP 
were associated with increased mortality, independent of age, functional class and 
ejection fraction (277). In the current study however, the sensitivity of BNP (57%) 
was too low to be clinically useful. There were six patients with a BNP value lower 
than our derived cut-off value (<130pg/ml), who died or required transplantation. For 
the subgroup of children with IPAH sensitivity and specificity of BNP predicting 
death or need for transplantation was better. In the subgroup of children with APH, 
BNP was found to be less useful with a lower sensitivity and specificity.  In addition, 
the BNP level may have been influenced by therapy. All children in the present 
cohort were receiving either epoprostenol, bosentan, sildenafil or a combination of 
these drugs. It has been suggested that long term treatment with epoprostenol (257) 
can lead to a reduction in the BNP level, suggesting that BNP might be a potential 
non-invasive tool to monitor the efficacy of advanced therapies in longitudinal 
studies (169).   
 
BNP is regarded as a useful biomarker of right ventricular dysfunction, but its role in 
the pathobiology of pulmonary hypertension is uncertain. BNP is synthesized and 
secreted by the ventricular myocardium, little is stored and rapid gene expression 
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with de novo synthesis regulates secretion. The main stimulus for secretion is 
increased myocardial wall stress (257,269,270,278,279). Like ANP, BNP is a 
pulmonary vasodilator causing elevation of intracellular cGMP and is essential in 
preventing myocardial hypertrophy and fibrosis (280,281). Humans exposed to 
hypoxia had an attenuated increase in mean PAP and PVR when infused with BNP 
(282). These and other studies indicate the potential benefit of enhancing BNP 
activity, either by using natriuretic peptide analogues / recombinant BNP, or 
reducing the breakdown of the endogenous product via inhibition of neutral 
endopeptidase or both.  In addition, BNP promotes natriuresis and suppresses plasma 
aldosterone, attributes which are relevant to the management of patients with a 
failing right ventricle (283).  
In conclusion, considering 32.7 pg/ml as the upper level of  normal value of BNP in 
healthy children as reported by Koch, the current study illustrates that BNP levels are 
elevated in 56% of children with PHT. 74% of children with IPAH had an elevated 
BNP as compared with 34% of those with APH.  A high BNP level in children with 
pulmonary hypertension should raise concerns about the optimization of medical 
therapy. A low BNP however, does not necessarily indicate that a patient is well and 
stable. The findings in the present study indicate that BNP determination can be a 
useful adjunct to the assessment of clinical status but should not be used in isolation 
as independent screening tool to predict outcome. 
 
 
  
103 
 
 
 
4. TREATMENT OF CHILDREN WITH PULMONARY HYPERTENSION 
 
4.1 EPOPROSTENOL THERAPY 
 
4.1.1  Background 
Epoprostenol therapy was the first available effective treatment for patients with 
severe established PHT. In a 12-week prospective, randomised trial, efficacy was 
proven in adults with IPAH. The trial demonstrated an improvement of exercise 
tolerance, quality of life, haemodynamics and survival (89).  
Data of the first paediatric trial were published in 1999, suggesting a treatment 
benefit also for children (5). Traditionally, epoprostenol is given to adults with IPAH 
and with PHT associated with connective tissue disease and to children with IPAH, 
all of whom are in WHO functional class 3 – 4 and do not show a positive response 
to acute vasodilator testing at cardiac catheterisation.  Over the last decade and with 
increasing experience, the use and indications in paediatric practice have widened. 
Epoprostenol has been successfully used in children with PHT, other than IPAH, 
such as connective tissue disease, congenital heart disease other than the 
Eisenmenger Syndrome and othertypes of APAH.  
 
This study reviews the UKSPHC experience with epoprostenol therapy in 39 
children with PHT. The majority of children were referred to the UKSPHC after its 
establishment in 2001-2. The study focuses on treatment indications, efficacy, 
response to therapy and the associated morbidity due to the permanent central venous 
access (Hickman line) needed for the administration of epoprostenol.    . 
 
4.1.2 Patients and Methods  
All patients were regularly assessed before and after initiation of epoprostenol 
treatment. A careful recent clinical history was obtained,exploring day-to-day life, 
physical activities and participation in activities with peers, such as playgroup, 
kindergarten or school. Special consideration was paid to the social and family 
environment, to judge whether epoprostenol treatment along with its high demands 
and commitment to the family/ child’s carers was in the child’s best interest and 
could be facilitated.   
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In addition to a physical examination, weight and height were recorded, and an 
electrocardiogram and transthoracic echocardiography were performed on every visit 
to clinic or ward. The functional status was assessed by WHO Functional Class. A 
6MWT was performed in children old enough to do the test reliably. The test was 
performed in a standardised manner by an experienced investigator monitoring the 
distance walked and the transcutaneous systemic arterial oxygen saturation at 
baseline and on exertion as outlined in the general methods section (159). Cardiac 
catheterisation was performed under general anaesthesia (see Chaper 2) before 
instituting treatment in all children.    Electrocardiograms were analysed specifically 
for evidence of right ventricular hypertrophy (RVH) and strain. On transthoracic 
echocardiography, evidence of right ventricular dilatation, hypertrophy and function 
was assessed and documented as outlined in Chaper 2.   
Statistics 
Kaplan–Meier survival plots were constructed from the start of epoprostenol 
treatment. Censoring events were transplantation and cessation of epoprostenol. Z-
scores of weight were calculated by z =(measured value-reference mean)/reference 
SD. Reference values were taken from CDC (Center of Disease Control) growth 
charts (175). 
 
4.1.3 Results 
Between 1997 and 2005, 39 children were treated with epoprostenol. Patient 
demographics are shown in Table 5.1.1. Of these children, 25 had IPAH, whereas 
associated pulmonary hypertension (APH) occurred in 14 children, including 
postoperative congenital heart disease, cardiomyopathy, connective tissue disease, 
chronic lung disease or HIV (Table 4.1.1).  
The male:female ratio was 1:1.8 for IPAH and 1.3:1 for APH. The median age at the 
onset of therapy was 5.4 years (range 4 months–7 years). 
 
 
 
 
7 
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Table 4.1.1. Patients’ characteristics. 
 
 
 
Patients n=39 
Male:Female 17:22 
Age (median) 5.4 years (4 months - 17 years) 
Weight 21.2 ± 15.3 kg 
 
 
Aetiology of PH 
 
IPAH n=25 
PH associated with 
 
• CHD 
• Cardiomyopathy 
n=6 
n=3 
• Connective tissue disease n=2  
• Chronic/interstitial  lung disease n=2  
• HIV n=1 
 
 
WHO functional class 
 
1 / 2 / 3 / 4 0 / 0 / 27 / 12 
 
 
Medication before commencement of Epoprostenol 
 
• Bosentan 8 
• Sildenafil 6 
• Calcium channel blocker 6 
• Bosentan and sildenafil 2 
• Bosentan and calcium channel blocker 2 
  
 
 
Pulmonary haemodynamics at onset of treatment   
 
• Mean pulmonary arterial pressure  59 ± 17 mmHg (25-88) 
• Mean systemic arterial pressure 62 ± 14 mmHg (42-95) 
• Right atrial pressure 8.1 ± 5.2mmHg (3-28) 
• Mean left atrial pressure/ PCWP 9.4 ± 4.6 (3-23) 
• PVRI - baseline 23.3 ± 11.6 units.m² (3.5- 49.8) 
• PVRI  -100% FiO2 20.4 ± 10.8 units.m² (8.7- 44.0)  
• PVRI  - 65%FiO2/20 ppm NO 19.5 ± 11.1 units.m² (2.5-39.0) 
• Pulmonary arterial saturation  65.9 ± 12.5 % (23-87) 
• Systemic saturation 96 ± 4.7 % (83-100) 
 
Data are shown as mean ± standard deviation. In addition the range is presented in brackets. 
CHD = congenital heart disease; HIV = human immunodeficiency virus infection; IPAH = 
idiopathic pulmonary arterial hypertension; NO= nitric oxide; ppm= parts per million; 
PCWP= Pulmonary capillary wedge pressure; PH = pulmonary hypertension; PVRI= 
Pulmonary vascular resistance index; SD = standard deviation; WHO = World Health 
Organization Functional Class; m²= meter squared 
 
Children were treated with epoprostenol when they presented severely symptomatic 
in WHO Class III or IV, or had failed to improve or to sustain an initial improvement 
  
on oral therapy for PAH.  
bosentan, sildenafil or a calcium channel blocker.
 
Baseline status 
All patients were severely symptomatic; 27 patients were in WHO functional class 
and 12 were in class 4
 
Figure 4.1.1.Improvement in functional class (WHO) on epoprostenol therapy:
children in each WHO function
after 1, 2 and 3 years. During the first year, no child died and one 
three children died during the second year, and three died and two had a transplant during 
the third year. 
 
 
At the time of establishment of epoproste
16.0 kg (mean [SD] 21.0 [15.3]
z-score of  -1.55 [1.74
showed evidence of 
wave in V1 plus the S wave in S
ventricular strain was present in 14 children and ‘possible strain’ in another 13 cases.
 
Transthoracic echocardiography showed RVH in all children, associated with right 
ventricular dilatation in 33 children. Right ventricular systolic function was impaired 
 In total, 24 children had previously been treated with 
 
 (Fig 5.1.1).  
al class at the start of the treatment with epoprostenol and 
underwent
nol, the median weight of all children 
 kg). The children were underweight and had a mean 
] range  -2.14 to -0.96). In all children, the electrocard
right ventricular hypertrophy (RVH). The amplitude of the R 
5 or S6 was 43.5 (20.7) mV. Evidence of right 
106 
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 transplantation, 
was 
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in 32 children. None of the children a significant pericardial effusion. Doppler 
pressure estimations of right ventricular pressure could be obtained in 34 children. 
Mean velocity was 4.6 m/s, suggesting a mean right ventricular systolic pressure of 
84 mmHg (plus right atrial pressure) according to the modified Bernoulli equation. 
Pulmonary regurgitation was present in 23 patients, but was not severe in any child.  
 
Table 4.1.2 Echocardiographic parameters at baseline and during epoprostenol 
treatment. 
 
 Baseline Epoprostenol therapy 
   
Right ventricular function  
Normal 7 11 
Mildly impaired 17 13 
Moderately impaired 13 12 
Severely impaired 2 3 
 
 
 
   
Tricuspid regurgitation   
None 2 0 
Trivial 3 9 
Mild 30 18 
Moderate 3 11 
Severe 1 1 
   
Vmax tricuspid valve 4.6±0.9 m/s (n=34) 4.2±0.8 m/s (n=36) 
   
Pulmonary regurgitation   
None 16 18 
Trivial 7 6 
Mild 13 14 
Moderate 3 1 
Severe 0 0 
   
End diastolic PR velocity  2.9±0.6 m/s (n=16) 2.8±0.5 m/s (n=12) 
 
PR = pulmonary valve regurgitation; Vmax = maximal velocity.   
 
At cardiac catheterisation, the mean pulmonary arterial pressure (PAP) was 59 (SD 
17) mmHg. In 26 children the PAP equalled or exceeded the systemic arterial 
pressure (see Table 4.1.1).  
 
The mean pulmonary vascular resistance index (PVRI) was 23.3 (11.6) units/m2 in 
the 34 children in whom it was assessed. The lowest PVRI was seen in a child with 
cardiomyopathy. The child had an elevated PAP, was thought to be a ‘high risk’ 
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candidate for heart transplantation alone and, in an attempt to avoid heart–lung 
transplantation, was treated with epoprostenol for a month and then successfully 
underwent heart transplant. There was little change in PVRI in children who were 
tested either with inhaled nitric oxide (n=31) or with an increased inspired oxygen 
concentration (n = 18) (Table 4.1.1). 
 In all children a Hickman line was placed under general anaesthesia and connected 
to a portable infusion pump (CADD legacy pump, Pharmacia Deltec, St Paul, 
Minnesota, USA). In each patient the drug was uptitrated according to the clinical 
response. The initiation dose in children we use is 2 ng/kg/min, a dose that is usually 
well tolerated. 
The rate was subsequently increased, with the rate of increase depending on the 
severity of the disease, clinical response to therapy and the development of side 
effects. In this series, the mean dose of epoprostenol was 29.6 (15.2) ng/kg/min 
(range 6–63 ng/kg/min). The lowest dose was given to a child with cardiomyopathy 
who underwent heart transplant 1 month later. The mean dose given to children with 
IPAH was 32.5 (12) ng/kg/min (10–63 ng/kg/ min). All children were kept in 
hospital under observation until clinical improvement was evident. Subsequently the 
parents received instructions how to further elevate the dose, so that further 
increments (and adjustments for weight gain) could be carried out at home.  
 
The mean follow-up time was 27 (21) months (range 1– 90 months). The Kaplan–
Meier analysis showed that the cumulative survival of all patients who received 
epoprostenol at 1, 2 and 3 years was 94%, 90% and 84%, respectively. The 
cumulative survival is illustrated in Figure 4.1.2a. Survival of patients with IPAH at 
is shown in Figure 4.1.2b, their survival at 1, 2 and 3 years was 96%, 91% and 83%, 
respectively.  
 
 
 
 
 
 
 
 
109 
 
 
 
 
a) 
 
 
b) 
 
 
Figure 4.1.2a and 4.1.2b Kaplan–Meier cumulative survival plots with 95% CIs of (a) all 
children treated with epoprostenol and (b) those diagnosed as having IPAH. Children were 
censored at the time of transplant and when epoprostenol treatment ceased. 
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Censoring events were transplantation and cessation of epoprostenol. In total, 32 of 
the 39 patients survived, four having been on epoprostenol treatment for more than 5 
years. Seven patients died after receiving treatment for a median of 29 months (range 
3–61 months). Four patients with IPAH died from disease progression despite 
maximum therapy. There was one death in a child with severe systemic sclerosis and 
two from corrected congenital heart disease. 
In six children, who had been on nifedipine, when epoprostenol treatment was 
commenced, nifedipine was discontinued, because of possible compromise of right 
ventricular function (284). Similarly, sildenafil was withdrawn in four unstable, sick 
children to avoid hypotension at initiation of epoprostenol treatment. Once 
established on epoprostenol, however, additional therapies were added in 14 
children: bosentan in 8, sildenafil in 5 and both in 1 child. In total, 17 children with 
syncope or pre-syncope had an atrial septostomy (285). 
 
Epoprostenol was discontinued in 10 children, eight of whom underwent 
transplantation. Six of the transplanted children had IPAH and two had  a 
cardiomyopathy. Of those transplanted children, four children with IPAH had a 
double lung transplantation, and two received a heart and lung transplantation. One 
child with a cardiomyopathy had a heart and lung transplant and one a heart 
transplant.  In these eight children, epoprostenol therapy was started at a median age 
of 4.8 years (range 1.2–16.8) and the mean duration of treatment before 
transplantation was 26.2 (16.4) months (range 1–51). For patients with IPAH, the 
mean duration of treatment was 32 (13.9) months, and for those with 
cardiomyopathy it was 1 and 17.2 months. Two patients could be successfully 
transitioned onto either bosentan or nifedipine. One child of these children had IPAH 
,presented with a  cardiac arrest and  was treated with epoprostenol before endothelin 
receptor antagonists were available.  She was successfully transitioned onto a dual 
endothelin receptor antagonist. The other child was electively treated with 
epoprostenol after a late surgical closure of atrial and ventricular septal defects. She 
had suffered from severe postoperative pulmonary hypertensive crises. Her cardiac 
catheterisation study 7 months after surgery showed a normal PAP and PVR and she 
was transitioned onto nifedipine. 
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The mean WHO functional class improved significantly during the first year of 
therapy, from 3.6 to 2.6 (p=0.001), and remained stable up to and during the third 
year of treatment at 2.6 (Figure 4.1.1). During the first year, an improvement in 
functional class was observed in 30 children; another 4 were stable, 3 deteriorated 
and 2 diedIn addition, the children gained weight. For weight, the mean z score 
improved significantly from -1.55 (1.74) (range -2.14 to -0.96) to -1.16 (1.8) p=0.03) 
during follow-up. 
 
A 6MWT was undertaken in patients old enough to perform the test reliably. Twelve 
children performed the test before they started epoprostenol therapy, 16 children 
performed their first test on treatment. For these 28 children the mean (SD) initial 
distance was 250 (93) m. After a follow-up of 11.4 (7.1) months, the distance walked 
increased to 327 (105) m (p=0.003), as illustrated in Figure 4.1.3. 
 
 
 
Figure 4.1.3 Six-minute walk test results at baseline and on treatment after 11.4 months of 
follow-up. 
 
Electrocardiography was unchanged and did not show any evidence of a significant 
reduction in either RVH (39.7 (21.2) vs 43.5 (20.7) mV, p = 0.07) or right ventricular 
strain. 
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Echocardiographic right ventricular function improved during the first year of 
treatment in 12, was unchanged in 19 and deteriorated in 8 patients (Table 4.1.2).  
At baseline, the tricuspid regurgitant jet velocity was 4.6 (0.9) m/s and 4.2 (0.8) m/s 
on treatment, suggesting a non-significant reduction in the systolic right ventricular 
pressure (p=0.08). There was little change in frequency or severity of pulmonary or 
tricuspid regurgitation on epoprostenol treatment: all in all, 37 children had tricuspid 
regurgitation and 23 patients had pulmonary regurgitation before treatment  while  39 
children had tricuspid regurgitation (TR) and 21 pulmonary regurgitation on 
treatment. The mean end-diastolic velocities as estimated by the pulmonary 
regurgitation jet, and before and after treatment they were 2.9 (0.6) m/s and 2.8 (0.5) 
m/s, respectively. 
 
Administration of epoprostenol was unproblematic in 24 patients. There were only 
0.33 Hickman line changes per patient year on treatment. In total, the line required 
replacement in 15 patients. The reasons included: infection on 20 occasions, a 
leaking line in 5 and catheter dislocation on 4 occasions. Courses of antibiotic 
treatment were required on 43 occasions, primarily for local site infections. Only on 
six occasions blood cultures were positive in four patients (Pseudomonas n = 
1,Methicillin-resistant Staphylococcus aureus (MRSA) n =1, other than MRSA 
Staphylococcus aureus, n = 3, Staphylococcus aureus and Candida in 1). 
 
4.1.4 Discussion 
This study shows that epoprostenol therapy represents an effective treatment for 
children with severe PHT. The natural history in children with PHT is worse than in 
adults. Historical data from a registry on IPAH of the National Institutes of Health 
suggested survival rates in adults of 68%, 48% and 34% at 1,3 and 5 years 
respectively, while median survival was 2.8 years (286). In children without 
treatment median survival is less than 1 year from the time of diagnosis (5,7). The 
current study illustrates that on treatment with epoprostenol the survival in children 
is at least comparable to that reported in adults. In the current study the survival in 
children with IPAH was 96%, 91% and 83% at 1, 2 and 3 years, respectively. These 
data compare favourably with those of other published series. Survival rates in one 
study on adults were 87.8%, 76.3% and 62.8% at 1, 2 and 3 years (131), and in a 
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more recent study the survival rates were 91%, 84% and 75% at 1, 2 and 3 years, 
respectively (287). A study of 35 children on epoprostenol treatment stated survival 
figures of 94%, 81% and 61% at 1, 5 and 10 years (288). 
 
The cohort reported here includes 36% of children with PHT which was not 
classified as ‘idiopathic’, and these children responded equally well to epoprostenol. 
A proportion of them had associated PHT secondary to congenital heart disease. 
Closure of a cardiac defect in the presence of an elevated pulmonary vascular 
resistance is an recognized risk and well known to accelerate the development of 
severe pulmonary vascular obstructive disease (289,290). Thus treatment with 
epoprostenol appears to be a logical step in these patients. Adult studies have shown 
its usefulness in patients with PHT associated with connective tissue disease and 
HIV (291-293). It is encouraging that the children in this series also benefited from 
epoprostenol treatment. This study also shows that the functional class and 6-minute-
walking-test improve on epoprostenol therapy.  The children gained weight, even 
improving their z-scores. In addition, echocardiographic right ventricular function 
remained stable on therapy.  
 
Despite the absence of a positive response to acute vasodilator testing in the 
catheterization laboratory, long-term treatment with epoprostenol was successful in 
this cohort of children with severe PHT. This is in agreement with the experience of 
other investigators (130,294). Overall, the clinical condition of the patients usually 
improved soon after the initiation of treatment. In adults with IPAH, the benefit of 
epoprostenol treatment is also most apparent soon after starting therapy, with only 
little additional improvement thereafter (131). It is hypothesized that early 
improvement might be due to the positive inotropic effect of epoprostenol (88). In 
patients with IPAH who receive epoprostenol, an early increase in cardiac output is 
well documented (89,131,133). Clinical improvement in the current study was 
accompanied by favourable changes in right ventricular function as assessed by 
echocardiography. The function either improved or did not deteriorate in 31 of the 39 
children. In addition, electrocardiographic measures of RVH and ECG signs of strain 
did not deteriorate, which against the background of pulmonary vascular disease 
being a chronic progressive disease with a poor prognosis, could be considered a 
therapeutic success. 
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Fourteen children remained on bosentan or sildenafil at the start of epoprostenol 
therapy, and another 14 children were given a second disease specific therapy when 
their clinical condition deteriorated. As pulmonary vascular obstructive disease can 
develop rapidly in children, maximum early intervention is desirable. The aim is to 
improve survival, enhance the quality of life and eventually be able to offer 
transplantation when medical treatment fails. Epoprostenol treatment plays an 
important role particularly in young children, helping them maintain their physical 
status and enabling  them to grow and survive to reach an age when lung or heart and 
lung transplantation  becomes feasible.  Treatment can also be considered as a 
pharmacological ‘bridge to transplantation’ until a suitable organ becomes available. 
 
Epoprostenol treatment represents an invasive ‘high maintenance’ therapy and 
requires careful consideration and assessment of the risk–benefit ratio. The 
international experience with epoprostenol has shown that it is the most effective 
treatment in severely symptomatic patients with IPAH. It has been successfully used 
as a rescue therapy in patients failing to respond to oral therapies such as bosentan 
and sildenafil.  
 
The policy of the UKSPHC  when this study was carried out was  to select children 
for epoprostenol treatment because they were clinically unstable, were in WHO 
functional class 3 or 4, or had either failed to respond to oral or were considered to 
be too sick and unlikely to respond quickly to oral therapy. These conditions comply 
with the management guidelines for IPAH prepared by the European Society of 
Cardiology (3) and the American Heart Association (37,295). Unfortunately, less 
invasive therapies such as the epoprostenol analogue treprostinil or inhaled iloprost 
are of limited value in children for reasons discussed in Chapter 1. In the present 
study, there was no mortality associated with the invasive mode of administration of 
epoprostenol itself. As anticipated, morbidity was primarily due to infections, which 
were generally limited to site infections. 
 
In conclusion, the results of this study indicate that epoprostenol therapy slows the 
progression of pulmonary vascular disease and can be effective in both children with 
IPAH and in those with APH. Epoprostenol therapy improves survival compared to 
historical controls, improves WHO functional class and exercise tolerance and 
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improves the ability to thrive in children with severe PHT. It is thought that 
epoprostenol can either slow down or stabilise the pulmonary vascular disease 
process, at least for a time. The particularly rapid course of the disease in childhood 
suggests that children should be treated promptly and effectively as soon as they 
present to the physician. Overall, this study supports the notion that epoprostenol 
represents an effective, feasible therapy with an acceptable morbidity even in young 
children with severe PHT. 
 
  
116 
 
 
4.2  ATRIAL SEPTOSTOMY – THE UKSPHC EXPERIENCE BETWEEN 1997 
and 2005 
 
4.2.1 Background 
Despite advances in medical therapy PHT remains an incurable progressive disease, 
eventually leading to right heart failure, functional incapacity, and death. The 
symptoms are non-specific and therefore presentation is late. In adult patients atrial 
septostomy has been shown  to be beneficial for selected patients (4,9,296,297). The 
procedure permits right to left shunting, decompresses the right heart and can 
increase left ventricular preload during an acute rise in pulmonary vascular resistance 
such as a pulmonary hypertensive crisis. Observed beneficial effects in adult 
populations include prolonged survival with deferral of transplantation and improved 
quality of life, symptoms, and haemodynamic function (112,117,119,120,298). 
Nevertheless, atrial septostomy has been associated with a considerable risk of 
intraprocedural and periprocedural mortality of up to 30% in some series 
(112,119,298). As experience using this procedure in children with pulmonary 
hypertension is limited a number of issues require clarification in paediatric patients. 
These include the optimal timing of the procedure, associated morbidity and 
mortality, and long term effectiveness. This study was performed to review the 
UKSPHC experience with atrial septostomy in the treatment of children with severe 
IPAH. 
 
4.2.2 Patients and Methods 
From the institutional database 20 children with severe PAH who underwent an 
interventional cardiac catheterisation to create an interatrial communication were 
identified. Nineteen patients had IPAH, nine boys and 10 girls. One girl had 
pulmonary hypertension associated with HIV (Table 5.2.1). The mean age at atrial 
septostomy was 8.4 years with a range between 0.25 and 17 years. 
All patients were highly symptomatic, 9 in WHO functional class 3 and 11 in class 4 
as shown in Table 5.2.1.The majority (65%) had recurrent syncope, the remaining 
patients (35%) were in right ventricular failure despite treatment. All patients had 
systemic arterial oxygen saturations of at least 90%. Among the 7 children who 
could perform a six-minute walk test, the mean distance walked was 326 m (range 
160– 432 m). At the time of the septostomy the treatment regimens of the children 
was as follows: 17 children were receiving specific pulmonary hypertensive 
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treatment as a single or dual therapy and 3 sick children were catheterised with 
septostomy when they first presented to the Service after being treated for 24 
hours.Transthoracic echocardiography showed a tricuspid regurgitant jet velocity of 
at least 4 m/s in 17 children and 3.1–3.4 m/s in the remaining patients. Seven patients 
had moderately or severely impaired right ventricular function (Table 4.2.2). Cardiac 
catheterisation (Table 4.2.2) was performed under general anaesthesia. The mean 
pulmonary artery pressure approached or exceeded the mean systemic arterial pre- 
ssure in 15 patients. The mean pulmonary vascular resistance index was 23 units/m2. 
Nineteen patients were not found to be responders on acute vasodilator testing with a 
combination of 65% oxygen and nitric oxide. One patient, however, who had several 
cardiac arrests before and on admission to hospital had a positive vasodilator 
response with the pulmonary artery pressure falling to one third systemic arterial 
pressure. Overall, the mean right atrial pressure of the patients was 9.3 mm Hg 
(range 3–19 mm Hg).  
The mean time from diagnosis to atrial septostomy was 2.5 years (range one month 
to 16 years). Eight of 20 (40%) patients had the septostomy performed within six 
months of the diagnostic cardiac catheterisation. Three children were so severely 
symptomatic when they presented that it was thought safer to begin treatment with 
intravenous epoprostenol for a week or more and then perform an atrial septostomy 
in the same session as the diagnostic cardiac catheterisation study, to avoid repeat 
general anaesthesia. Three other children admitted for atrial septostomy, were felt to 
be unstable, particularly due to their right ventricular function on echocardiography, 
and epoprostenol was started the day before the procedure and maintained 
subsequently. 
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Table 4.2.1 Patient characteristics.  
 
Patient Gender 
Age at 
procedure 
(years) 
Diagnosis WHO Class Indication 
Therapy 
before 
procedure 
Subsequent 
Therapy  
    
   
 
1 M 0.25 IPAH III Syncope PGI2 Sild PGI2 Sild 
2 M 1.5 IPAH III RVF PGI2 PGI2 
3 F 2.5 IPAH III Syncope Bos Bos PGI2 
4 F 3 IPAH III-IV Syncope, RVF Ilopr Nifed Ilopr Nifed 
5 M 3.5 IPAH IV Syncope nil PGI2 
6 F 4 IPAH III-IV Syncope Bos Sild PGI2 Bos Sild  
7 M 5 IPAH IV RVF PGI2 Bos PGI2 Bos 
8 M 5.5 IPAH IV RVF Nifed PGI2 Nifed PGI2 
9 M 5.5 IPAH IV Syncope nil PGI2 
10 F 6 IPAH III Syncope Nifed PGI2 
11 F 6.5 IPAH IV RVF PGI2 Sild PGI2 
12 F 9 IPAH III Syncope Nifed PGI2 
13 M 9.5 IPAH III RVF nil PGI2 
14 F 12.5 IPAH III Syncope Bos Bos 
15 M 13.5 IPAH IV Syncope    Nifed Nifed 
16 F 14 IPAH III-IV Syncope Bos, Sild Bos, Sild 
17 F 15.5 IPAH IV RVF PGI2 PGI2 
18 F 16.5 IPAH III-IV Syncope Bos Bos 
19 M 17 IPAH III RVF Nifed PGI2 
20 F 16.5       APH (HIV) III Syncope Bos PGI2, Bos 
   
    
 
 
IPAH = idiopathic pulmonary arterial hypertension; Associated PH = secondary pulmonary 
hypertension.  
Bos = bosentan, Nifed = nifedipine, PGI2 = epoprostenol, Sild = sildenafil, RVF = right 
ventricular failure. 
 
 
4.2.3 Results 
Technique of atrial septostomy 
The interventional procedure was performed under fluoroscopic and 
transoesophageal echocardiographic guidance with general anaesthesia in all 
children.  The atrial septostomy was carried out using different techniques as shown 
in Table 5.2.3. Eight children underwent graded balloon septostomy, two blade 
septostomy, and a combination of a blade plus graded balloon septostomy was 
employed in the remaining three patients. More recently, a graded balloon approach 
was followed by the introduction of a custom made fenestrated atrial septal defect 
(ASD) Amplatzer device, which was implanted in seven patients and is described in 
detail in the next section. 
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Procedural complications 
An adequate interatrial communication could be successfully created in all but one 
patient (case 20). The mean size of the created communication – as measured by 
echocardiography immediately post procedure - was 7 mm. Table 4.2.3. shows the 
size of the communication for all patients. The procedure was uncomplicated in 16 
cases. Relevant complications occurred in four patients but all eventually made a 
good recovery. One case was complicated by arrhythmias and cardiac arrest just 
before the atrial septostomy (case 3). The patient remained intubated, and 
mechanically ventilated until a successful graded balloon septostomy was carried out 
13 days later. In another patient (case 6) who had presented with syncope the 
implantation of a 5 mm fenestrated ASD Amplatzer device was complicated by a 
cardiac arrest, and the patient required mechanical ventilation for 13 days. In case 17 
insertion of a fenestrated device was complicated by hypoxaemia and acidosis 
leading to an emergency re-intubation and mechanical ventilation for five days. As 
mentioned above the procedure failed in one patient (case 20). In this patient there 
was considerable systemic arterial desaturation from 98% at baseline to 58% during 
graded balloon septostomy. The patient required prompt implantation of a 14 mm 
Amplatzer ASD occluder device. This patient had a high right atrial pressure of 19 
mm Hg. The patient was mechanically ventilated for 24 hours and eventually 
discharged on epoprostenol and remains well. 
 
Outcome 
The mean systemic arterial oxygen saturation decreased from 98% before 
septostomy to 90% after 3–6 months (P=0.01). In addition, WHO functional class 
improved with 6 children moving from WHO class 4 to 3, and four from WHO class 
3 to 2 (P<0.001). In contrast, no significant change was found in the 6-minute walk 
test distance. Echocardiography showed an improvement in right ventricular function 
in seven patients and no deterioration in the rest. The velocity of the tricuspid valve 
regurgitant jet remained unchanged. A bidirectional flow was generally seen at rest 
across the atrial communication. All patients could be discharged home after the 
procedure. The majority of patients were treated with continuous epoprostenol 
infusions as shown in Table 4.2.1. Recurrent syncope abolished in all except one 
child (case 1) who died two months after the procedure. The seven other patients in 
right heart failure improved as judged clinically. In one case (patient 19), chest pain 
120 
 
 
did not improve after the first septostomy and a second, successful procedure was 
performed a few months later, resolving symptoms. In case 17 a second procedure 
with a fenestrated device insertion was done 16 months after the first improving right 
ventricular function. 
After a mean follow up of 2.1 years (one month to 6.7 years) clinical improvement 
has been maintained in 18 of the 19 patients with a successful atrial septostomy; the 
remaining patient is also well and at college. Two children since underwent bilateral 
lung transplantation (cases 5 and 9). In addition to the baby who died at 5 months of 
age, one patient (case 10) died suddenly five years later with a severe episode of 
haemoptysis. 
 
Table 4.2.2 Echocardiographic and hemodynamic parameters before atrial septostomy 
 
Patient 
 
Echo. RVF 
score 
(1-4) 
Mean 
PAP/SAP 
(mmHg) 
RAP 
(mmHg) 
PVR 
(units.m2) 
1 2 58/57 7 19 
2 3 53/56  5 14 
3 2 65/61 10 26 
4 2 71/67  - 23 
5 2 56/47  6 38 
6 3 25/54 3 12 
7 4 70/65 18 13 
8 2 71/58 7 14 
9 2 66/59 9 27 
10 3 80/75 - 22 
11 4 63/45 8 39 
12 2 56/74 3  5.6 
13 2 80/71  10 27 
14 2 59/74  12 12 
    15 - 78/69 9 20 
16 2 53/73 7 18 
17 3 49/50  18 21 
18 2 49/75 13 13 
19 2 71/61 3 14 
20 3 80/63 19 22 
 
 
Echo. RVF = echocardiographic assessment of right ventricular function [11], PAP = 
pulmonary arterial pressure; PVR = pulmonary arterial resistance; RAP = right atrial 
pressure; SAP = systemic arterial pressure;  
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Table 4.2.3 Procedure type and immediate outcome 
 
Patient Type of Procedure Size [mm]  Ventilator days 
1 BAS 5 0 
2 Fen. ASD device  5 0 
3 BAS  5 12 
4 Blade/BAS 10 0 
5 BAS 5 0 
6 Fen. ASD Device  5 13 
7 Fen. ASD Device  5 0 
8 Blade/BAS 7.5 0 
9 BAS  5 0 
10 Blade  6 0 
11 BAS 10 0 
12 BAS 7  0 
13 Fen ASD device  8  0 
14 Fen. ASD device  8 0 
15 Blade  4.5 0 
16 Fen ASD device  7 0 
17 Fen. ASD device  6 10 
18 BAS 7 0 
19 Blade/BAS 8 0 
20 BAS  14 7 
 
Fen.= fenestrated, ASD = atrial septal defect; BAS = 
balloon atrial septostomy; Blade = blade atrial septostomy 
 
 
4.2.4 Discussion 
This study shows that atrial septostomy can be performed safely and is effective in 
children with IPAH. None of the patients died and the procedure was successful in 
19 of 20 patients. Syncope was abolished and right heart failure improved in the 
majority of patients. In addition, WHO functional class and right ventricular function 
improved. Longer term outcome is also reassuring, with 17 of the 19 children who 
had an atrial septostomy being alive after a mean follow up of 2.1 years.  Two 
patients have had a successful bilateral lung transplantation highlighting the potential 
role of atrial septostomy as bridge to transplantation in selected patients. Overall, the 
mean systemic arterial oxygen saturation dropped by approximately 8% points.  In 
one patient severe right to left shunt immediately after creation of the interatrial 
communication lead to severe cyanosis and required emergency closure of atrial 
septal defect. The right atrial pressure was high in this case at 19mmHg. This case 
highlights the problem of high right atrial pressures. In fact, current guidelines 
recommend to avoid atrial septostomy in patients with a right atrial pressure above 
20 mmHg. This case, however, illustrates that severe complications can also occur at 
right atrial pressures that are lower, but approaching this threshold. Although much 
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has been speculated about a possible improvement of tissue oxygen delivery as a 
consequence of successful atrial septostomy, it appears that the main effect is the 
ability to shunt right-to-left during periods of high pulmonary resistance and 
elevation of pulmonary artery pressure or when a higher systemic cardiac output is 
required.  It has been said that he inter-atrial communication allows the patient to 
maintain an adequate systemic cardiac output at the expense of a (modest) reduction 
in oxygen saturation (123). This notion is supported by the results of the current 
study showing that syncope was abolished in the majority of children.  
 
In conclusion, this study demonstrates that atrial septostomy improved symptoms 
and quality of life in a group of severely symptomatic children with IPAH. The 
procedure was effective with no fatalities. Complications can, however, arise in these 
fragile patients and atrial septostomy should only be performed in experienced 
centres. As the atrial communication can close spontaneously regular follow up is 
essential.  
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4.3 ATRIAL SEPTOSTOMY – EFFICACY AND LONG-TERM PATENCY OF 
FENESTRATED AMPLATZER DEVICES   
 
4.3.1 Background 
The use of fenestrated atrial devices is appealing in patients with PHT who undergo 
atrial septostomy in an attempt to guarantee long-term patency of the atrial 
communication. Fenestrated Amplatzer devices (Amplatzer, AGA Medical, Golden 
Valley, MN) have been successfully used for ASD closure, whilst maintaining a 
small atrial communication of predefined size in various patient groups, for example 
the elderly (299,300). Fenestrated devices have also been used in patients after the 
Fontan operation to create an interatrial communication percutaneouly in order to 
abolish problems caused by an elevated central venous pressure, such as protein-
losing enteropathy or persistent pleural effusions (301,302). Fenestrated atrial 
devices are especially appealing in patients with PHT (285). Despite the obvious 
need for this type of device, custom-made fenestrated occluders are no longer 
commercially available. Use of modified Amplatzer devices could be a feasible 
alternative. Experience with fenestrated devices in the paediatric population, 
however, is limited. This study presents the indications, the procedural and long-term 
complications and data on the long-term patency and efficacy of custom-made and 
modified Amplatzer devices in a group of children with PAH. 
 
4.3.2 Patients and Methods 
Ten children (5 male) between 1.5 and 15.5 years of age (median 4.5 years) had a 
fenestrated Amplatzer device inserted between 2003 and 2007. Table 5.3.1 provides 
details to patients’ demographics. Six patients had custom-made fenestrated devices 
inserted (modified by the manufacturer MM, Special order Amplatzer, AGA 
Medical, Golden Valley, MN, Figure 4.3.1), while modified standard atrial septal 
occluders were used in four patients of because custom-made fenestrated devices 
were no longer available. Written consent was obtained from all parents before the 
interventional procedure after extensive explanation of the risks and benefits of the 
insertion of a fenestrated device. The Amplatzer device consists of Nitinol metal 
with smooth rounded disks and polyester fabric inside the meshed discs. A 
fenestration was created through the occluding portion of the disc using 4.0 sutures 
and removal of fabric (Figure 4.3.2). The device was subsequently checked for 
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deformation and it was ensured that it could be easily stretched and regained its 
double disc shape without any deformation. The device was loaded onto the 
introducing sheath, and delivered by the technique used for atrial septal occluders.  
In children with an intact atrial septum, transatrial septal puncture was performed 
using a standard needle, dilator, and sheath combination (St Jude Medical, Fullerton, 
CA) under transoespophageal echocardiographic monitoring. With release of the 
device the hat sprang back into the disc shape. No further dilatation of the self-
fabricated fenestration was necessary in those four patients who received a modified 
device. Flow across the fenestration was demonstrated by echocardiography at the 
time of the interventional procedure. 
 
All children were regularly followed in outpatient clinic and assessed with 
transthoracic echocardiography to monitor the patency of the device. Right 
ventricular function was assessed semiquantitatively by echocardiography and 
quantified as normal, mildly, moderately or severely impaired, as described 
previously (218,285). Patients’ functional class was assessed using the WHO 
classification (1-4). Special attention was paid to those symptoms, which had lead to 
the insertion of the device.  
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Table 4.3.1 Patients’ data. 
 
 Age 
[years] 
Sex Diagnosis Indication for 
Device 
WHO 
pre 
WHO            
post 
RVF 
pre 
RVF 
post 
Symptom 
resolved 
 
         
1 1.3 M T 21, PHT ASD II 3 2 1 1 Y 
2 1.5 M PHT RV-failure 3 3 3 2 Y 
3 3.1 M T 21, PHT ASD II 2 2 1 1 Y 
4 3.1 F ECMO Offload LA 4 - 4 - Y 
5 4 F PHT Syncope 3 3 3 2 Y 
6 5 M PHT RV-failure 3 3 4 3 Y 
7 9.5 F PHT RV-failure 3 2 3 2 Y 
8 12.5 M PHT Syncope 3 3 2 2 Y 
9 14 F PHT Syncope 3 2 2 2 Y 
10 15.5 F PHT RV-failure 4 3 3 3 Y 
 
         
 
ASD II = secundum type atrial septal defect, ECMO= extracorporal membrane oxygenation, 
F=female, LA= left atrium, M=male, N= no, PHT= pulmonary hypertension, RV= right 
ventricular, RVF= Right ventricular function (semiquantitatively described as) 1= normal, 
2= mildy, 3= moderately, 4= widely impaired. T 21= Trisomie 21, WHO= Functional class 
according to World Health Organization (1-4), Y=yes,  
 
 
 
 
 
Figure 4.3.1 Custom-made fenestrated Amplatzer device.
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Table 4.3.2  Haemodynamic data and device follow-up. 
 
 Device Size 
(mm) 
Fen 
size 
(mm) 
PAP/AoP PVRI RAP LAP Anticoag./ 
Antiplatelet  
Follow-up 
(months) 
Device 
Patency 
 
          
1 modified 12 5 26/60 - 8 - Aspirin 19.5 N 
2 custom 10 5 53/56 14 5 9 Aspirin 26.7 Y 
3 modified 14 5 34/62 3.6  - Aspirin 23.8 N 
4 modified 11 5 - - - - Heparin 0.1 Y 
5 custom 11 5 25/54 19 3 5 Aspirin 28.5 N 
6 custom 10 5 70/65 13 18 - Warfarin 28.2 Y 
7 custom 14 8 80/71 27 10 10 Warfarin 31.0 Y 
8 custom  14 8 61/72 17 12 - Warfarin  24.0 Y 
9 modified 9 7 53/73 18 7 14 Warfarin 17.8 N 
10 custom 14 6 49/50 21 18 - Warfarin 23.6 Y 
 
          
 
Anticoag.= Anticoagulation therapy, AoP= Mean Aortic pressure, Fen. = fenestration, mm= millimetre, N= no, PAP= Mean 
pulmonary artery pressure, PVRI = pulmonary vascular resistance index, RAP= right atrial pressure, Y=yes,  
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Figure 4.3.2  Modified standard Amplatzer atrial septal occluder with self-made 
fenestration. 
 
 
4.3.3 Results 
In nine patients, devices were implanted for PHT. Seven of those patients underwent 
atrial septostomy with fenestrated device insertion (four children for right heart 
failure, three for recurrent syncope). The remaining two patients were children with 
Down’s syndrome and a haemodynamically relevant atrial septal defect. In addition, 
one patient with dilated cardiomyopathy on extracorporal membrane oxygenation 
had a fenestrated atrial device inserted to offload the left atrium.   Patients with 
pulmonary hypertension were all in WHO functional class 3 or 4, whereas the two 
patients with pulmonary hypertension and haemodynamically relevant atrial septal 
defect were in functional class 2 and 3, respectively. The patient on ECMO was 
classified as functional class 4. 
 
Catheterization and device delivery was successful in all patients without any 
procedural complications. All modified Amplatzer devices were easily stretched and 
were loaded without any problems onto the delivery system. Devices were well 
seated and an adequate flow across the created fenestration could be demonstrated 
immediately after device delivery in all patients with transthoracic or 
transoesophageal echocardiography (Figure 4.3.3). 
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In those patients who had a fenestration created for right heart failure, right 
ventricular function improved (Table 4.3.1). One child underwent heart-lung-
transplantation 23.6 months after device insertion. At the time of transplantation the 
device was found to be still patent. Episodes of syncope abolished in two of three 
patients who received a fenestrated device for syncope. One child presented with a 
recurrent syncope two years after device implantation. Echocardiography at this time 
confirmed that the fenestration was no longer patent.  The two patients with Down 
syndrome, who received the device to reduce shunting through a significant atrial 
septal defect but to maintain a small communication as a blow–off valve, are well 
and thriving. The patient on EMCO, in whom an atrial communication was created to 
offload the left atrium, was transplanted three days after the intervention. As a 
consequence, this child was not included in the long-term follow-up.  
 
In 8 patients the device remained in situ after a mean follow-up of 24.5 months 
(range: 17.5 -31.0 months).  Device patency was confirmed in 5 patients (all custom-
made) after 26 months follow up (range: 23.6 – 31 months), 4 children being treated 
with warfarin, one child with  aspirin.  Device patency could not be demonstrated in 
4 other children after a median follow-up of 10 months (range: 2.8 – 14.5 months). 
One custom-made and three  modified devices occluded. Of these children three 
were treated with aspirin, one was treated with warfarin. 
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Figure 4.3.3 Transesophageal echocardiogram demonstrating left 
to right shunt across fenestration of the device. 
 
 
4.3.4 Discussion 
In this case series the implantation of fenestrated atrial devices was found to be 
feasible and clinically effective but long-term patency could not be guaranteed. In 
addition, the results indicate that anticoagulation with warfarin may be more 
effective than aspirin in preventing closure of the fenestration.  
 
In patients with PHT improved survival has been reported in patients with a native 
atrial communication (303). The creation of an atrial septostomy is an established 
treatment in selected patients with intact atrial septum (112,118,119,296). The 
majority of patients in the present case series had PHT and were treated with 
advanced therapies, and all showed symptomatic benefit from the creation of an 
inter-atrial communication.  Right heart failure and syncope were reduced.  Previous 
studies have shown that atrial septostomy improves haemodynamics and prolongs 
survival in patients with severe PAH (112,117-121). In the paediatric population it 
may be especially useful in children presenting with syncope (40). Atrial septostomy 
allows augmenting systemic blood flow, potentially benefiting organs that lack the 
ability to autoregulate blood flow at low blood pressures. It has been suggested that a 
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mean arterial pressure of at least 60 mmHg is required to enable cerebral 
autoregulation (122). Interestingly, atrial septostomy has been demonstrated to be 
especially effective in abolishing syncope. Atrial septostomy could protect against 
syncope by maintaining systemic cardiac output, particularly when the pulmonary 
arterial pressure rises acutely (113). In the situation of desperately poor systemic 
blood flow, autoregulation may not be able to successfully maintain flow to some 
vital territories - an increase in total flow could permit autoregulatory processes to 
restore perfusion to vital organs. In addition, it has been suggested that atrial 
septostomy increases oxygen delivery to the tissues due to an increase in cardiac 
output, despite the modest reduction in systemic arterial oxygen saturation 
septrostomy (113). However, a recent analytical study revealed this does not coincide 
with an improved tissue oxygenation and is merely a consequence of the way raw 
arterial oxygen delivery is defined (123). According to current guidelines atrial 
septostomy should, thus, be considered in PAH who continue to be symptomatic 
despite optimal medical PAH treatment (3).  
 
Alternative indications for a fenestrated ASD device include reducing a left to right 
shunt in patients prone to develop pulmonary vascular disease. In fact, two of the 
patients had Down syndrome with significant left to right shunts through native atrial 
septal defects. Both patients had echocardiographic evidence of right ventricular 
volume overload and pulmonary hypertension (with mean pulmonary arterial 
pressures of 26 and 34 mmHg, respectively). It was felt, therefore, that complete 
closure of the atrial septal defect could be detrimental and potentially result in 
significant morbidity. It is recognized that children with Down syndrome have a 
reduced number of alveoli and pulmonary capillaries leading to rarefication of the 
pulmonary vasculature (304).  As a consequence, volume overload of the pulmonary 
circulation is detrimental and can result in pulmonary vascular disease (305,306 ). 
Though development and progression of pulmonary vascular disease is difficult to 
foresee in this patient group (307), use of a fenestrated device was recommended.  
Maintenance of a small communication is useful in offloading the right ventricle as 
pulmonary vascular disease progresses. Closure of a significant atrial septal defect 
with standard devices would make an atrial septostomy later in life technically 
impossible but insertion of a fenestrated device addressed this problem. This 
approach may also be taken with children without Down Syndrome but other risk 
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factors for progressive pulmonary vascular disease, such as chronic lung disease and 
pulmonary dysplasia (307,308).  
 
It is perhaps no surprise that manufacturer modified devices seem superior to the 
operator modifications of standard atrial septal occluders. Fenestrations in 3 of the 4 
operator modified devices were occluded on long-term follow-up in the current 
series.  However, the mechanisms for closure of fenestrations are not entirely clear. 
The most likely reason for closure of fenestrations within atrial septal devices is 
tissue in-growth and thrombosis. In modifying custom-made devices, the created 
communication more often had an oval or uneven shape rather than the desired 
circular opening, probably due to the memory of the nitinol wires. Therefore, it can 
be speculated that a more turbulent flow though an uneven opening might have made 
fenestrations more susceptible to spontaneous closure.  Interestingly, explanted 
prototype manufacturer modified devices have shown that the dimension of the 
fenestration may also reduce as a result of loss of metal shape memory (309). This 
observation provides the rationale for further catheter intervention to re-establish or 
improve patency of fenestrations.  The use of endovascular stents is an obvious 
alternative but this technique adds complexity to the procedure and may lead to 
complications such as injury to the atrial wall.   
 
The optimal anticoagulation policy for atrial septal occluders to prevent thrombotic 
adhesions to the surface of the device is unclear. At Great Ormond Street Hospital, 
younger children with PHT receive Aspirin, while older children are anticoagulated 
with warfarin as part of their standard treatment for pulmonary hypertension. Most of 
the children included in this series were already on such treatment at the time of the 
procedure.  In this series 3 of the 4 children in whom the communication closed were 
on aspirin there were too few patients to draw a definitive conclusion.  
 
In conclusion, implantation of fenestrated atrial devices is technically feasible and 
safe in children with PHT. However, continued patency of the fenestration is not 
assured.  This study points out the need for manufactured shunt devices, providing a 
safe and effective possibility of treating patients who would benefit from such a 
device. 
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4.4 TRANSPLANTATION IN CHILDREN WITH PULMONARY 
HYPERTENSION 
 
4.4.1 Background 
Advanced medical therapies have transformed quality of life and outcome in patients 
with IPAH (89,131,288). Despite these advances in medical therapy, however the 
long-term outlook is poor (4,131). When medical therapies are exhausted lung (LTx) 
or heart-lung (HLTx) transplantation remains the only option for end-stage disease. 
The outcome of pediatric lung/ heart-and-lung transplantation has improved recently 
as a result of increased experience and better regimens of immunosuppressant 
therapy. However, transplantation does not represent a cure, as it involves the risk of 
early and late rejection, bronchiolitis obliterans syndrome, drug related problems and 
lymphoproliferative disease. As a consequence, contemporary registry data 
suggested a median survival following pediatric lung/ heart-lung transplantation of 
4.3 years (124). Deciding when to place a child on the active transplant list, 
therefore, remains a challenge. Optimal timing represents a balance between 
obtaining a donor organ in time, and being offered a graft while the child remains 
relatively well on medical treatment, bearing in mind the inherent risks of 
transplantation. At present there are no clear criteria for the optimal timing at which a 
child with IPAH should be listed for transplantation.   
 
The aim of this retrospective case series was to review the clinical experience with 
children with IPAH referred for transplantation assessment between 1/2002-6/2007, 
when the UKSPHC was established. The characteristics and outcome of children 
listed for transplantation were compared with those of patients who were not listed in 
order to identify distinguishing features between the two groups.  
 
4.4.2 Patients and Methods 
All IPAH patients are regularly reviewed by the UKSPHC team. Those patients 
treated with advanced medical therapies, including continuous intravenous 
epoprostenol, are referred to the Transplantation Team for assessment. The decision 
as to whether or not a child should be listed for transplantation is based on the 
clinical judgement of both  physicians and surgeons. 
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Data on children with IPAH who were, and who were not listed for transplantation 
were analysed retrospectively. The two groups were compared focusing on 
differences in age at diagnosis, weight, height, functional class (WHO 1-4), resting 
oxygen saturation (SpO2), minimal SpO2 during 6MWT, 6MWT distance, drug 
treatment, serum-BNP (Triage-test, Biosite), the forced expiratory volume in one 
second (FEV1), functional vital capacity (FVC), semiquantitative echocardiographic 
assessment of right ventricular function (1=normal, 2=mildly, 3=moderately, 4= 
severely impaired), mean baseline pulmonary artery pressure (mPAP), mPAP/ mean 
aortic pressure (mAP) ratio, pulmonary vascular resistance index (PVRI) and the 
PVRI on vasodilator testing (100% FiO2 and 20 ppm NO) and cardiac index.  
 
After transplantation children were treated according to a standardized 
immunosuppressive regime. As a routine, induction immunosuppressive therapy with 
basiliximab is used and following transplantation a combination of tacrolimus, 
mycophenolate mofetil and steroid treatment is given. All patients undergo regular 
routine follow-up surveillance transbronchial biopsy according to a set protocol 
(310). Depending on the histopathological findings action is taken to treat early signs 
of rejection and prevent the potential onset of obliterative bronchiolitis. 
 
Statistical analysis 
For statistical analysis, WHO class and echocardiographic measures were considered 
as a categorical variable and the Spearman rank correlation was used. For all 
analyses a two-sided p-value of <0.05 was considered statistically significant. 
Statistical analyses were performed using the StatView 5.0 (Abacus Concepts, 
Berkeley, CA, U.S.A.) and MedCalc 8.2.1 (MedCalc Software, Mariakerke, 
Belgium) packages. 
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Table 4.4.1 Patient Demographics. 
 
 
ASD = Atrial septal defect, BAS = Balloon atrial septostomy, cm = centimeter, Dx = 
diagnosis, Epo = Epoprostenol, FU = follow up, IAS = interatrial septum, kg = kilogram, n = 
number of patients, n.s. = not significant, Tx = transplantation. 
 
 
Table 4.4.2 Patient Characteristics. 
 
 All patients Listed for Tx No listed p-value 
     
WHO at assessment 2.9 (2-4) 3.5 (3-4) 2.5 (2-2.5) 0.0006 
SO2 at rest 95 (83-100) 98 (86-98) 98 (83-100) n.s. 
6MWT minimal SO2 84 (52-93) 76.5 (52-82) 89 (84-93) 0.0001 
6 MWT distance 269 (40-515) 154 (40-310) 330 (300-515) 0.0023 
FEV1 % 81 (49-110) 94 (60-110) 73 (49-100) n.s. 
FVC% 81 (45-132) 87.5 (66-132) 78 (45-85) n.s. 
BNP (pg/ml) 74.0 (7.6-1210.0) 410 (7.6-1210.0) 37.6 (10.5-241) n.s. 
Echocardiographic RVF 2.8 (2-4) 3.0 (2-4) 2.0 (2-4) n.s. 
Mean PAP 64 (25-80) 66 (56-71) 64 (25-80) n.s. 
PAP/ AoP ratio 1.2 (0.5-1.9) 1.2 (1.1-1.5) 1.0 (0.5-1.9) n.s. 
RAP 7.7 (3-12) 9 (4-12) 6.5 (3-10) n.s. 
PVRI baseline (WU*m²) 26.8 (12-44) 34.4 (13.5-39) 26.6 (12-49) n.s. 
PVRI vasodilator testing (WU*m²) 24.5 (10.5-39) 34 (15.5-39) 14.6 (10.5-33) 0.03 
Cardiac index (l/min/m2) 1.9 (1.3-3.1) 1.9 (1.3-3.1) 2.0 (1.5-2.6) n.s. 
     
 
AoP = Aortic pressure, BNP = B-type natriuretic peptide, CI= Cardiac index, FEV1 % = 
Forced expiratory volume in one second, FVC% = Functional vital capacity, l= liter, m² = 
meter squared, min = minute, ml = milliliter, n.s. = not significant, PAP = Pulmonary artery 
pressure, pg = picogramm, PVRI = Pulmonary vascular resistance index, RAP = Right 
atrial pressure, RVF = Right ventricular function, SO2= saturation, Tx = transplantation, 
WHO = World Health Organization, WU = Wood units, 6MWT = Six-minute walk test.   
 All patients Listed for Tx Not listed p-value 
     
n ( male) 14  7  7  
Gender ( male/ female)  8 / 6 5 / 2 3 / 4  n.s. 
Age at Dx (years) 3.7 (0.4-9.5) 4.5 (0.9-6.1) 3.0 (0.4-9.5) n.s. 
Age at follow-up (years) 8.6 (4.6–14.5) 7.6 (4.6-14.5) 9.0 (5.6-13.1) n.s. 
Weight (kg) 23.3 (13.5-41.1) 19.0 (13.5-35.4) 24.1 (17.0-41.1) n.s. 
Height (cm) 120 (92-155) 110 (92-155) 124 (110-151) n.s. 
FU after Tx - 2.2 (0.21-2.39) - - 
Age at FU (Tx patients) - 7.4 (4.7-10.7) - - 
Epo+Bosentan (+Sildenafil)  11 (3) 6 (1) 5 (2)  
Warfarin/ Aspirin 8 / 6 3 / 4 5 / 2  
Atrial communication  
(ASD/ BAS/ intact IAS) 
8 / 4 / 1 4 / 3 / 0 2/ 4/ 1  
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4.4.3 Results  
Since 2002 fourteen children (8 male) with IPAH were referred for transplantation 
assessment. The patient demographics are presented in Table 4.4.1.  
All patients were treated with pulmonary hypertension-specific medicines such as 
epoprostenol and bosentan (dual endothelin-receptor-antagonist). Five patients also 
received sildenafil (phosphodiesterase-5-inhibitor). Seven children were listed for 
transplantation. The median time from diagnosis to listing was 3.6 years (1.4-9.3).  
Five children were subsequently transplanted (LTx n=3; HLTx n=2). Their median 
waiting time was 81 days (16-301) and the median age at transplantation was 5.4 
(4.5-8.3) years. Two patients died on the active transplant list after being listed for 81 
and 202 days, respectively. Seven children were considered to not be sick enough for 
listing, on a clinical basis. These patients remained under close clinical review and 
were reassessed for transplantation on a regular basis. All patients remained alive and 
stable on combination therapy. 
 
Children who were listed for transplantation were in a worse functional class (WHO 
3.5 vs 2.5; p=0.0006). These patients had a lower minimal oxygen saturation on 
exercise (76.5 vs 89%; p=0.0001) and the distance walked in six-minutes was lower 
compared to those not listed (154 vs 330m; p=0.0023). Echocardiographic RV-
function was worse in those listed (4 vs 3; p=0.03), and pulmonary vascular resistance 
index (PVRI) was higher on vasodilator testing (34 vs 14.6 u.m ; p=0.03). The mean 
baseline PVRI of the listed patients was also higher than in those not listed although 
the difference was not statistically significant (Table 5.4.2). Age at diagnosis and at 
assessment/listing, weight, height, mPAP, mPAP/mAP ratio, cardiac index, resting 
SO2, FEV1%, FVC% and serum-BNP did not differ between the two groups as shown 
in Table 4.4.2.  
 
The median postoperative mechanical ventilation time was 6 days (2-59), stay in the 
intensive care unit was 6 days (4-10) and total hospitalization time 24 days (16-81) in 
those children who underwent transplantation. The patient with the longest 
hospitalization time required a temporary tracheostomy due to slow weaning from 
ventilation and prolonged oxygen requirement. The patient, however, made a good 
recovery and is now doing well. In one child who underwent bilateral lung 
transplantation the atrial septostomy created before transplantation for recurrent 
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syncope became haemodynamically significant in the setting of a normal 
pulmonaryarterial pressure. The ASD was not closed at the time of transplantation, 
as the size of the ASD was underestimated on echocardiography due to equalisation 
of right and left atrial pressures and minimal net shunt in this setting. The child 
subsequently underwent surgical closure of the atrial septal defect 19 months 
following the transplantation after an attempt at interventional closure had failed. 
 
All 5 transplanted patients were alive after a median follow-up of 2.8 (0.7-2.9) years, 
with a good functional outcome (WHO function class 1). None of the children has 
clinical evidence of obliterative bronchiolitis or post-transplant lymphoproliferative 
disease. Weight has improved in some children, but the change in z-score did not 
reach statistical significance (p=0.06; Figure 4.4.1) (175). 
 
 
Table 4.4.3 Patients transplanted. 
 
Time Dx to listing (years) 3.6 (1.4-9.3) 
Age at admission to Tx list  5.9 (3.9-13.8) 
Days on list  81 (16-301) 
Age at Tx  (years) 5.4 (4.5-8.3) 
FU after Tx 2.2 (0.21-2.39) 
Time ventilated 6 (2-59) 
Days O2 post extubation 5 (0-9) 
ICU stay 6 (4-12) 
Hospitalized 24 (14-81) 
CPB time 160 (130-243) 
X clamp time 190 (0-243) 
Age at FU (Tx patients) 7.4 (4.7-10.7) 
FEV1 % post Tx 100 (82-103) 
FVC% post Tx 109 (99.9-114) 
 
CPB= Cardio-pulmonary bypass, Dx= Diagnosis, ICU=Intensive Care Unit, FEV1 % = 
Forced expiratory volume in one second, FVC% = Functional vital capacity, FU=Follow 
up, Tx=Transplantation, O2=Oxygen, X clamp= Cross clamp 
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Figure 4.4.1 Thriving of children after transplantation 
 
 
 
 
 
 
Figure 4.4.2  Example of improvement in radiographic appearance comparing pre and post 
transplantation chest X-rays in a child with IPAH. Left: Chest X- rays of a 5 year old boy, 
before (a) and 4 weeks after (b) bilateral lung transplantation showing in a) cardiomegaly 
with prominent central pulmonary arteries and b) a normal cardiac silhouette and pulmonary-
vascular markings. 
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4.4.4 Discussion 
The decision as to whether or not a child should be listed for transplantation was 
based on clinical judgement.  All the IPAH patients included in the current study 
were on maximum medical therapy. This retrospective analysis showed that the 
children listed for transplantation had a worse WHO functional class, walked less far 
in 6 minutes, had a worse right ventricular function as judged by transthoracic 
echocardiography and a less favourable haemodynamic response to vasodilator 
testing at cardiac catheterisation.  Five of the seven children listed underwent lung or 
heart-lung transplantation and are alive and well. In addition, all the children 
considered too well to be listed are still alive. Only the children who were listed but 
not transplanted died. All the transplanted patients have an exercise capacity 
comparable to their peers as judged by their parents are back at school or nursery.  
 
There are no established criteria for the optimal time at which children with IPAH 
should be listed for transplantation, unlike other diseases (311-313). Children with 
IPAH would normally be considered for transplantation if death within 6 months to 2 
years seems likely (314). In principle, the decision to list a child with IPAH for 
transplantation is similar to that used for adult patients, namely a poor short term 
prognosis/or a poor quality of life despite optimal medical therapy, but unlike 
objective criteria to guide clinicians are sparse in children. Survival probability 
models for adults have been developed, based on data obtained from the National 
Institutes of Health registry on IPAH and waiting times for single lung 
transplantation according to the United Network for Organ Sharing (315). The 
6MWT and cardiopulmonary exercise testing have prognostic implications and cut-
off values for 6MWT distance and peak oxygen consumption have been described 
(135,136).  Adults whose exercise tolerance is less than these derived cut-off values 
are expected to have a survival benefit from transplantation. In children, however, 
the feasibility of doing a six–minute walk test and cardiopulmonary exercise testing 
is influenced by the child’s age and level of understanding (316). In addition, the 
association between 6MWT distance and outcome is less clear in children. Although 
a good correlation of WHO functional class with outcome has been described in 
children listed for transplantation by other paediatric transplantation centres (317), 
categorization into a functional class is confounded by the parents’ and clinicians’ 
perception, particularly in younger children and may be misleading.    
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It has been suggested that haemodynamic evaluation – providing objective 
measurements – may be more helpful in assessing the need for transplantation for 
lung transplantation in children with IPAH. The product of the mean right atrial 
pressure and pulmonary vascular resistance may allow for the estimation of 
probability of death at 1 and 2 years after catheterization (318).This probability 
factor was derived by combining two previously known equations, one predicting 
survival in adults with PHT and one based on a retrospective study of a 
heterogeneous group of children with PHT (IPAH and congenital heart disease). 
There was a significant association between the predictive scores and death before 
transplantation (317). The major limitation of this approach is the necessity of 
carrying out cardiac catheterisation on patients with severe pulmonary hypertension 
(82,164) and the fact that this score was developed before the advent of oral 
advanced therapies or the widespread use of epoprostenol. Non-invasive approaches 
are clearly preferable but their prognostic value is limited at present.  In the current 
study a semi-quantitative assessment of right ventricular function demonstrated a 
greater degree of functional impairment in those listed for transplantation. More 
refined techniques such as tricuspid annular excursion, tissue-Doppler imaging or 
speckle tracking echocardiography may prove to be more helpful in future (319,320), 
as may evaluation of right ventricular function by cardiac magnetic resonance 
imaging (321,322). 
 
Especially in paediatric patients there is a shortage of donor organs and a long 
waiting time can be expected. Regular reassessment every 3-6 months is mandatory 
to ensure that cardiac function remains reasonable and a double-lung transplantation, 
rather than heart-and-lung-transplantation, is still feasible; as well as to re-evaluate 
clinical and nutritional status and to evaluate end-organ function. The current 
approach at Great Ormond Street Hospital London is to offer double-lung 
transplantation, not heart-and-lung-transplantation in the expectation that right 
ventricular function will recover.  
 
The obvious limitations of this study are its retrospective nature and the relatively 
small number of patients included. It is,of course, impossible to know how those 
patients who were transplanted would have fared without transplantation.  
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In conclusion, this study emphasises the difficulties of assessing children with IPAH 
for lung transplantation and indicates the need to define objective listing criteria for 
these patients as part of multi-institutional efforts. Nevertheless, it is reassuring that 
clinical judgement appears to have been correct in deciding who should and should 
not have been listed for transplantation. Outcome after transplantation in 
contemporary children with IPAH has been encouraging. Though transplantation is 
not a cure, it represents a worthwhile choice, giving the child a good quality of life.  
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5. DISCUSSION 
 
The clinical picture and outcome of severe PHT has been transformed by the 
introduction of new disease-specific therapies, but it is more difficult to manage 
children than adults with this condition. Evidence-based treatment algorithms have 
been developed for use in adults and more recently have been modified for use in 
children. Choice of therapy depends on an assessment of clinical status and, as 
outlined in Chapter 1 of this thesis, it is difficult to quantify clinical status and 
response to treatment in children. The traditional endpoints used in adult studies, 
such as change in exercise capacity or the six-minute walk test distance are often 
difficult to apply in a paediatric population. A further difficulty is defining ‘treatment 
success’ in patients with a chronic progressive disease. Gaining stability or avoiding 
further deterioration may well be regarded as treatment success in this setting, since 
pulmonary vascular disease is a progressive disease and a decline of exercise 
tolerance and progressive worsening of symptoms is to be expected. Nowadays, the 
major challenge for clinicians is to know how to risk stratify patients, how and when 
to adjust medication and when additional therapies, such as atrial septostomy or 
listing for transplantation, are required. In view of an anticipated longer waiting time 
for a suitable organ in children, particularly for younger children, outweighing the 
inherent risks of transplantation and the chance of getting an organ in time is 
challenging.  
 
Taking advantage of the rare opportunity afforded by having a single UK centre for 
paediatric PHT this thesis attempts to clarify the potential clinical value of non-
invasive prognosticators and to evaluate the two most aggressive forms of pulmonary 
hypertension therapy, namely epoprostenol and atrial septostomy in children with 
PAH. The results of these studies have indicated how best to proceed in evaluating 
and treating children with pulmonary hypertension. 
 
Evaluation starts with describing the child’s clinical state. How ill and how 
incapacitated is the child. The WHO or NYHA Functional Classification designed 
for use in adults is also used in children, as it has been in the work presented in this 
thesis, but it has severe limitations when used in children. It does not take into 
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account age, development, size, or maturation. In future it will be important to design 
an age-specific functional classification for children. 
 
A progressive reduction in exercise capacity is a feature of sustained PAH. Exercise 
capacity has been well studied in adults with PAH but not in children. Most 
randomized controlled adult trials in the setting of PHT have used the 6-minute walk 
test distance as a primary endpoint and it is an important parameter for guiding 
therapy. Unfortunately, the value of the 6-minute walk test distance is less well 
established in paediatric patients. It cannot obviously be used in young children but 
even in older children there are concerns that the test may be age dependent and 
affected by growth, maturation and level of understanding. The present study 
demonstrated that performing a 6MWT is feasible and can be done reliably in 
children as young as 4 years of age. The studies in this thesis aimed to established 
normal values for the 6-minute walk test distance in UK school children between 4 
and 11 years of age. They provide data against which the exercise tolerance of sick 
children can be compared. A limitation of the study is that only one walk test was 
performed by each child and so possible training effects could not be studied. Also, 
due to limitations in time and resources the number of children needed to create 
meaningful gender and age specific percentile curves for 6-minute walk test distance 
in UK children could not be recruited. In addition, the children were of different 
ethnicities, although mainly Caucasian, and ethnic specific data are needed.  
 
As cardiopulmonary exercise testing with gas exchange monitoring is regarded by 
many as the gold standard for assessing exercise capacity the relationship between 
parameters of cardiopulmonary exercise testing and the 6-minute walk test distance 
was also investigated. We found that both tests are feasible and safe to perform, 
supervised by an experienced medical team. In adults the 6MWT is considered as a 
test, which assesses exercise capacity at sub-maximal level. The results of this thesis, 
however, demonstrate that in children the 6MWT distance actually reflects maximal 
rather than sub-maximal exercise in those who cannot walk more than 300 m in 6 
minutes, or who cannot reach a peak oxygen consumption above 20 ml/kg/min. 
CPET should be considered as a complimentary test in children, particularly when 
their 6MWT is above the 300m threshold. Interestingly, in adults the current 
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European guidelines include a 6-minute walk test distance below 300 metres as one 
of the criteria for escalation of PHT therapy (3). 
 
 There were several limitations in the present studies. While most children at the 
UKSPHC regularly undergo a 6MWT only a limited number were referred for 
CPET, based on the treating physician’s discretion. The patients included in this 
study may, therefore, be a biased sample. Furthermore, the predicted normal values 
of 6MWT used in the present study were derived from a publication in 564 children, 
published by Geiger in 2007 (160). The authors of this study employed a measuring 
wheel to assess the walk test distance and this represents a slight modification of the 
conventional technique of performing a 6MWT, as used in our studies. While it 
appears unlikely that this modification alters the results of the test significantly, this 
possibility cannot be excluded. We used the normal values reported by Geiger 
because the 6MWT studies on UK children were still ongoing at that time.   Due to 
the limitations of the equipment (bicycle) we were unable to offer cardiopulmonary 
exercise testing to children with a body height of <140 cm. There is an ongoing 
effort to develop smaller machines, for example, toddlers’ go-cars with computer 
simulators that are suitable for younger children who can cooperate with a breathing 
mask.  
 
Symptoms and outcome in PHT are mainly determined by the ability of the right 
ventricle to cope with a chronically elevated afterload and this, in turn, affects left 
ventricular function. Therefore the study of biventricular function in children with 
PHT is important. Using tissue Doppler echocardiography, this thesis demonstrates 
that despite not being evident on conventional 2D and M-mode echocardiography, 
left ventricular systolic and diastolic performance is impaired in children with PHT. 
This finding probably reflects the detrimental impact of right ventricular dysfunction, 
dilatation and hypertrophy, on the left ventricle (i.e. ventricular-ventricular 
interaction). The work highlights interesting parallels with patients who have 
congenital heart disease. In tetralogy of Fallot, for example, left ventricular 
dysfunction – due to ventricular-ventricular interaction – was thought to be a simple 
bystander of right ventricular dilatation and systolic impairment (323). More recently 
it has emerged that left ventricular systolic dysfunction is independently related to an 
increased risk of sudden cardiac death in patients with tetralogy (324). As patients 
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with tetralogy of Fallot and PHT share important pathophysiologic features which 
increase the propensity for malignant arrhythmia, such as right ventricular 
enlargement, myocardial fibrosis and autonomic dysfunction (76,323,325-327), one 
may speculate that left ventricular dysfunction may be prognostically adverse in 
children with PHT. This question should be addressed in future studies. Speckle 
tracking echocardiography may provide additional insights into the pathophysiology 
of biventricular dysfunction. Tissue Doppler echocardiography provided important 
insights into cardiac physiology and pathophysiology in the present study, but 
experience shows that it has failed to establish itself in clinical practice over the last 
15 years. In contrast, it appears that speckle tracking echocardiography has the 
potential to become part of clinical routine, mainly due to its ability to provide 
simple measures of global systolic function (328). This approach could be helpful. A 
recent study showed that global systolic strain – which can be obtained semi-
automatically using contemporary echocardiography systems – is superior to ejection 
fraction in predicting prognosis in adult heart failure patients (329). Further studies 
should therefore, assess the prognostic value of these novel speckle tracking 
echocardiography derived measures of biventricular function in children with PHT. 
 
Unfortunately, in the present echocardiographic study the follow-up time was short 
and therefore the number of endpoint events was insufficient to make it possible to 
investigate the prognostic value of tissue Doppler echocardiography. The choice of 
other possible prognostic markers was guided by the two most common modes of 
death in this population, namely progressive heart failure and sudden – presumably 
cardiac related – death (330). 
 
Electrocardiographic parameters of autonomic dysfunction have emerged as 
powerful prognostic markers of sudden death in several cardiac conditions (212-
216). As sudden death is not uncommon in PHT and the pathophysiologic substrate 
for malignant arrhythmias is likely present in the right ventricle of PHT patients (76) 
this study investigated the prognostic value of parameters of heart rate variability 
(HRV) in children with PHT. Parameters of HRV are objective markers and can be 
measured easily and repeatedly even in small children. Determination of HRV 
indicated that a low HRV is predictive of death or transplantation. An abnormal 
HRV has been shown to be a powerful and independent predictor of adverse 
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prognosis in paediatric patients with congenital heart disease (209-211),  in adults 
with ischaemic heart disease (212-216) and in the general population (217). It 
reflects autonomic dysfunction and is related to the risk of malignant arrhythmias 
(217). The current study indicates that parameters of HRV carry prognostic 
information independently of 6-minute walk test distance. It is tempting to speculate 
that parameters of HRV may be more suited to predict arrhythmic events, while the 
6-minute walk test distance relate to the risk of heart failure related complications. 
Therefore, the use of these non-invasive tools in combination in the setting of 
paediatric PHT is conceptually appealing and deserves further study. The main 
limitations of the present study are that HRV was not studied in consecutive children 
with PHT, but rather children who were referred for a Holter-ECG based on 
symptoms or resting-ECG evidence of arrhythmia. Therefore this is a biased sample. 
Future studies should include longitudinal studies of HRV in all children with PHT. 
It would be interesting to measure additional parameters of autonomic dysfunction 
such as heart rate turbulence and baro-reflex sensitivity, potentially providing 
supplemental prognostic information (331).   
 
B-type natriuretic peptide is a recognized marker of myocardial dysfunction and is 
related to mortality in various cardiovascular cohorts (332,333). This thesis therefore 
investigated the prognostic value of BNP in children with PHT. It emerged that BNP 
levels were elevated in 60% of children with PHT. This proportion was higher in 
children with IPAH than in children with associated PHT (73% versus 46 %, 
respectively). Although BNP was related to mortality and need for transplantation, it 
became apparent that BNP may not be sensitive enough to guide PHT therapy. While 
a high level of BNP should raise concerns about the optimization of medical therapy, 
a low BNP does not necessarily indicate that a patient is well and stable. The results 
of this study indicate that routine BNP measurement can be a useful adjunct to the 
assessment of clinical status but should not be used in isolation as independent 
screening tool to predict outcome. Repeat measures of BNP or NT-pro BNP in a 
longitudinal patient follow-up however, have been used in adults to assess response 
to therapy (334) and their prognostic value in paediatric PHT patients requires 
further investigation.  
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In summary, it is hoped that knowledge of the value and limitations of non-invasive 
prognostic markers such as exercise capacity, echocardiographic measures of 
ventricular function, HRV and BNP will eventually assists clinicians in selecting 
adequate treatment options for children with PHT and help to risk stratify patients. 
The need for further study is self-evident.  It is unlikely that any single measure will 
prove to be the ideal prognosticating factor. Having optimised all current techniques, 
combining relevant material selected from specific investigations to produce a 
combined prognostic factor may be the way forward. 
 
A further aim of this thesis was to evaluate certain treatment options in children with 
severe PAH, namely continuous intravenous epoprostenol treatment and atrial 
septostomy. This study shows that epoprostenol treatment is feasible in children, 
appears to slow disease progression and to improve survival. In addition, 
epoprostenol improves WHO functional class, exercise tolerance and ability to thrive 
in children with PAH, thereby improving quality of life despite the morbidity and 
potential complications associated with a continuous epoprostenol infusion. Thus 
epoprostenol represents an effective, feasible therapy with an acceptable morbidity in 
young children with severe pulmonary hypertension. The majority of children were 
also receiving sildenafil and an endothelin receptor antagonist. Therefore all the three 
signalling pathways known to be abnormal in pulmonary vascular disease were being 
modified. The use of aggressive combination therapy in children needs further study 
particularly with regard to whether or not it should be started when a child first 
presents with IPAH. 
 
Creation of an atrial communication has been advocated to abolish syncope and 
unload the compromised right ventricle in patients with PHT. The retrospective 
review of a series of children who underwent atrial septostomy showed that this 
intervention is feasible in children with PAH and can improve symptoms. The 
procedure is only safe however, if the right atrial pressure is not high, as illustrated in 
one of our syncopal patients. The right atrial pressure was 19 mm Hg and the 
systemic arterial oxygen saturation fell from 98% at baseline to 58%. An Amplatzer 
ASD occluder device was inserted immediately, with no ill effects. The current 
guidelines recommend that atrial septostomy should not be done in patients 
presenting with a right atrial pressure above 20 mmHg (3). There is also an inherent 
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risk of creating too large a communication, inducing severe cyanosis. In the current 
study oxygen saturation fell on average from 97.8% before septostomy to 90% after 
3–6 months. Fenestrated devices may reduce the risk of oversizing the atrial 
septostomy and the retrospective study described in this thesis showed that 
implantation of fenestrated devices is feasible and safe in children. However, 
custom-made as well as self-made fenestrated devices can close spontaneously with 
time. This study highlights the need for new, improved fenestrated devices. Given 
the far superior survival prospects of Eisenmenger patients compared to patients with 
IPAH (335) it is tempting to contemplate ways to create an “Eisenmenger-like” 
physiology in patients with IPAH. In addition to creating shunts non-invasively at 
atrial level, recently it has been suggested that IPAH patients (including children) 
with suprasystemic pulmonary arterial pressures may benefit from the creation of an 
anastomosis between the left pulmonary artery and the descending aorta (i.e. Potts 
anastomosis) (336,337). However, current knowledge on the long-term effects and 
the adequate dimensions of such shunts are limited and further research using 
analytical models, experimental animals and clinical data is required before this 
technique before considering its use in children with PHT. Operating on a child with 
a high pulmonary arterial pressure is extremely dangerous. 
 
Deciding when to list a child for lung transplantation is difficult. Keeping the child 
well on medical treatment for as long as possible is desirable because the mean 
survival remains relatively poor, although it has improved over the last decade due to 
better immunosuppression strategies and post-transplant patient care,. Also, there are 
few donor organs available. This present study showed that the decision as to 
whether or not a child should be listed for transplantation is subjective and chiefly 
based on clinical judgement.  In retrospect, a worse WHO functional class, lower 6-
minute walk test distance, more impaired right ventricular function as judged by 
transthoracic echocardiography and a less favourable haemodynamic response to 
vasodilator testing at cardiac catheterisation emerged as the main criteria related to 
listing for transplantation. It is reassuring that, despite being a subjective decision 
based on a combination of parameters all the children considered too well to be listed 
are still alive while only children who were listed but not transplanted died. This 
suggests that the currently employed process of evaluating and risk stratifying 
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patients is effective but highlights the pressing need for more objective markers and 
defined criteria to allow comparison of outcomes between transplantation centres.    
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6. CONCLUSION 
 
The studies presented in this thesis highlight that the optimal non-invasive risk 
marker for children with pulmonary vascular disease has yet to be found and the 
ideal treatment option for this devastating and progressive disease does not exist. 
There is no cure at the present time. Awareness of the limitations and weaknesses of 
prognostication markers should be helpful in improving patient care and in the  
design of future studies. Using combinations of different non-invasive markers is 
likely to more helpful but further studies are required to create and validate risk 
models for children with PAH. 
 
An ideal risk prognosticator should be non-invasive, highly specific, sensitive and 
cost-effective. One day there may be an ideal risk prognosticator but until then 
combining current, recognised prognosticating factors may help improve patient 
management, together with clinical judgement and regular re-evaluation of the 
patient. Ventricular dysfunction and heart failure are associated with considerable 
morbidity in the setting of PHT and are a principal cause of mortality. Unfortunately, 
traditional markers of ventricular dysfunction such as ejection fraction have clear 
limitations in the setting of right ventricular disease and alternative markers of right 
ventricular dysfunction should be sought. Assessment of longitudinal ventricular 
function, such as TAPSE, tissue Doppler imaging as used in Chapter 3 of the thesis 
or speckle tracking based parameters used alone or in combination with BNP 
measurements (a serum marker of ventricular dysfunction) may be a way forward.  
In view of the echocardiographic limitations in assessing right ventricular function, 
MRI may be a promising non-invasive alternative to quantify ventricular function 
and dimensions. The studies in this thesis have demonstrated left ventricular systolic 
dysfunction in children with PHT and MRI assessment should focus on left 
ventricular impairment and biventricular interaction.  Technical advances in MRI are 
desirable to avoid the need for heavy sedation or general anaesthesia.   
 
An accurate assessment of clinical status and quality of life is essential in guiding the 
management of a child. A functional classification designed specifically for children 
is needed, rather than trying to apply the WHO or NYHA classification designed for 
adults.  Consideration of quality of life is important in a disease which cannot be 
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cured. Quality of life questionnaires (e.g. SF-6) or scores have been used in children 
with PHT (338). As expected, the scores for physical performance using the SF-6 
questionnaire were low but the psychosocial scores were significantly higher. 
Comparing the answers and judgement of the older children who were asked to 
complete the questionnaire (e.g. SF-6) themselves and those filled in by their parents 
revealed interesting differences of perception.  The children’s judgement of their 
quality of life often seemed more optimistic than the parents’ impression of the 
child’s quality of life.  Despite various assessment modalities, individual definition 
and perception of quality of life does differ tremendously. Perception can be 
influenced by religious, ethical and personal attitudes, which are beyond the scope of 
a scientific approach. Also, an individual’s expectations change in the setting of 
chronic disease. The clinician should aim to provide children and parents with the 
best possible objective information, evidence and available scientific data.  An 
empathic relationship with the families, ongoing support and comfort, link and 
introduction to support systems (such as the Pulmonary Hypertension Association 
UK and community networks) and, last but not least, an open mind to the individual 
patient’s and family’s needs and wishes should be paramount and should lead the 
counselling process. 
 
Given the better survival prospects in the current era the focus of outcome measures 
should move from classical mortality related end-points, such as death and 
transplantation to morbidity using composite endpoints such as hospitalization, need 
for escalation of therapy or other parameters of clinical worsening. Quality of life 
and exercise capacity are additional important markers of morbidity. Exercise 
capacity has been extensively used as an endpoint in trials in adult patients with 
PHT, mainly in the form of 6-minute walk test distance. Using raw 6-minute walk 
test distance may be relatively unproblematic in adults, but as shown in the present 
thesis, the 6-minute walk test distance is age and gender dependent in normal 
children. In order to compare the 6-minute walk test distance of patients with normal 
values, it is necessary to have percentiles or at least the mean and standard deviations 
of normal values in order to calculate z-scores.  
 
In view of the still devastating outlook and poor prognosis new medicines are 
urgently needed.  Traditional randomized placebo controlled trials are unethical 
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however, because there are drugs on the market which give symptomatic 
improvement and increase survival. Alternative concepts and study designs are 
needed. Economic constrains are obvious, although potentially less dominant in 
paediatric practice compared to adult services. However, given the cost implications 
of disease targeting therapies, cost utility analyses are required and preliminary data 
are emerging in adult patients (339). 
 
In conclusion, it is hoped that this thesis will contribute to a better understanding of 
pulmonary hypertension in children, advance studies on risk stratification and inform 
clinicians about treatment options in children with pulmonary hypertension.   
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